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ABSTRACT 
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is 
a novel procedure for the diagnosis of mediastinal lymphadenopathy. Its utility in 
clinical practice for the diagnosis of patients presenting with mediastinal 
lymphadenopathy is unknown. This thesis describes the learning curve associated 
with EBUS-TBNA using cumulative sum analysis and then the diagnostic yield of 
EBUS-TBNA in different clinical scenarios. 
EBUS-TBNA was combined with standard bronchoscopy in patients with suspected 
sarcoidosis in a prospective trial. The role of EBUS-TBNA in patients with 
tuberculous lymphadenopathy and also patients with extra-thoracic malignancy was 
then clarified in multi-centre studies. A further prospective trial (REMEDY) aimed 
to ascertain whether mediastinoscopies could be prevented in patients presenting 
with isolated mediastinal lymphadenopathy. The utility of the specimens from 
EBUS-TBNA for sub-typing and genotyping of non-small cell lung cancer are also 
described in a multi-centre study. Finally, the results from a major multi-centre 
randomised controlled trial (Lung-BOOST) are presented, investigating whether 
EBUS-TBNA should be implemented as a first test in patients with suspected lung 
cancer.  
The data included in this thesis demonstrate that EBUS-TBNA has high diagnostic 
yield in patients with sarcoidosis, tuberculosis and extra-thoracic malignancy. For 
the first time, the REMEDY trial demonstrates that EBUS-TBNA can prevent 87% 
of mediastinoscopies in patients with isolated mediastinal lymphadenopathy. In 
patients with lung cancer, specimens from EBUS-TBNA are suitable for sub-typing 
and genotyping of NSCLC and results from the randomised Lung-BOOST trial 
demonstrate that when EBUS-TBNA is used as an initial investigation in patients 
with suspected lung cancer the time to treatment decision is significantly reduced. 
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CHAPTER 1: INTRODUCTION 
 
1.1 MEDIASTINAL LYMPHADENOPATHY 
 
Mediastinal lymphadenopathy refers to the enlargement of lymph nodes within the 
mediastinum and determining the diagnosis of mediastinal lymphadenopathy is a 
common problem faced by respiratory physicians. The differential diagnosis of 
enlarged mediastinal lymph nodes (MLN) includes neoplasm, granulomatous 
disease, infection and reactive hyperplasia. Neoplastic causes are most commonly 
metastatic lung cancer, lymphoma or metastatic disease from the oesophagus, breast, 
kidney or head and neck. Sarcoidosis and tuberculosis result in granulomatous 
lymphadenopathy. Fungal infections such as histoplasmosis and coccidiodomycosis 
may also cause enlarged MLNs. Rarer causes of mediastinal lymphadenopathy 
include Castleman’s disease, angioimmunoblastic lymphadenopathy, chronic 
berylliosis, Wegener’s granulomatosis and chronic mediastinitis. 
 
In UK practice, the most common causes of mediastinal lymphadenopathy are 
sarcoidosis, metastatic lung cancer, tuberculosis and lymphoma. These four 
important conditions have vastly different treatments and prognoses. Moreover their 
symptoms are often non-specific. Fevers, night sweats and weight loss may be a 
common feature of each diagnosis and does not help with their differentiation. 
Therefore, a tissue diagnosis of mediastinal lymphadenopathy is critical to allow 
patient management.  
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1.2  MEDIASTINAL LYMPH NODE MAP 
 
Assigning a location to mediastinal lymph nodes is important to allow accurate and 
reproducible lymph node sampling and to facilitate discussion between clinicians 
and researchers. There are 2 lymph node maps currently in use internationally. The 
Japanese Naruke lymph node map has largely been replaced by the American 
Thoracic Society mediastinal lymph node classification, first described by Mountain 
and Dresler (1997) and shown in Figure 1.1. 
 
Figure 1: The mediastinal lymph node map. (Mountain and Dresler 1997). 
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1.3 CURRENT TECHNIQUES FOR THE DIAGNOSIS OF MEDIASTINAL 
LYMPHADENOPATHY 
 
A combination of radiological, minimally invasive and invasive techniques is 
currently employed in the diagnosis of mediastinal lymphadenopathy.  Computed 
tomography (CT) with intravenous contrast is a first line investigation in order to 
delineate the location of enlarged MLNs. Positron Emission Tomography (PET) and 
integrated PET-CT are more sensitive and specific tests than CT for mediastinal 
nodes and are currently recommended in the staging non-small cell lung cancer but 
have limited utility in other disease processes. Tissue sampling of mediastinal lymph 
nodes may currently be performed by bronchoscopy with conventional 
transbronchial needle aspiration. Surgical techniques and in particular 
mediastinoscopy are currently considered to be the gold standard for the diagnosis of 
MLNs. The newer techniques of endoscopic ultrasound guided fine needle aspiration 
(EUS-FNA) and endobronchial ultrasound guided transbronchial needle aspiration 
(EBUS-TBNA) are emerging for the diagnosis of benign as well as malignant 
mediastinal lymphadenopathy. Each of these techniques is discussed below in the 
context of non-small cell lung cancer and isolated mediastinal lymphadenopathy. 
 
1.4  MEDIASTINAL STAGING OF NON-SMALL CELL LUNG CANCER 
 
1.4.1  Importance of mediastinal lymph node staging in NSCLC 
 
The mediastinal staging of non-small cell lung cancer (NSCLC) is a critical process 
that determines treatment options and prognosis as well as allowing accurate 
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comparison in clinical trials. In patients with NSCLC who are fit for surgery and 
have no evidence of extra-thoracic disease, the status of the mediastinum 
differentiates operable from inoperable candidates (Rusch et al. 2007). Mediastinal 
staging may be best achieved with a multidisciplinary approach that involves 
pulmonary, surgical, oncology, and radiology input to establish whether curative 
surgical resection is possible. Those patients with no evidence of mediastinal 
metastases on staging investigations may be offered surgery. The remaining patients 
with mediastinal spread are offered chemotherapy and external beam radiotherapy or 
neo-adjuvant treatment in the context of a clinical trial (Spira & Ettinger 2004). 
Currently, clinical stage IA disease has a 5-year survival rate after surgery of 50% 
(Goldstraw et al. 2007). Of the recurrences, most occur from metastatic involvement 
at presentation, which are missed by existing staging modalities. Deficiencies of 
staging techniques therefore result in 21-45% of thoracotomies being futile at 1 year 
(Fischer et al. 2009;Herder et al. 2002;van Tinteren et al. 2002) with the 
consequence of removing lung function without curing the disease.  Patients with 
clinical stage II disease (T1N1M0 or T2N1M0) have a 5-year survival rate after 
surgery of 25% and benefit from adjuvant treatment. At clinical stage IIIA, the 5-
year survival rate is 18%, and at stage IIIB it is only 8% (Goldstraw et al. 2007). 
Patients with clinical stage IIIA-N2 disease, however, represent a heterogeneous 
group with widely ranging survival rates. Those with bulky central mediastinal 
disease have a worse prognosis than those with single station ipsilateral disease. All 
patients with N2 mediastinal lymph node involvement remain poor candidates for 
initial surgical resection even if neoplastic invasion is limited to a single mediastinal 
station (Cerfolio & Bryant 2008;Ohta et al. 2006). The 5-year survival rate for 
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patients with stage IV disease is virtually nil, and this disease is treated either with 
chemotherapy and supportive care or with supportive care alone.  
Therefore, it is of paramount importance to stage accurately as the treatment 
modalities and subsequent patient outcomes vary widely based on stage designation. 
By staging patients with NSCLC more accurately, patients are more likely to receive 
appropriate treatment, with a reduction in futile thoracotomies and improvement in 
morbidity and mortality.  
  
1.4.2 Techniques for the mediastinal staging of non-small cell lung cancer 
 
1.4.2.1 Computed tomography scan 
 
Contrast enhanced computed tomography (CT) scanning is the first step in the 
assessment of mediastinal lymph node (MLN) staging for NSCLC. It is widely 
available and provides excellent anatomical detail, but relies on the size of MLN to 
differentiate potentially benign from malignant lymphadenopathy. A criterion of 1 
cm in short-axis is generally employed to distinguish potentially malignant MLNs (≥ 
1 cm in diameter) from benign MLNs (< 1 cm in diameter). Using this paradigm, a 
meta-analysis of 43 studies demonstrated that the sensitivity of CT in the diagnosis 
of MLN metastasis is low at 51% with a specificity of 86%, in a population with a 
median prevalence of mediastinal metastases of 28% (Silvestri et al. 2007). 
Therefore, MLNs less than a 1cm in short-axis may still harbor malignancy in up to 
20% of cases. Even in cases of clinical stage 1A disease on the basis of CT, 
mediastinal lymph node dissection may demonstrate MLN metastases in 10% of 
cases (Cerfolio et al. 2005). Importantly, 40% of enlarged mediastinal nodes may be 
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benign (Kerr et al. 1992), particularly in the context of obstructive pneumonitis 
(McLoud et al. 1992). Therefore, in patients with discrete nodal enlargement, relying 
on CT alone for mediastinal staging would both over and under-stage patients with 
the potentially catastrophic consequences of a missed opportunity to operate or futile 
surgery. These limitations highlight the importance of pathological confirmation of 
lymph node status and MLN staging cannot be judged on CT appearances alone. 
However, CT does remain an important initial investigation and delineates the 
anatomy of the mediastinum allowing selection of the appropriate invasive staging 
tool.  
1.4.2.2 Positron emission tomography 
 
Functional imaging with positron emission tomography (PET) and fusion PET-CT is 
a valuable addition in the assessment of stage in NSCLC. The radio-labeled glucose 
analogue 18-fluoro-2-deoxy-D-glucose (FDG) undergoes the same cellular uptake as 
glucose and is phosphorylated, generating 18F-FDG-6-phosphate. The accumulation 
of 18F-FDG-6-phosphate in malignant cells can then be identified using a PET 
camera. By utilizing the abnormally high function of malignant cells within lymph 
nodes, PET can differentiate normal from malignant cells. Therefore, PET has 
superior sensitivity and specificity in staging the mediastinum as compared with CT 
and has an important clinical role in the diagnosis, staging, re-staging, therapy 
planning and monitoring of disease in non-small cell lung cancer. 
The PLUS randomized controlled trial highlighted the importance of PET in the 
staging of NSCLC. 188 patients from nine hospitals were assigned to undergo either 
conventional workup (CWU) or CWU and PET. Thoracotomy was regarded as futile 
if the patient had benign disease, explorative thoracotomy, pathological stage IIIA-
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N2/IIIB, or postoperative relapse or death within 12 months of randomization. The 
study included a high incidence of thoracotomy for benign lesions and in addition 
half of the comparator CT scans were performed without intravenous contrast, 
excluded the liver and were non-spiral. However, by detecting previously 
unsuspected metastatic disease, the addition of PET to conventional workup 
prevented unnecessary surgery in one out of five patients. Conversely, another 
randomized trial of pre-operative PET suggested that it did not alter the number of 
thoracotomies performed (Viney et al. 2004).  
The standardized uptake value (SUV) is the measure of metabolic activity detected 
by PET and provides predictive information regarding treatment response and 
survival. The maximum SUV (SUVmax) in a region of interest (ROI) has been 
adopted as an approach to characterize metabolically active lesions. A cut-off of 2.5 
is generally applied. However, non-neoplastic lesions, in particular granulomatous 
disorders and infections may also generate positive lesions on PET scanning. 
Therefore, an overlap exists between true and false positives in MLNs with an 
SUVmax ≥ 2.5. PET scanning falsely identifies malignancy in 25% of patients with 
nodes that are enlarged for other reasons (Silvestri et al. 2007). Labeling PET 
positive MLNs as malignant without pathological confirmation, may result in a 
missed opportunity to operate. Consequently, current guidelines advocate that PET 
positive mediastinal nodes should be invasively investigated, before surgery is 
precluded (Detterbeck et al. 2007). An SUV of 5.3 has been proposed in an attempt 
to improve specificity and accuracy without significant loss to sensitivity (Bryant et 
al. 2006). A retrospective study of 110 patients who underwent CT, PET scan and 
mediastinoscopy suggested that mediastinoscopy could be avoided in patients with 
MLNs having an SUVmax of less than 5.3 (Lee et al. 2008a). This however requires 
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further confirmation in prospective trials to determine its effect on patient outcomes, 
before this approach can be adopted.  
Although PET positive mediastinal lesions require pathological confirmation of 
malignancy, it is generally considered that PET negative (SUV ≤ 2.5) lesions reliably 
exclude malignancy, particularly in lymph nodes < 1cm in short axis. However, 
recent evidence has tempered enthusiasm for PET since false negatives can and do 
occur and performance characteristics are dependent on nodal size. A meta-analysis 
by De Langen et al. (2006) of patients with lymph nodes measuring ≥ 16 mm on CT 
and a negative FDG-PET result demonstrated a post-test probability for N2 disease 
of 21%. The authors concluded that patients with MLN ≥ 16mm should be planned 
for invasive mediastinal staging prior to possible thoracotomy to prevent futile 
surgery in this subset of patients. Size of MLN is therefore a key factor in the 
accuracy of PET. 
Previously unsuspected metastatic mediastinal disease is seen in 10% of patients 
with negative CT and PET studies of the mediastinum and it is generally accepted 
that these patients can be referred for radical treatment without further clinical 
staging tests (Vansteenkiste 2003). However, specificity and accuracy decrease 
significantly in larger mediastinal lymph nodes (Al-Sarraf et al. 2008). Therefore, 
MLN ≥ 1cm should be invasively sampled, even if they are judged to be 
metabolically inactive by PET scan (Detterbeck et al. 2007). PET remains justified 
however for patients with enlarged MLNs, because of its ability to direct invasive 
biopsy and also to detect previously unsuspected M1 disease (Silvestri et al. 2007). 
Integrated PET-CT has superior sensitivity to either technique in isolation, with a 
faster learning curve for radiologists.  In a prospective study of 50 patients with 
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known or suspected NSCLC, PET-CT had higher accuracy for MLN metastases than 
PET alone or visual correlation of PET and CT (Cerfolio et al. 2004). However, 
problems with false positives and negatives persist. Sensitivity and specificity of 
fusion PET-CT range from 64 – 86% and 81 – 94% respectively (Silvestri et al 
2007).  To date, pre-operative PET-CT has been examined in 2 randomised 
controlled trials. Fischer and colleagues (2009) compared PET-CT and conventional 
staging procedures followed by further invasive diagnostic procedures (such as 
mediastinoscopy) versus conventional staging and invasive diagnostic procedures. In 
both groups, mediastinoscopy was mandatory. The primary endpoint chosen was 
futile thoracotomies as per the PLUS trial. It was intended that 430 patients were to 
be recruited, but the trial was closed after enrolment of 189 participants due to slow 
accrual. 98 patients were allocated to the PET-CT arm. PET-CT significantly 
reduced the number of thoracotomies and the number of futile thoracotomies (52% 
to 35%) by detecting previously unrecognized metastases in 13 patients (9 distant 
and 4 mediastinal metastases). However, survival was similar in the two arms 
(Fischer et al. 2009). One limitation of the trial was that mediastinoscopy was 
routinely employed, which is not the current standard of care in most institutions and 
may have masked the benefit of PET-CT of the mediastinum. The second 
randomised trial of PET-CT in NSCLC demonstrated that PET-CT identifies more 
patients with mediastinal and extra-thoracic disease than conventional staging and 
therefore spared more patients from stage-inappropriate surgery (Maziak et al. 2009). 
However, PET-CT also incorrectly upstaged disease in more patients. 
Despite the apparent advance in imaging modalities, pre-operative invasive 
mediastinal lymph node sampling cannot be prevented and the need for 
mediastinoscopy may have even increased by the detection of false positive nodes 
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(Tournoy et al. 2007). Current guidelines recommend that invasive mediastinal 
staging remains indicated for FDG-avid mediastinal disease, PET positive hilar N1 
disease (Hishida et al. 2008), where there is low FDG uptake of the primary tumour 
or for any MLNs ≥ 1cm on CT scan (Detterbeck et al. 2007). 
 
1.4.2.3 Surgical techniques for mediastinal lymph node staging 
 
Mediastinoscopy is currently considered the gold standard technique for pre-
operative MLN staging in NSCLC. Performed under general anesthesia, an incision 
is made above the suprasternal notch and the mediastinoscope is inserted along the 
trachea, allowing visualization and biopsy of MLNs. The procedure is usually 
performed as a day-case with low morbidity (2%) and mortality is rare (Porte et al. 
1998). Mediastinoscopy affords access to paratracheal nodes (stations 2R, 2L, 4R, 
4L), pre-tracheal nodes (station 3) and anterior subcarinal nodes (station 7). 
However, lymph nodes in the aorto-pulmonary window (station 5), sub-aortic fossa 
(station 6), posterior subcarinal nodes (station 7) and inferior mediastinal nodes 
(stations 8 and 9) are not accessible by this technique (see figure 1.1). Biopsy 
samples allow for micro-metastases in normal sized lymph nodes to be detected and 
the procedure enables the surgeon to determine extra-capsular spread, conferring 
inoperability. However, the sensitivity of detecting mediastinal metastases in patients 
with NSCLC is as low at 80% (range 67 – 92%) with a false negative rate of 10% 
(Detterbeck et al. 2007). This inaccuracy (for the gold standard technique) is in part 
explained by the limited access of mediastinoscopy to the mediastinum.  
30 
 
Mediastinoscopy is also considerably underutilized in routine clinical practice. Little 
et al. (2005) collated data from 11,668 patients undergoing thoracotomy for lung 
cancer in 729 US hospitals. Only 27% of patients had pre-operative mediastinoscopy 
and of those performed only 47% had lymphoid tissue samples obtained. Smulders 
and colleagues (2005) demonstrated that only 40% of mediastinoscopies were 
performed according to gold standard techniques in non-university teaching hospitals 
in the Netherlands. The authors also showed that systematic mediastinal lymph node 
sampling was performed in only 50% of cases and estimated that 18% of 
thoracotomies could have been avoided if gold standard techniques had been 
observed. Of 39 cases with unexpected N2 disease at thoracotomy, 16 were 
accessible by mediastinoscopy (Smulders et al. 2005). Therefore, mediastinoscopy 
tends to be underemployed in the mediastinal staging of lung cancer. Furthermore, 
when it is carried out, only half of the procedures obtain diagnostic tissue. Even in 
expert hands, the entire mediastinum is inaccessible. Despite these clear limitations 
and lack of standardization of the technique, mediastinoscopy currently remains the 
gold standard for the staging of mediastinal lymphadenopathy. At present, it is not 
routinely recommended for pre-operative mediastinal staging of lymph nodes that 
are less than 1cm in short axis and negative on FDG-PET scan, due to low yield and 
lack of cost-effectiveness (Meyers et al. 2006). 
The advent of videomediastinoscopy has improved the standard procedure allowing 
better visualization and in addition to usual MLN stations, sampling of posterior 
station 7 lymph nodes. Video-assisted mediastinal lymphadectomy (VAMLA) may 
also be performed using this technique and allows complete lymph node dissection 
without the need for thoracotomy. VAMLA offers a standardized approach to 
surgical MLN sampling and may be superior to standard cervical mediastinoscopy 
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with an accuracy of 88% and negative predictive value of 83% in a recent cohort of 
234 patients (Leschber et al. 2008). Surgical expertise in this technique however is 
far from universal. 
Nodes in the aorto-pumonary window (APW), to which left upper lobe cancers 
commonly spread, can be accessed by anterior mediastinotomy, also known as the 
Chamberlain procedure. An incision is made under general anesthetic in the 2
nd
 or 3
rd
 
intercostal space just to the left of the sternum and overnight stay is usually required. 
Few studies have addressed the accuracy of the procedure although it is employed as 
the definitive staging technique for nodes in the APW. Extended cervical 
mediastinoscopy is performed in some centres. In one series this has a sensitivity of 
69% and false negative rate of 11% in 100 patients with a prevalence of mediastinal 
disease of 29% (Ginsberg et al. 1987). Video-assisted thorascopic surgery (VATS) 
can access one side of the mediastinum with the right side being technically easier. 
Few prospective data are available, although the procedure appears to have an 
acceptable safety and accuracy profile and may be regarded as an adjunct procedure 
to standard techniques. Its role may be best limited to the diagnosis of lesions 
inaccessible by other means, assessment of mediastinal invasion (T4 disease) and 
sampling of APW nodes. 
1.4.2.4 Trans-bronchial needle aspiration 
 
Blind transbronchial needle aspiration (TBNA) is a safe procedure for mediastinal 
lymph node staging and was first described in 1978 (Wang, Terry, & Marsh ). It is 
planned with the aid of CT (and PET if available) to identify the lymph node to be 
sampled and its relationship to bronchial landmarks is noted. During standard 
bronchoscopy, a TBNA needle is introduced into the biopsy channel and punctures 
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the bronchial wall allowing the mediastinal lymph node to be aspirated. This is most 
safely done in the subcarinal lymph node station but lower paratracheal and hilar 
lymph nodes can also be sampled. The procedure may be carried out with a 18, 19 or 
22 gauge needle. 
A meta-analysis of patients undergoing TBNA showed a pooled sensitivity of 39% 
for the technique when the prevalence of mediastinal metastases was 34% (Holty, 
Kuschner, & Gould 2005). Four modifiable factors have been shown to optimize the 
diagnostic yield of blind TBNA. First, at least 5 and up to 7 passes in the same area 
may maximize diagnostic tissue (Chin, Jr. et al. 2002;Diacon et al. 2007). Second, 
the presence of a cytologist within the endoscopy suite to evaluate aspirates as they 
are produced, may significantly improve accuracy (Diacon et al. 2005). Rapid on-site 
evaluation (ROSE) allows an immediate diagnosis of malignancy or can confirm the 
adequacy of a specimen by identifying lymphocytes (Baram, Garcia, & Richman 
2005). Third, the use of CT fluoroscopy allows imaging of MLN during TBNA and 
may improve yield (Garpestad et al. 2001). Finally, since blind TBNA is highly 
operator dependent, focused education and experience in the technique are 
invaluable in improving results (Haponik et al. 1995;Hsu, Liu, & Ko 2004). The 
highest yield is seen in lymph nodes >1cm in the right paratracheal and subcarinal 
locations and it is this patient group that may benefit most from TBNA (Harrow et 
al. 2000). 
Although blind TBNA is an important technique in selected patients, it remains 
underemployed for MLN sampling in NSCLC. However, uptake in the US may be 
improving. In a survey by Haponik and Shure (1997) only 10% of pulmonary 
fellows in the US routinely practiced TBNA. More recently, 91% of fellows were 
trained in TBNA and 69% were competent according to fellowship directors (Pastis, 
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Nietert, & Silvestri 2005). Figures outside the US are likely to be considerably 
lower. 
Assessment of the endobronchial tree is performed at the same sitting as TBNA. In 
addition, it is cheap and a well tolerated outpatient procedure that can be performed 
under conscious sedation. A positive result from TBNA may obviate the need for 
further invasive tests, particularly when combined with PET (Bernasconi et al. 
2006). However, the generally low diagnostic yield and negative predictive value 
mean that further tests are necessary in the event of a non-diagnostic sample. 
1.4.2.5 Endoscopic ultrasound guided fine needle aspiration 
 
Endoscopic ultrasound guided fine needle aspiration (EUS-FNA) of mediastinal 
lymphadenopathy has been available for over fifteen years (Silvestri et al. 1996). 
Under conscious sedation, an endoscope is placed in the oesophagus. Radial 
echoendoscopes provide cross-sectional imaging but do not allow tissue samples to 
be obtained and have been superseded by an integrated linear ultrasound probe that 
allows visualization of the mediastinum (Figure 1.2). Aspiration with a 22-guage 
adjustable-length Echotip needle is performed through the wall of the esophagus 
under direct vision. Due to the anatomical location of the esophagus, EUS-FNA is 
able to sample mediastinal lymph nodes in stations 2L, 4L, 5, 7, 8 and 9. 
Furthermore, aspiration of the celiac axis nodes, left lobe of the liver and left adrenal 
gland via EUS can provide additional important staging information (Singh et al. 
2007). 
Samples obtained by EUS-FNA with a 22-guage needle are suitable for 
cytopathological analysis. Consistency and reproducibility of reporting of cytology 
samples can be easily achieved, particularly by experienced pathologists and those 
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with less experience have a steep learning curve (Skov et al. 2007). Occasionally 
core samples are obtained by EUS-FNA and may be sent for histopathological 
investigation. Core tissue samples may be more reliably obtained using a 19-guage 
Trucut needle. This method requires that the mediastinal lymph node be at least 
20mm in the direction of the biopsy. Adding Trucut biopsy to fine needle aspiration 
may improve the diagnostic accuracy and the adequacy of sampling (Wittmann et al. 
2006). Another factor that may affect the adequacy of the sample is the availability 
of rapid on-site evaluation (ROSE). This involves a cytologist being present in the 
endoscopy suite and by using rapid staining techniques (e.g. modified May-
Grunwald–Giemsa stain), the cytologist is able to make an immediate assessment of 
the sample with high accuracy, eliminating inconclusive or inadequate samples 
(Tournoy et al. 2005). This arrangement has also been shown to be cost-effective 
(Pellise et al. 2007). The issue of the number of passes into the lymph node by EUS-
FNA for optimal diagnostic yield has also been addressed. Diagnostic yield can be 
maximized by performing 3 – 5 passes (Leblanc et al. 2004;Wallace et al. 2001).   
Cohort studies have demonstrated that EUS-FNA is a safe and efficacious procedure 
for the mediastinal staging of NSCLC. A meta-analysis of 18 studies (Micames et al. 
2007), totaling 1201 patients demonstrated a pooled sensitivity of 83% (range 45% – 
100%) and specificity of 97% (range 88% – 100%), with a median prevalence of 
mediastinal disease of 65% . These studies only included patients with mediastinal 
lymph nodes accessible to EUS-FNA. 
The position of EUS in the lung cancer staging algorithm is yet to be fully addressed 
in randomized trials. Tournoy et al recruited 40 patients requiring invasive 
mediastinal staging and randomly allocated them to undergo mediastinoscopy (21 
patients) or EUS-FNA (19 patients). Negative EUS-FNA results were followed by 
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mediastinoscopy. A negative mediastinoscopy in each arm allowed thoracotomy and 
definitive MLN sampling. The authors showed that only 32% of patients allocated 
EUS required mediastinoscopy (p<0.001). EUS therefore significantly reduced the 
need for mediastinoscopy in patients with NSCLC requiring invasive MLN staging 
(Tournoy et al. 2008). Another randomized study of 104 patients compared 
conventional work-up (CWU) to a strategy where all patients were offered EUS-
FNA in addition to CWU (Larsen et al. 2005). Fifty-one patients underwent CWU 
and 54 patients were allocated to routine EUS-FNA and CWU. The number of futile 
thoracotomies was again chosen as the primary endpoint and defined as an 
exploratory thoracotomy without tumour resection or death or evidence of tumour 
recurrence during follow-up. PET scanning was only available for 30-50% of 
patients. Preliminary results demonstrated that the number of futile thoracotomies 
was 5 (9%) in the routine EUS-FNA group and 13 (25%) in the CWU group (P = 
0.03) after a median follow-up of 1.3 years.  
Unfortunately, in these 2 randomized controlled trials, healthcare costs were not 
reported and patients undergoing mediastinoscopy typically required an overnight 
stay, which is not the current standard of care in the USA. The studies do however 
suggest that EUS-FNA may reduce the number of mediastinoscopies and futile 
thoracotomies in patients requiring invasive MLN staging and further randomized 
studies including healthcare cost analysis are awaited. 
Although randomized controlled trials of unselected patients may provide the highest 
level of evidence for a new procedure (Van den Bruel et al. 2007), cohort studies are 
important to demonstrate efficacy in different situations (Bossuyt, Lijmer, & Mol 
2000). EUS-FNA has been examined in patients as a first test after CT, in patients 
with enlarged or small and PET positive or PET negative mediastinal nodes. Singh 
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and colleagues employed EUS-FNA as a first test after CT scan in 93 patients (Singh 
et al. 2007). By sampling the mediastinum, coeliac axis nodes, left lobe of the liver 
and left adrenal they were able to provide a tissue diagnosis and stage in a single test 
in 70% of cases. They detected metastases to celiac axis nodes in 11% of cases, half 
of which had not been suspected on CT scan. The study also highlighted the 
improved accuracy of EUS-FNA over CT and PET scanning for the detection of 
metastases from lung cancer and the poor prognosis of coeliac axis nodal 
involvement. 
EUS-FNA is able to provide minimally invasive sampling of the posterior areas of 
the mediastinum that cannot be reached by standard mediastinoscopy. Annema et al. 
showed that adding EUS-FNA to routine mediastinoscopy in 100 patients changed 
pre-operative staging in 16% of cases (Annema et al. 2005). In the study, all 80 
patients with negative mediastinoscopy (regardless of EUS-FNA findings) 
underwent thoracotomy and lymph node dissection. Two (7%) false positive results 
from EUS-FNA of subcarinal nodes were identified, assuming these nodes were 
adequately sampled at lymph node dissection.  If EUS is performed after CT, PET 
scan and negative mediastinoscopy, malignant N2/N3 disease may still be detected 
in 37% of patients (Eloubeidi et al. 2005b). EUS-FNA detected metastases in lymph 
nodes inaccessible to mediastinoscopy, re-enforcing the importance of test selection 
based on lymph node distribution seen on non-invasive imaging. 
The size of mediastinal nodes and their avidity for 
18
FDG, as well as their location 
are important determinants of diagnostic yield by EUS-FNA. In patients with 
enlarged lymph nodes seen on CT scan, pooled sensitivity from meta-analysis was 
90% and specificity was 97% (Micames et al. 2007). Several studies have evaluated 
the sensitivity of EUS in patients with no CT evidence of metastatic disease. 
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However, when lymph nodes <1cm are considered, pooled sensitivity drops to 58%, 
with a specificity of 98%. Nonetheless, the detection of mediastinal metastases in 
posterior lymph nodes less than 1cm in short axis on CT scan is an important 
finding. Since posterior lymph nodes are inaccessible to standard mediastinoscopy, 
these patients would have previously undergone futile thoracotomy. 
Several studies have demonstrated the value of EUS-FNA in diagnosing metastases 
in FDG-avid lymphadenopathy. Annema and colleagues (2004) recruited 36 patients 
with FDG avid mediastinal lymph nodes, each of whom underwent EUS-FNA. 
N2/N3 positive disease was diagnosed by EUS-FNA in 25 out of the 36 patients. 
Mediastinal metastases were missed in 1 PET positive and 1 PET negative lymph 
node. The sensitivity, negative predictive value and accuracy of EUS-FNA in this 
small study was 93%, 80% and 94% respectively. Another study based in the 
Netherlands evaluated PET positive lesions in 81 patients with proven or suspected 
lung cancer (Kramer et al. 2004). 50 patients in this trial had a positive diagnosis of 
metastatic disease by EUS-FNA, conferring inoperability. Metastases in 19 patients 
were missed by EUS-FNA and confirmed by surgery or clinical follow-up. However, 
the study showed that EUS-FNA targeting of PET nodes was a cost-effective 
strategy, reducing surgical staging procedures by more than 50% and saving 40% of 
staging costs. The unreliability of negative EUS-FNA samples, however, means that 
surgical staging techniques still have an important role. 
Other studies have compared the performance of CT, PET and EUS-FNA and 
concluded that EUS-FNA has a higher positive predictive value and overall accuracy 
than the other staging modalities (Eloubeidi et al. 2005a;Fritscher-Ravens et al. 
2003). Several studies have also specifically evaluated the ability of EUS-FNA to 
detect metastases in mediastinal lymph nodes < 1cm in short axis (Leblanc et al. 
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2005;Wallace et al. 2004). Their results suggested that metastatic disease could be 
detected in 25% of patients, resulting in a change of management.  However, these 
studies did not employ routine PET scanning as part of their protocol and currently 
the routine deployment of EUS-FNA (or mediastinoscopy) in PET and CT negative 
nodes cannot currently be justified, due to the high negative predictive value of PET 
and CT combined in stage 1 disease. A US study of 153 patients, included 136 
patients thought to have clinical N0 disease and with no evidence of extra-thoracic 
disease (Cerfolio, Bryant, & Eloubeidi 2006). These patients underwent routine 
EUS-FNA and mediastinoscopy, followed by thoracotomy if both were negative. 
The authors found that EUS-FNA and mediastinoscopy detected metastatic 
mediastinal disease in only 3.7% and 2.9% of cases respectively. Unsuspected N2 
disease was found in a further 4.4% of patients at thoracotomy. Therefore, although 
EUS-FNA can detect metastases in MLNs <1cm , it is not required if PET scan 
demonstrates an SUVmax of <2.5. The yield of detection of pre-operative N2 
disease is much higher in patients with clinical hilar (N1) disease at 41% and 
therefore invasive mediastinal staging should currently be advocated for this group 
of patients (Hishida et al. 2008). 
Primary NSCLCs of the left upper lobe have a predilection for metastasis to 
mediastinal lymph nodes in the aorto-pulmonary window (station 5) and para-aortic 
lymph nodes (station 6), often skipping left hilar (N1) nodes (Cerfolio & Bryant 
2006). Although EUS-FNA is often able to sample station 5 nodes, the para-aortic 
area is generally inaccessible to minimally invasive techniques (Figure 1.1). Few 
studies have evaluated the best approach for the mediastinal staging of patients with 
left upper lobe tumours. A retrospective study of 112 patients with suspected 
metastases in lymph node stations 5 or 6 suggested that EUS-FNA had an accuracy 
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of 66%, whereas the preferred staging procedure was left VATS, with an accuracy of 
100% in this group of patients (Cerfolio, Bryant, & Eloubeidi 2007).  
EUS-FNA has been utilized as a tool to determine mediastinal invasion of the 
primary tumour (T4 disease).  In one small retrospective analysis, 3 out of 10 
patients thought to have mediastinal invasion by EUS, were found to have T2 
disease at surgery and underwent successful resection (Varadarajulu et al. 2004). 
Accurately determining mediastinal invasion is of paramount importance as patients 
with T4 (stage IIIB) disease have a five-year survival of less than 5% and are 
generally not offered surgery. Although further data from other centres is required, 
assessing mediastinal invasion by EUS alone cannot currently be advocated due to 
its high false positive rate. 
Employing EUS-FNA in the staging algorithm for NSCLC may represent significant 
healthcare cost-savings by minimizing the number of surgical procedures. Various 
staging strategies have been compared for a hypothetical patient with NSCLC and 
1cm subcarinal lymphadenopathy (Harewood et al. 2002). If the sensitivity of EUS-
FNA exceeded 76% or the probability of the node being malignant was greater than 
24%, EUS-FNA as a first test was the most cost efficient model. Mediastinoscopy, 
PET, CT–guided biopsy, blind TBNA but not endobronchial ultrasound was 
included in the evaluation. Another study demonstrated that EUS in an ambulatory 
setting before mediastinoscopy as an inpatient is a cost effective strategy, even with 
a negative predictive value of EUS-FNA as low as 22% (Aabakken et al. 1999). 
EUS-FNA represents an important advance for the accurate mediastinal staging of 
NSCLC. It is cost efficient and may be a particularly useful method for sampling 
posterior FDG-avid MLN. However, issues around utilization, availability, training 
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and expertise in the procedure remain. A recent survey in the United States 
suggested that over 60% of oncologists felt that EUS would not impact on staging 
NSCLC (Reddy et al. 2008). Furthermore, in centres where EUS was available, less 
than 20% of oncologists would employ the service for lung cancer staging. The 
recent incorporation of EUS-FNA into lung cancer staging guidelines and the 
increased multidisciplinary approach to lung cancer should encourage its uptake. 
 
1.5 ISOLATED MEDIASTINAL LYMPHADENOPATHY 
 
1.5.1    Differential diagnosis and importance of pathological diagnosis 
 
Isolated mediastinal lymphadenopathy refers to enlarged MLNs (≥1cm in short axis) 
in the absence of a lung parenchymal lesion ≥1cm in short axis. In UK clinical 
practice the most common causes are reactive (or anthracotic) lymph nodes, 
sarcoidosis, lung cancer, tuberculosis and lymphoma (Table 1.1).    
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Table 1.1: Causes of isolated mediastinal lymphadenopathy according to disease 
frequency 
 
The differential diagnosis of isolated mediastinal lymphadenopathy 
 
 
Common 
 
Reactive hyperplasia  
Sarcoidosis 
Thoracic malignancy 
Tuberculosis 
Lymphoma 
 
 
 
 
Uncommon 
 
Metastases from extra-thoracic 
malignancy 
Histoplasmosis 
Coccidiodomycosis  
Castleman’s disease 
Angioimmunoblastic lymphadenopathy 
Chronic berylliosis 
Wegener’s granulomatosis 
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Since each of these conditions have different prognoses and treatments it is 
important to differentiate them. Patients with enlarged lymph nodes due to 
sarcoidosis (stages I and II) often have a benign course and occasionally may require 
oral corticosteroid treatment. Patients with tuberculous lymphadenopathy require 
anti-tuberculous chemotherapy and have an excellent outlook. However, those 
patients with enlarged MLNs due to malignancy have a poor prognosis. Metastatic 
spread with incurable disease is implied and treatment is often chemotherapy with 
palliative intent. The exception is lymphoma which may respond satisfactorily to 
chemotherapy and/or radiotherapy. Conversely, reactive lymphadenopathy requires 
no further intervention. The diverse treatments for isolated MLNs highlight the 
importance of establishing an accurate diagnosis. The current available methods for 
the diagnosis of isolated MLNs are discussed below. 
1.5.2 Techniques for the diagnosis of isolated mediastinal 
lymphadenopathy 
 
1.5.2.1 Chest radiograph and Computed tomography scan 
 
On the chest radiograph, the ease with which MLN enlargement can be recognized 
depends on the particular location.  Enlargement of the right upper paratracheal 
nodes causes uniform or lobular widening of the right paratracheal stripe, and an 
increase in density of the superior vena cava of which the border may become 
convex to the lung. Enlarged right lower paratracheal nodes push the azygos vein 
laterally increasing the diameter of the combined opacities of both node and azygos 
arch. Aorto-pulmonary nodes may cause a bulge in the angle between the aortic arch 
and the main pulmonary artery. If they are substantially enlarged, the left upper 
paratracheal nodes induce mediastinal widening. The radiographic features of 
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subcarinal node enlargement include the displacement of the azygo-oesophageal line 
that becomes convex to the lung, an increased opacity of the subcarinal space on the 
posteroanterior film and a lack of visibility of the external surface of the medial wall 
of the intermediate bronchus. Enlargement of the anterior mediastinal nodes may be 
substantial to be visible on the chest films. In such case, mediastinal widening is 
frequently bilateral and lobulated in outline. The radiographic signs of enlargement 
of hilar lymph nodes are hilar enlargement, or a rounded mass in a portion of the 
hilum.  
On CT scan, lymph node enlargement is defined on the basis of a short-axis node 
diameter exceeding 1 cm. A coalescence of enlarged nodes suggests infection, 
granulomatous disease or malignancy. Diffuse mediastinal involvement is more 
typical of lymphoma, large cell undifferentiated carcinoma and acute or chronic 
mediastinitis. Computed Tomography (CT) can also be used to define the density of 
lymph nodes. Enlarged nodes may be calcified, or low in density and necrotic in 
appearance or can enhance following intravenous injection of contrast media. Low 
attenuation lymph nodes after administration of contrast media, with or without rim 
enhancement typically reflect the presence of necrosis. This finding is commonly 
seen in patients with tuberculosis, metastatic carcinoma and lymphoma. Post-
contrast enhancement of enlarged hilar and MLNs may suggest Castleman’s disease, 
angioimmunoblastic lymphadenopathy or vascular metastases in particular from 
renal cell carcinoma. This feature of enhancement may however also be found in 
sarcoidosis and tuberculous lymphadenopathy. Therefore, CT appearances are 
insufficiently specific to allow a definitive diagnosis and pathological diagnosis 
remains necessary. CT does however provide accurate anatomical information and 
acts as a road-map for further investigations. In addition, CT also provides images of 
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the lung parenchyma which may aid in the diagnosis of isolated MLNs. In particular, 
patients with sarcoidosis may have characteristic lung appearances, most commonly 
with small nodules (<1cm) in a perilymphatic distribution and along the fissures. 
1.5.2.2 Positron emission tomography 
 
PET enables detection of MLNs with abnormally high functional activity (e.g. 
tumour metastases), a feature that CT lacks. Because of this advantage and because 
of the limitations of using size criteria with CT to diagnose malignant MLNs, PET 
has superior sensitivity, specificity and accuracy in diagnosing mediastinal 
metastases as compared with CT. However, reactive and inflammatory mediastinal 
lymph nodes especially due to tuberculosis or sarcoid may also be positive on PET 
scanning.  
Scientific data on the role of PET or integrated PET-CT in sarcoidosis is limited. 
One study suggested that the sensitivity of PET in detecting sarcoid was high for 
radiographic stages I and II (where enlarged MLNs are a feature) and may predict 
disease activity and reponse to treatment (Teirstein et al. 2007). However, specificity 
remains low. SUVmax values between 2 and 15 have been reported in MLNs due to 
sarcoid and therefore FDG avid mediastinal lymph nodes are non-specific and 
require pathological diagnosis.  
Functional imaging with 18-FDG PET and integrated PET-CT increase the 
sensitivity and specificity of lymphoma assessment and may also predict outcome 
and direct future therapies (Zinzani et al. 2009). Once again, however there are no 
specific appearances on PET images that will preclude the need for pathological 
diagnosis. Active tuberculosis (TB) infection including asymptomatic and extra-
pulmonary disease may be detected with PET-CT (Hofmeyr, Lau, & Slavin 2007). It 
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may also be a useful tool in the assessment of latent TB, to exclude active disease 
prior to treatment. PET/CT has the potential for monitoring response to anti-
tuberculosis treatment. Metabolic response may also indicate clinical response and 
guide duration of anti-mycobacterial therapy. 
Despite advances in imaging techniques, pathological confirmation of mediastinal 
lymphadenopathy remains necessary.  
1.5.2.1 Mediastinoscopy 
 
Cervical mediastinoscopy is currently considered the best investigation for the 
diagnosis of mediastinal lymphadenopathy. The procedure is performed under 
general anaesthesia and provides access to the upper and lower paratracheal lymph 
nodes and occasionally the anterior subcarinal station. Although rare, complications 
do occur. One percent of patients experience complications including haemorrhage, 
vocal cord dysfunction, tracheal injury and pneumothorax. Mortality rate is 
considered to be 0.1%, usually from damage to major vessels intra-operatively.  
The largest published series of mediastinoscopy examined 2145 procedures over a 
nine year period in a single centre (Lemaire et al. 2006). In patients with lung cancer, 
their false negative rate was 5.5% when the disease prevalence was 23.5%.  
A recent study of 47 patients with isolated MLN examined the diagnostic yield of 
mediastinoscopy and compared it to the clinical diagnosis (McManus et al. 2008). 
The sensitivity and specificity of the pre-operative clinical diagnosis was 87% and 
78% respectively. 1 patient with suspected tuberculosis was revealed to have 
lymphoma on biopsy. Five out of the 12 patients with a pre-operative diagnosis of 
malignancy had a final diagnosis of sarcoidosis. Nine cases of isolated MLN were 
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identified incidentally. Of these, 7 had tuberculosis, 1 sarcoid and 1 non-small cell 
lung cancer. All but one patient had a definitive diagnosis reached at 
mediastinoscopy. 
Another large study of mediastinoscopy for the diagnosis of MLN, prospectively 
evaluated 271 patients with isolated MLN and 127 patients with a pulmonary or hilar 
lesion of unknown aetiology (Porte et al. 1998). Overall there were 17 false negative 
results (4.3%). The sensitivity of mediastinoscopy in patients with isolated MLN was 
96% and in patients with a pulmonary or hilar lesion the sensitivity was 92%. 
Interestingly, 76% of the samples were performed in the right paratracheal lymph 
node station (4R), with 12.5% from the subcarinal lymph node station (7) and 7.8% 
in the left paratracheal lymph node station (4L). There were no deaths and morbidity 
was low (2.25%). Importantly, mediastinoscopy altered the pre-operative suspected 
diagnosis in 74 patients (18.5%). 
Mediastinoscopy therefore offers a sensitive and safe technique for the diagnosis of 
mediastinal lymphadenopathy and is currently considered the gold standard 
investigation. However, several limitations of the procedure must be recognised. 
First, standard cervical mediastinoscopy does not allow complete access to the 
mediastinum. In particular, posterior subcarinal nodes (station 7), the aorto-
pulmonary window (stations 5 and 6) and inferior lymph node stations (stations 8 
and 9) are usually inaccessible to the standard technique. Also, general anaesthesia is 
required and overnight inpatient stay is still necessary in the UK for the majority of 
patients. These latter considerations in addition to surgical time are responsible for 
high healthcare costs associated with the procedure. 
1.5.2.4 Bronchoscopy and transbronchial needle aspiration 
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Standard bronchoscopy is commonly performed for the diagnosis of isolated MLNs. 
During standard bronchoscopy, a dedicated transbronchial aspiration needle is 
introduced into the biopsy channel and blindly punctures the bronchial wall allowing 
the mediastinal lymph node to be aspirated. As discussed above, in patients with 
lung cancer sensitivity is low at 39%, with a false negative rate of 28%, when the 
prevalence of mediastinal metastases was 34% (Holty, Kuschner, & Gould 2005).  
One study has examined the utility of conventional TBNA for the diagnosis of 
isolated MLN (Cetinkaya et al. 2004). TBNA procedures were performed using a 
flexible bronchoscope and a 22-gauge Wang needle in 60 consecutive patients with 
isolated MLN. A diagnosis was reached in 45 of 60 patients (75%). Diagnoses 
included tuberculosis (n=21), sarcoidosis (n=21), carcinoma (n=15), and lymphoma 
(n=3). TBNA had high sensitivity for TB, but diagnosed 1 case (out of 3) of 
lymphoma.  
Several other studies have examined the role of conventional TBNA in patients with 
MLN due to suspected sarcoid and tuberculosis. They have found similar 
sensitivities of the procedure of 75 – 79% (Bilaceroglu et al. 2004;Trisolini et al. 
2008). However, overall, the relatively low diagnostic yield and high negative 
predictive value mean that TBNA is poorly utilized (Haponik & Shure 1997) and 
further tests are commonly necessary in the event of a non-diagnostic or negative 
sample. 
1.5.2.5 Endoscopic ultrasound-guided fine needle aspiration 
 
As discussed above, studies have clearly demonstrated the utility of EUS-FNA in the 
mediastinal staging of NSCLC and data is now emerging on the utility of EUS for 
the diagnosis of sarcoid (Annema, Veselic, & Rabe 2005). In one study, EUS-FNA 
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demonstrated non-caseating granulomas without necrosis in 41 of 50 patients (82%) 
with a final diagnosis of sarcoidosis. Similar high yields were obtained in patients 
with intra-thoracic lymph node tuberculosis (Puri et al. 2010;Song et al. 2010). 
Currently, there are no reports on its value in patients with MLNs due to lymphoma.  
Although EUS-FNA is a promising tool for the diagnosis of isolated MLNs, there 
are several restrictions. EUS cannot sample right-sided or hilar lymph nodes stations 
and these areas are commonly involved in patients with sarcoidosis and tuberculosis 
(particularly 4R). In addition, EUS does not allow visualization of the endobronchial 
tree which may provide additional diagnostic information in patients with 
granulomatous diseases. The equipment and skilled personnel are also not widely 
available and this has meant that EUS (like conventional TBNA) is underutilized for 
the diagnosis of isolated MLN.  
 
1.6. ENDOBRONCHIAL ULTRASOUND-GUIDED TRANSBRONCHIAL 
NEEDLE ASPIRATION 
 
1.6.1 The equipment and procedure 
 
EBUS-TBNA, using a linear echoendoscope, was first described in 2003 (Krasnik et 
al. 2003). The procedure allows TBNA with a 22 or 21-gauge needle under real-time 
ultrasound guidance. This progress in technology allows the respiratory physician 
and thoracic surgeon for the first time to sample the majority of the mediastinum in a 
minimally invasive manner with high sensitivity. Lymph nodes stations 1, 2, 4, 7, 10 
and 11 are readily accessible, representing an increased range compared to standard 
mediastinoscopy. EBUS-TBNA routinely provides samples from the posterior sub-
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carinal space and hilar areas that are out of reach of cervical mediastinoscopy. Nodes 
in stations 5 and 6 as well as the lower paraoesophageal stations (8 and 9) are not 
accessible by EBUS-TBNA. 
Prior to 2003, the procedure was initially performed by placing a catheter with a 
radial ultrasound mini-probe at the tip, in the working channel of the bronchoscope. 
When the lymph node to be sampled had been located, the catheter was withdrawn 
and replaced with a TBNA needle. The lymph node was then sampled blindly with 
TBNA. More recently, an integrated curvilinear ultrasound bronchoscope has been 
developed and allows TBNA under real-time ultrasound guidance (Figure 1.2b). This 
progress in technology allows sampling of the mediastinum in a minimally invasive 
manner with high sensitivity.  
The integrated bronchoscope [Olympus BF-UC160F-OL8, Olympus Medical 
Systems, Tokyo, Japan] has a convex ultrasound transducer at the distal end with a 
7.5Mhz frequency and allows visualization of para-bronchial structures up to a depth 
of 5cm. The outer diameter of the insertion tube is 6.2mm and that of the tip is 
6.9mm. The distal end of the scope can be adjusted 160° upwards and 90° downward 
and the endoscope has a biopsy channel of 2 mm. The fibre-optic lens is oblique 
forward-viewing at 30° and the ultrasound image is in parallel to the scope, with a 
scanning angle of 50°. After intubation with the EBUS scope, a saline-filled balloon 
is inflated to maintain contact with the airway wall. Vascular structures are located 
using the power Doppler. Once the target lymph node is identified on the 
ultrasonography monitor, a dedicated 22 or 21 gauge needle (XNA-202C; Olympus 
Ltd) is inserted into the working channel. The needle can then be observed to pierce 
and enter the lymph node under direct ultrasound vision. Suction is applied and the 
needle is moved to and fro within the lesion. Using this technique, mediastinal 
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lymph nodes as small as 4mm may be sampled. The procedure is carried out in the 
outpatient setting, under conscious sedation. Lymph nodes that may represent N3 
(contralateral mediastinal or hilar) metastases are sampled first, followed by N2 
nodes and finally ipsilateral hilar nodes, so that any contamination will not result in 
false over-staging. A diagnostic plateau is reached after 3 passes per lymph node 
(Lee et al. 2008b).   
Lymph nodes stations 1, 2, 3, 4, 7, 10 and 11 are readily accessible, representing an 
increased range compared to standard mediastinoscopy. EBUS-TBNA routinely 
provides samples from the posterior subcarinal space and hilar areas that are out of 
reach of cervical mediastinoscopy. Previous randomized studies have compared the 
use of the mini-probe ultrasound guided TBNA to the blind technique with 
conflicting results (Herth, Becker, & Ernst 2004;Shannon et al. 1996). Data now 
exists that confirms the theoretical benefit of real-time linear EBUS-TBNA over the 
blind method. A single centre study from the US prospectively examined 138 
consecutive patients with suspected or proven lung cancer (Wallace et al. 2008). 
Each patient sequentially underwent blind TBNA, EBUS-TBNA (and EUS-FNA) 
and 30% of patients in the cohort had mediastinal metastases. The study 
demonstrated that linear real-time EBUS-TBNA had a significantly superior 
sensitivity for detecting mediastinal disease than standard TBNA (69% vs 36%). 
 
1.6.2 Current evidence in the mediastinal staging of non-small cell lung 
cancer 
 
Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) 
may represent a significant advance in the mediastinal staging of NSCLC. To date, 
however there are no completed randomized trials investigating the effects of EBUS-
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TBNA on patient outcome and healthcare costs. An early study of EBUS-TBNA 
from Japan in 2004 demonstrated a sensitivity of 95.7% for MLN involvement in 70 
patients with a prevalence of disease of 67% (Yasufuku et al. 2004). In a large cohort 
of 502 patients from Germany, the US and Denmark, a sensitivity of 93.5% in 502 
patients was observed (Herth et al. 2006a). Meta-analysis of EBUS-TBNA in 1299 
patients from expert centres has demonstrated a pooled sensitivity of 93% (Gu et al. 
2009). Reported complications of linear EBUS-TBNA are rare but include 
pneumothorax requiring intercostal drainage (Bauwens et al. 2008) and an infected 
pericardial space (Haas 2009).  
Given the high diagnostic accuracy, it is a natural progression to compare EBUS-
TBNA to the gold standard of mediastinoscopy. One study has suggested that 
EBUS-TBNA is superior to mediastinoscopy for MLN staging in patients with 
enlarged mediastinal nodes (Ernst et al. 2008). Consecutive patients with suspected 
lung cancer on the basis of clinical and CT findings were included. All patients had 
enlarged mediastinal adenopathy (≥ 10mm in short axis) confined to lymph node 
stations 2, 4 or 7 and data from PET was not available. Cervical mediastinoscopy 
was performed on all patients. EBUS-TBNA was also performed on all patients, 
either as a separate procedure 1 week before or at the same time as mediastinoscopy. 
Surgical lymph node dissection was the diagnostic standard. One hundred and 
twenty mediastinal lymph nodes (in 66 patients) were sampled by EBUS-FNA and 
mediastinoscopy. 7 patients had benign disease and of the remaining 59 patients, 57 
had NSCLC, 1 had small cell lung cancer and there was 1 case of lymphoma. The 
diagnostic yield (combining true positives and true negatives) of EBUS-FNA was 
109/120 (91%). This was statistically superior to the yield from mediastinoscopy 
94/120 (78%) with a P value of 0.007. The observed difference was due to the 
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supremacy of EBUS-FNA over mediastinoscopy for subcarinal nodes and may be 
explained by the fact that posterior subcarinal nodes are beyond the reach of 
mediastinoscopy. Another important finding of this trial was that all positive results 
from EBUS-TBNA were verified by surgical lymph node dissection, confirming a 
specificity of 100% for the technique. 
The false negative (FN) rate from invasive mediastinal tests (EBUS-TBNA, EUS-
FNA, mediastinoscopy) may result from either limitation in mediastinal access or 
sampling error within a lymph node. The FN rate for mediastinoscopy may be 
explained by the fact that only certain MLN stations can be accessed. The technique 
does however provide histological samples, allowing detection of micro-metastases. 
EBUS-TBNA has greater mediastinal (and hilar) access than mediastinoscopy but 
relies on needle aspiration. Sampling error within a MLN may therefore be 
responsible for the FN rate seen with needle aspiration techniques. Up to 25% of 
malignant MLNs may contain metastatic disease in the marginal area of the lymph 
node only, corresponding closely to the FN rate observed in clinical studies. Due to 
this FN rate, negative EBUS-TBNA results (including adequate samples) should be 
investigated further with surgical staging investigations.  
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As with EUS-FNA, EBUS-FNA has been evaluated in specific patient groups. A 
Belgian study looked at 102 patients with NSCLC and FDG-avid MLN (Bauwens et 
al. 2008). They found a prevalence of mediastinal disease of 58% and EBUS-TBNA 
had a sensitivity of 95% with a NPV of 91%. Mediastinoscopy was prevented in 59 
cases and therefore EBUS-TBNA was a highly effective initial alternative to 
mediastinoscopy in patients with PET positive MLNs. 
Yasufuku and colleagues performed CT, PET and EBUS-TBNA on 102 
radiologically operable patients on the basis of CT scan (Yasufuku et al. 2006). They 
found that the sensitivity of CT, PET and EBUS-TBNA for detecting mediastinal 
spread of NSCLC in this context was 76.9%, 80.0%, and 92.3% respectively. This 
illustrates that CT and PET miss mediastinal metastases in patients with clinical 
stage 1 disease and that this disease may be detected by EBUS-TBNA.  
Herth et al. (2006b) examined 100 patients with a radiographically normal 
mediastinum on staging CT scan. Current guidelines do not advocate the use of 
ultrasound guided mediastinal aspiration in patients with MLNs less than 1cm in 
short axis. However, in this study mediastinal metastasis was detected in 1 in 6 
(a) (b) (b) 
Figure 1.2: Endoscopic (a) 
and endobronchial (b) 
ultrasound echoendoscopes 
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patients, with a sensitivity of 92% and NPV of 96%. Furthermore, EBUS-TBNA can 
detect malignancy in 9% of MLNs that are less than 1cm in short axis and negative 
on PET scan with a sensitivity of 89% (Herth et al. 2008). A further 60 patients in 
the study by Wallace et al. (2008)  also were negative on CT and PET. 12 patients 
were found subsequently to have MLN metastases, half of which were detected by 
EBUS-TBNA. Currently, patients with no enlarged MLNs which are also negative 
on PET scan are offered curative surgery or radical radiotherapy, in the absence of 
proven extra-thoracic disease. These studies therefore argue that EBUS-TBNA can 
detect MLN metastases in small nodes and may have an important role in the pre-
operative assessment of patients with NSCLC and may prevent futile thoracotomies. 
In the absence of available cost-effectiveness data and also the variable yield 
associated with blind TBNA, EBUS-TBNA has been slow to be incorporated into 
international diagnostic and staging algorithms for NSCLC, despite advantages over 
other staging modalities (see Table 2). Currently in the US, issues surrounding re-
imbursement and in the UK, a lack of a specific NHS tariff may hinder the uptake of 
EBUS-TBNA. The advent of EBUS-TBNA and EUS-FNA and emerging data 
regarding their use for the MLN staging in NSCLC do however represent a 
significant advance for patients with NSCLC and the multi-disciplinary team 
charged with their care. However, the position of EBUS-TBNA in the diagnostic 
algorithm for NSCLC requires clarification. 
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Table 1.2: Comparison of different techniques for mediastinal lymph node staging in non-small cell lung cancer. Sensitivities from American 
College of Chest Physician Clinical Practice Guidelines (Silvestri et al. 2007; Detterbeck et al. 2007). 
Investigation Sensitivity Specificity Advantages Disadvantages 
Computed 
tomography 
51% 86% Delineates anatomy. 
 
Uses 1cm short-axis cut-off for 
malignancy. 40% of enlarged nodes are 
benign. 20% of normal sized nodes contain 
malignancy. 
Positron emission 
tomography 
74% 85% High negative predictive value for stage 1 
disease. Accurate systemic staging. 
25% false positive rate. Inaccurate in 
lymph nodes >1 cm . 
Transbronchial needle 
aspiration 
78% 99% Cost effective. Allows simultaneous airway 
inspection. 
Variability in results and utilization. 
Usually limited to enlarged nodes in 
stations 4 and 7. 
Mediastinoscopy 78% 100% Considered gold standard. Allows detection of 
micro-metastases and extra-capsular extension. 
Risks of general anaesthesia and surgery. 
Lymph nodes stations 5, 6, 8, 9 and 11 not 
accessible to standard technique. 
Endoscopic ultrasound 84% 99.5% High sensitivity in para-esophageal lymph node 
stations. Access to celiac axis nodes, liver, left 
adrenal gland. Can detect malignancy in normal 
sized nodes. Minimally invasive and 
complimentary to EBUS-TBNA. 
Requires specialized training and 
equipment. Lymph node stations 2R, 4R, 
5, 10 and 11 and endobronchial tree cannot 
be assessed. 
Endobronchial 
ultrasound 
90% 100% High sensitivity for majority of mediastinum. 
Can detect malignancy in normal sized nodes 
and may be easily repeated. Minimally invasive 
and complimentary to EUS-FNA. 
Requires specialized training and 
equipment. Lymph node stations 5, 6, 8 
and 9 cannot be assessed. 
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1.6.3 Current evidence in the diagnosis of isolated mediastinal  lymphadenopathy 
 
Prior to this thesis, the published utility of EBUS-TBNA in the diagnosis of sarcoidosis is 
limited to under 200 patients, which suggest a sensitivity of 85 – 90% (Garwood et al. 
2007;Oki et al. 2007;Wong et al. 2007). One randomised trial has confirmed that EBUS-
TBNA is superior to conventional TBNA in patients with sarcoidosis (Tremblay et al. 2009). 
However, there is only a case report of a diagnosis of tuberculosis with EBUS-TBNA in an 
HIV positive individual (Steinfort et al. 2009) and a just single cohort study of 11 patients 
with lymphoma out of whom a diagnosis was reached in 10 with EBUS-TBNA (Kennedy et 
al. 2008). To date, the role and performance characteristics of EBUS-TBNA for the 
prospective diagnosis of isolated MLNs have not been investigated. 
 
1.7  COMBINING ENDOBRONCHIAL AND ENDOSCOPIC ULTRASOUND 
 
EUS and EBUS provide complimentary access to the entire mediastinum with the exception 
of the station 6 MLN. This combined approach is able to access mediastinal stations beyond 
the scope of mediastinoscopy. Several centres have employed combined EUS-FNA and 
EBUS-TBNA under conscious sedation at the same sitting for minimally invasive 
mediastinal staging in NSCLC. Initial results are encouraging. In one study of 33 patients, 31 
were able to undergo both procedures sequentially under the same sedation (Vilmann et al. 
2005). EBUS-TBNA provided additional information to EUS-FNA and vice versa. Using the 
combined procedure, sensitivity for detecting mediastinal metastases was 100%. Importantly, 
the combined procedure was well tolerated. In addition, EUS-FNA is able to detect extra-
thoracic disease and EBUS allows visualization of the endobronchial tree.  Applying both 
techniques in combination is therefore a very attractive prospect. The European randomized 
ASTER trial comparing EBUS-TBNA and EUS-FNA in a combined procedure (followed by 
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mediastinoscopy if negative) versus mediastinoscopy alone has recently been reported 
(Annema et al. 2010). One hundred and twenty three patients were randomised to the 
endosonography arm and 118 were allocated to the surgical staging arm. The sensitivity of 
endosonography followed by surgical staging (in 65 patients) was 94%, compared to 79% by 
surgical staging alone. The sensitivity of endosonography alone was 85% and was not 
statistically superior to surgical staging alone. There were significantly fewer unnecessary 
thoracotomies in the endosonography group (7% vs. 18%).  
The new standard of re-operative mediastinal staging of NSCLC may therefore be regarded 
as combined endoscopic and endobronchial ultrasound followed by mediastinoscopy if 
endosonography is negative. However, questions linger over the widespread applicability of 
this approach. Currently, resources and expertise in EUS-FNA and EBUS-TBNA are limited, 
particularly outside the US. A further consideration is the healthcare costs of this combined 
methodology, particularly when compared to a radiological or PET targeted approach to the 
mediastinum. Finally, a limitation of the ASTER trial was that data on individual EBUS-
TBNA and EUS-FNA procedures alone was not collected and so it is unknown if similar 
results could have been achieved with EBUS-TBNA or EUS-FNA alone. 
  
58 
 
CHAPTER 2:  
THE LEARNING CURVE FOR ENDOBRONCHIAL ULTRASOUND 
 
2.1 INTRODUCTION 
 
It has been previously recognised that outcomes of complex procedures improve with 
operator experience. This association has been demonstrated in studies involving endoscopic 
ultrasound (EUS).  It has been reported that the sensitivity of EUS-guided aspiration of 
pancreatic masses improves after the first 30 cases (Mertz & Gautam 2004), while assessment 
of the T stage of oesophageal cancer with EUS may require 100 procedures before optimal 
results are achieved (Fockens et al. 1996). As the use of EBUS-TBNA extends to more 
hospitals, the learning curve of the procedure becomes increasingly important for training, 
validation and patient safety. This study reports our learning curve for the application of 
EBUS-TBNA in consecutive unselected patients. 
 
2.2 METHODS 
 
In our institution, a London teaching hospital, EBUS-TBNA has been carried out by two 
respiratory physicians (Neal Navani, Sam M Janes) since February 2008. Both operators were 
proficient in standard bronchoscopy and attended a two day course dedicated to EBUS-
TBNA, but had limited prior experience in conventional TBNA (less than 20 procedures 
each).  All patients had CT scan (or integrated PET-CT) and enlarged (≥1cm in short-axis) 
mediastinal lymph nodes or masses in areas accessible to EBUS-TBNA. Pathological 
evaluation of mediastinal lymph nodes was clinically indicated in all cases, as determined by 
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the referring physician, surgeon or multi-disciplinary team. Lymph node location was 
described according to the Mountain and Dresler  (1997) classification. 
EBUS-TBNA was performed in all cases under conscious sedation with an integrated linear 
ultrasound fibre-optic bronchoscope. In patients requiring mediastinal staging of malignancy, 
N3 nodes were sampled before N2 and then N1 nodes in order to prevent over-staging. In 
cases where endobronchial disease was visible, EBUS-TBNA of enlarged mediastinal / hilar 
lesions was performed with minimal suction before being replaced with a standard 
bronchoscope for sampling of the endobronchial lesion. The colour Doppler function was 
used to confirm the location of vascular structures to be avoided. Once identified, the para-
bronchial lymph node or mass was aspirated with a dedicated 22G fine needle. Each lymph 
node was aspirated 1 to 4 times, depending on the macroscopic appearance of the material 
obtained or the on-site cytopathologist’s evaluation of adequacy, or both. Cytological 
samples were smeared directly onto slides. Any histological specimens obtained were fixed 
in formalin. When available, on-site microscopic evaluation of the cell content of the samples 
was performed using the modified rapid Giemsa stain. 
Ethical approval for this retrospective study was not required due to the observational nature 
of the study. Samples from EBUS-TBNA were judged to be negative when they contained 
lymphoid cells only with no specific pathology, and were referred for surgical sampling 
where possible. The reference standard for negative EBUS-TBNA samples was considered to 
be surgical pathological sampling by mediastinoscopy, VATS, mediastinal lymph node 
dissection at thoracotomy or clinical and radiological follow-up of at least 6 months duration. 
The results of EBUS-TBNA were therefore classified as true positive (TP), true negative 
(TN) or false negative (FN) per patient.  Standard definitions of sensitivity (TP / [TP + FN]), 
specificity (TN / [TN + false positives]), positive predictive value (TP / (TP + false 
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positives]), negative predictive value (TN / [TN + FN]) and accuracy ([TP + TN] / [TP + TN 
+ FP + FN]) were used. 
The results were analysed using cumulative sum analysis (CUSUM) to assess the learning 
curve associated with the procedure (Bolsin & Colson 2000;Wohl 1977). A CUSUM chart 
was created, with an acceptable diagnostic inaccuracy rate of 5% and an unacceptable rate of 
15%. Alert and alarm lines were plotted at 80% and 95% confidence respectively to show 
whether acceptable accuracy rates had been obtained and maintained. So as not to 
overestimate the level of accuracy, patients found to be without disease were excluded from 
this analysis.  
In the CUSUM analysis, a positive result from EBUS-TBNA is s and that of a false negative 
procedure is (1-s). Using the methods described by Bolsin and Colson (2000), the value of s 
was determined by the acceptable and unacceptable failure rates (5% and 20% respectively) 
to be 0.15. The CUSUM graph climbs by s when the success rate is below that expected. 
When the success rate of EBUS-TBNA is below expected, the CUSUM graph climbs by 1-s. 
This means that more than 1 successful procedure is needed to redress the balance following 
a false negative EBUS-TBNA.     
Univariate logistic regression was used to investigate the relationship between lymph node 
size and disease prevalence. A two-sided significance level of 0.05 was used. Analyses were 
carried out using STATA version 10 (Stata Corp., College Station, TX). 
 
2.3 RESULTS 
 
Between February 2008 and November 2008, 120 patients underwent EBUS-TBNA of 136 
nodes. 81 (68%) patients were male and the median age was 64 (range 24 - 88) years.  The 
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indications for EBUS-TBNA and their frequency are listed in Table 2.1, with isolated 
mediastinal lymphadenopathy (in the absence of a known malignancy) being the most 
common indication. No complications of EBUS-TBNA were observed. The diagnoses 
obtained are summarised in Table 2.2. 
Assuming that patients would have been referred for mediastinoscopy in the absence of 
EBUS-TBNA, mediastinoscopies were prevented in 55 (46%) patients. The sensitivity of 
EBUS-TBNA for the overall cohort was 90% with a diagnostic accuracy of 93% and negative 
predictive value of 83% when the disease prevalence was 68%. No false positives were 
observed and therefore the specificity and positive predictive values were 100%.  
In order to assess our learning curve, we separated the cohort into 6 groups of 20 consecutive 
patients each. The sensitivity, accuracy and negative predictive value per group, along with 
mean lymph node size, location and utilisation of on-site cytopathology are shown in Table 
2.3. There was no difference between the groups for lymph node size, location, number of 
passes and number of patients with on-site cytopathological evaluation. There was no 
significant difference in sensitivity or accuracy between any of the groups. A CUSUM 
analysis (Figure 2.1) indicated no significant learning curve, with a high level of accuracy 
obtained from the initial patients. The chart shows a very slight learning curve over the first 
twenty patients – although levels of accuracy never approach unacceptable levels – but after 
this, accuracy of at least 90% is observed over the whole series, and no periods of poor 
performance were identified. The right paratracheal (station 4R) and subcarinal (station 7) 
lymph node areas were the most frequently sampled. However, sensitivity and accuracy did 
not depend upon lymph node location. The size of mediastinal lymph nodes was noted to be 
significantly associated with disease prevalence (Table 2.4), with lymph node size being 
highly significant (p-value <0.001) in the logistic regression.  
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Table 2.1 Indications for EBUS-TBNA 
Indication Number of procedures (%) 
Mediastinal staging of known or 
suspected lung cancer 
42  (35) 
Para-bronchial mass 13  (11) 
Isolated mediastinal lymphadenopathy 53  (44) 
Re-staging following chemotherapy 3  (3) 
Suspected metastases of extra-
pulmonary malignancy 
9 (8) 
 
Table 2.2: Diagnoses by EBUS-TBNA 
Diagnosis 
 
Number (%) 
Reactive, anthracotic or normal 
lymph node 
38 (32) 
Non-small cell lung cancer 37 (31) 
Sarcoidosis 17 (14) 
Tuberculosis 11 (9) 
Small cell lung cancer 9 (8) 
Breast cancer 3 (3) 
Colorectal carcinoma 2 (2) 
Lymphoma 1 (1) 
Oesophageal carcinoma 1 (1) 
Endometrial carcinoma 1 (1) 
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Table 2.3: Sensitivity, negative predictive value and diagnostic accuracy of EBUS-TBNA according to operator experience 
Group Patient 
number 
Sensitivity 
(%) 
NPV 
(%)* 
Accuracy (%) Disease prevalence 
(%) 
Mean lymph 
node size (mm) 
Number of patients with on-
site evaluation of samples 
1 1 – 20 90 91 95 50 18 5 
2 21 – 40 85 78 90 65 19 2 
3 41 – 60 94 75 95 85 21 8 
4 61 – 80 86 75 90 70 22 0 
5 81 – 100 86 75 90 70 22 3 
6 101 – 120 100 100 100 70 18 5 
Overall  90 83 93 68 20 23 
 
NPV - Negative Predictive Value 
64 
 
Table 2.4: Disease prevalence and diagnostic accuracy varies according to lymph node size 
 
Lymph node size No of patients Disease prevalence 
(%) 
Sensitivity (%) Negative predictive 
value (%) 
≤15mm 50 45 79 85 
16 -  20mm 18 56 100 100 
21 – 25mm 19 94 100 100 
>25mm 33 93 93 50 
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Figure 2.1: CUSUM chart of the learning curve for EBUS-TBNA. 
 
CUSUM chart of the learning curve of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) at University 
College London Hospital using an acceptable false-negative rate of 5% and an unacceptable rate of 20%. Internationally recognised 
standards were achieved after 20 cases.
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2.4 DISCUSSION 
 
The results of this study suggest that there is no significant learning curve for 
performing EBUS-TBNA and high standards of sensitivity and diagnostic accuracy 
can be reached after only 20 patients. These results should provide an impetus for 
centres that currently do not perform TBNA to consider EBUS-TBNA given its clear 
advantages over other modalities for the diagnosis of mediastinal lymphadenopathy 
(MLN).  
 
First, EBUS-TBNA provides a greater range of access to the mediastinum than other 
invasive modalities. Lesions adjacent to the main airways and MLN in the upper and 
lower paratracheal regions, subcarinal area and hilar lymph node stations are 
sampled with EBUS-TBNA. Endoscopic ultrasound guided fine-needle aspiration 
(EUS-FNA) provides samples from left-sided and posterior MLNs due to the 
anatomical location of the oesophagus, while cervical mediastinoscopy allows direct 
vision and biopsy of anterior and superior lymph nodes. Notably, standard 
mediastinoscopy cannot visualise the posterior subcarinal space nor the hilar lymph 
nodes. 
 
A second advantage of EBUS-TBNA over mediastinoscopy is that general 
anaesthesia is not required. In this study, the procedure was carried out under 
conscious sedation in all patients, using titration of intravenous midazolam and 
fentanyl. No complications related to sedation or the procedure were observed in this 
cohort. Reports of a pneumothorax requiring intercostal drainage in one patient 
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(Bauwens et al. 2008) and post-procedure infectious complications in two patients 
(Haas et al. 2009) have been documented following linear EBUS-TBNA. However, 
mediastinoscopy is associated with an important but small morbidity and mortality 
(<1%) (Lemaire et al. 2006). 
A further advantage of EBUS-TBNA is that it may be easily combined with other 
procedures to maximize diagnostic information at the same sitting. In cases of lung 
cancer, following mediastinal lymph node sampling with EBUS-TBNA, the scope 
may be replaced with a standard videobronchoscope for careful inspection of the 
airways and sampling of the primary tumour. In cases of suspected sarcoid, 
transbronchial biopsy may also be performed. By combining EBUS-TBNA with 
EUS-FNA it is possible to sample the entire mediastinum with the exception of the 
para-aortic lymph node station. Previous studies have shown this to be a feasible 
prospect (Vilmann et al. 2005; Wallace et al. 2008). More recently, it has been 
suggested that the EBUS scope may be placed in the oesophagus (after the 
pulmonary route has been utilised in the interests of hygiene) to allow more 
convenient access to left paratracheal lymph nodes, the posterior subcarinal area and 
lower paraoesophageal mediastinal nodes (Hwangbo et al. 2009).  
 
American college of chest physician guidelines (referring to the radial miniprobe 
technique of EBUS) suggest that practioners should perform at least 50 EBUS-
TBNA procedures in a supervised setting to establish competency (Ernst, Silvestri, 
& Johnstone 2003). The joint ERS/ATS statement also suggests a long learning 
curve for EBUS (Bolliger et al. 2002). However, in addition to the current study, a 
previous report from a thoracic surgical unit suggested a considerably shorter 
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learning period for linear real-time EBUS-TBNA (Groth et al. 2008). In that study 
however, all procedures were performed via an endo-tracheal tube under general 
anaesthesia, on-site evaluation of samples was utilised for every case and lymph 
node size was not reported. The current data are also consistent with the opinion of 
Sheski and Mathur (2008) who suggested approximately 20 procedures are required 
to achieve competence. Analyses of a learning curve for conventional TBNA have 
provided conflicting evidence. Traditionally, TBNA was thought to have a protracted 
training period (Hsu et al. 2004) that in part was responsible for poor uptake of the 
procedure. However, a more recent report has suggested that the learning curve for 
conventional TBNA has been exaggerated (Hermens et al. 2008). The EBUS-TBNA 
operators in this study (NN, SMJ) had limited experience in conventional TBNA and 
therefore proficiency in conventional TBNA does not appear to be a pre-requisite for 
EBUS-TBNA. 
 
Several factors may comprise the learning process in EBUS-TBNA. Initially, 
manipulation of the EBUS scope requires practice as the viewing angle is 30 degrees 
oblique to the direction of the scope. Interpretation of the ultrasound image, 3-
dimensional knowledge of the mediastinal anatomy in different planes to CT scans 
and operation of the dedicated TBNA needle are also skills that need to be acquired. 
However, attendance at an EBUS course followed by cases performed in an auto-
educational setting allow the experienced bronchoscopist to be proficient in EBUS-
TBNA after a relatively few cases. The preparation and interpretation of cytology 
specimens are similar to other samples already obtained in secondary care (e.g. 
bronchial brushings smeared onto slides) and therefore their analysis is not 
associated with a learning curve.   
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Correct interpretation of the results from EBUS-TBNA is important. This study 
highlights that larger mediastinal nodes have higher disease prevalence and therefore 
a lower negative predictive value is expected when sampling enlarged lymph nodes. 
In a meta-analysis of 918 patients who underwent EBUS-TBNA, the pooled negative 
predictive value for the cohort was 80%, when the disease prevalence was 68% 
(Detterbeck et al. 2007). It is therefore recommended that negative (as well as 
inadequate) samples from EBUS-TBNA of MLNs should be invasively sampled 
again by EUS-FNA or mediastinoscopy. The interpretation of positive results is 
subject to review at the multi-disciplinary meeting. No false positive results have 
been observed in ours or other studies (Ernst et al. 2008; Herth et al. 2008). 
 
Several limitations of the data must be recognised. Lymph nodes less than 1cm in 
short-axis on CT scan were excluded from the learning curve period of the study. 
Since smaller nodes have lower disease prevalence, it may be expected that 
sensitivity of the procedure may fall. This may be avoided in cases of NSCLC by 
employing FDG PET-CT scanning prior to EBUS-TBNA and aspirating those <1cm 
nodes that are FDG avid, in addition to all other nodes that are ≥1cm in short axis, 
regardless of FDG-avidity. Although the study is retrospective, a dedicated database 
was set-up prior to the first case and data was entered prospectively. The study also 
represents the experience of a single centre and 2 operators. However, patients were 
consecutive and unselected and therefore not subject to selection bias and represent 
real clinical practice. 
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The indications for EBUS-TBNA are increasing and the evidence to support its use 
has is gathering. As well as the mediastinal staging of NSCLC, EBUS-TBNA is 
likely to gain prominent roles in the diagnosis of para-bronchial lesions, isolated 
mediastinal lymphadenopathy due to sarcoid and tuberculosis and also restaging of 
the mediastinum following treatment of NSCLC. As further supporting data 
emerges, it is likely that the use of EBUS-TBNA will increase. A growing number of 
physicians will consider using EBUS and this study demonstrates that the use of 
EBUS-TBNA by experienced bronchoscopists is associated with a short learning 
curve of less than 20 patients. 
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CHAPTER 3:  
COMBINATION OF ENDOBRONCHIAL ULTRASOUND-
GUIDED TRANSBRONCHIAL NEEDLE ASPIRATION WITH 
STANDARD BRONCHOSCOPIC TECHNIQUES IN PATIENTS 
WITH STAGE I AND II SARCOIDOSIS 
 
3.1 INTRODUCTION 
 
A pathological diagnosis of sarcoidosis is required in patients to exclude other 
differential diagnoses and to justify the use of immunosuppressive treatment. It may 
only be avoided in patients with clear evidence of bilateral hilar lymphadenopathy on 
chest radiograph, arthritis and erythema nodosum - Loefgren’s syndrome (Iannuzzi, 
Rybicki, & Teirstein 2007). In patients with enlarged intra-thoracic lymph nodes due 
to suspected sarcoidosis, other diagnoses such as tuberculosis and malignant 
disorders must be excluded.  
Pathological confirmation of pulmonary sarcoidosis is most commonly 
accomplished with flexible bronchoscopy which has a yield of approximately 70%, 
with higher yields obtained in patients with more advanced radiographic stages 
(Bilaceroglu et al. 1999). Flexible bronchoscopy under conscious sedation permits 
transbronchial needle aspiration (TBNA) and transbronchial lung biopsy (TBLB). 
Additional endobronchial biopsy (EBB) is also routinely recommended in addition, 
and may demonstrate non-caseating granulomas even when no endobronchial 
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disease is evident (Shorr, Torrington, & Hnatiuk 2001). Despite combining TBLB 
and EBB approximately one-third of bronchoscopies do not provide a diagnosis of 
sarcoidosis.  
Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) is 
gaining momentum as an important new technique for the diagnosis of enlarged 
lymph nodes due to sarcoidosis. Recent randomised data have demonstrated its 
superiority to conventional TBNA with a 19 gauge needle in the diagnosis of 
pulmonary sarcoidosis (Tremblay et al. 2009). Cohort studies of highly selected 
patients with radiographic stage I and II sarcoidosis and high disease prevalence 
(>90%) suggest sensitivities of between 85 and 93% (Wong et al. 2007; Oki et al. 
2007; Garwood et al. 2007; (Nakajima et al. 2009).  
No data is currently available on the safety and efficacy of combining the standard 
bronchoscopic techniques of TBLB and EBB with EBUS-TBNA for the diagnosis of 
sarcoidosis. We hypothesised that the diagnostic yield from the combination of 
EBUS-TBNA and standard bronchoscopy carried out under the same conscious 
sedation would be higher than with standard bronchoscopy alone. A prospective 
study was therefore conducted to evaluate the safety and diagnostic yield from 
EBUS-TBNA, TBLB, EBB and their combination in consecutive patients with 
enlarged intra-thoracic lymph nodes due to suspected sarcoidosis.  
 
3.2 METHODS 
 
3.2.1 Patients 
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Consecutive patients with enlarged intra-thoracic lymph nodes (≥1cm in short-axis) 
and suspected sarcoidosis were recruited between August 2008 and July 2009 at 
University College London Hospital, a tertiary London teaching hospital. Informed 
written consent was obtained from all patients and the institutional review board 
approved this prospective study. In all patients, pathological confirmation was 
clinically required to exclude other diseases or to support systemic treatment of 
sarcoidosis. All patients underwent chest X-ray, computed tomography (CT) or 
positron emission tomography (PET) scanning and on the basis of the clinical 
scenario and radiology were suspected to have stage I or II sarcoidosis (Figure 3.1a).  
Lymph node location was described according to the American Thoracic Society 
lymph node map proposed by Mountain and Dresler (1997). Patients underwent 
sequential EBUS-TBNA followed by TBLB and EBB under conscious sedation with 
midazolam and fentanyl and topical anaesthesia with 2 and 4% lidocaine. All 
procedures were conducted in the ambulatory care setting without the presence of an 
anaesthetist. In all cases, EBUS-TBNA was performed prior to standard 
bronchoscopy in order to avoid airway contamination following TBLB and EBB. 
 
3.2.2 EBUS-TBNA procedure 
 
An integrated linear ultrasound fibre-optic bronchoscope was used (BF-UC160F-
OL8, Olympus, Tokyo), which scans in a direction parallel to the insertion of the 
bronchoscope. The scope offers endobronchial views (at a 35 degree forward oblique 
angle) and when in contact with airway wall, the 7.5MHz convex ultrasound 
transducer provides imaging of parabronchial structures (figure 3.1b). A balloon may 
be inflated around the tip of the scope in order to maintain contact with the airway 
wall. Once the target lymph node has been located (and vascular structures excluded 
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with the Doppler function) a compatible 22 or 21 gauge needle is placed in the 
working channel of the EBUS scope. The tip of the sheath of the needle is seen on 
the endobronchial view, and then the needle is allowed to pierce the airway wall and 
enter the lymph node using the jabbing technique under direct ultrasound guidance 
(figure 3.1b). Suction is applied and the needle is moved to and fro within the lymph 
node. A minimum of 4 passes per node were performed, in accordance with previous 
data (Garwood et al. 2007). Samples were smeared directly onto slides and air-dried 
before being transferred to the laboratory for cytological analysis. If histological 
cores were obtained these were placed in formalin. On site evaluation of samples 
was not employed. 
 
3.2.3 Standard bronchoscopic procedure 
 
After the EBUS scope was withdrawn, it was immediately replaced with a standard 
flexible videobronchoscope. Further topical lidocaine was applied when required. 
TBLB was performed from the lobe that was demonstrated to be abnormal on 
imaging. In patients with normal lung parenchyma (stage 1 sarcoidosis) TBLB was 
performed from the most convenient location at the operator’s discretion. At least 4 
TBLBs per patient were performed in order to maximize diagnostic tissue as 
recommended by current guidelines (Bradley et al. 2008). Fluoroscopy was not 
utilised and all TBLBs were carried out by experienced bronchoscopists (NN and 
SMJ) who each perform more than 100 bronchoscopies per year. After the 
completion of TBLBs, EBBs were performed. Areas of endobronchial cobblestoning 
were sampled preferentially. Where no endobronchial macroscopic abnormalities 
were evident an area chosen to be suitable by the operator was biopsied. At least 4 
75 
 
EBBs were obtained to maximize diagnostic yield. Broncho-alveolar lavage was also 
performed in selected cases depending upon the clinical scenario. All patients 
underwent routine post-procedure chest radiograph in order to detect pneumothorax. 
 
3.2.4 Diagnostic criteria for sarcoidosis 
 
Non-caseating granulomas on cytology (Figure 3.1c and 3.1d) or histology with 
negative mycobacterial and fungal cultures in the absence of malignancy were 
deemed to be consistent with sarcoidosis. All patients were followed up clinically 
and radiologically for at least 6 months. The reference standard for negative EBUS-
TBNA samples was considered to be surgical pathological sampling by 
mediastinoscopy, VATS, mediastinal lymph node dissection at thoracotomy or 
clinical and radiological follow-up of at least 6 months duration. The results of 
EBUS-TBNA, TBLB and EBB were each classified as true positive (TP), true 
negative (TN) or false negative (FN) per patient. 
 
3.2.5 Statistical analysis 
 
We used standard definitions of sensitivity (TP / [TP + FN]), specificity (TN / [TN + 
FP]), positive predictive value (TP / (TP + FP]), negative predictive value (TN / [TN 
+ FN]) and accuracy ([TP + TN] / [TP + TN + FP + FN]). The unit of analysis was 
the patient. Comparison of yield from diagnostic modalities was carried out using the 
chi-squared test or Fischer’s exact test. A p value of <0.05 was taken to denote 
statistical significance. 
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3.3 RESULTS 
 
Forty consecutive patients with suspected sarcoidosis were scheduled to undergo 
EBUS-TBNA, TBLB and EBB. 22 patients were male and mean age was 46 years 
(range 19 - 68). On radiological grounds, 27 patients were considered to have stage I 
sarcoidosis, while 13 patients were considered to have stage II sarcoidosis. Thirty-
four patients had symptoms of cough, fevers or weight loss. Six patients were 
asymptomatic but required a tissue diagnosis due to immunosuppression for another 
disorder, infection with the human immunodeficiency virus or prior malignancy. 
Patient characteristics are summarised in Table 3.1. 
Thirty-nine patients had sequential EBUS-TBNA, TBLB and EBB under conscious 
sedation. One patient was unable to undergo standard bronchoscopy following 
EBUS-TBNA due to intolerance of sedation. Total procedure time ranged from 40-
55 minutes. Overall, 27 patients were diagnosed with sarcoidosis, 8 had TB, 2 had 
reactive lymphadenopathy, 2 had lymphoma (diagnosed on EBUS-TBNA and 
confirmed on bone marrow biopsy) and 1 had metastatic adenocarcinoma (Figure 2). 
All patients were followed up for at least 6 months duration and reviewed in a multi-
disciplinary setting. No false positive results were obtained. 71 nodes in 40 patients 
were sampled with EBUS-TBNA with a median of 4 passes per lymph node (range 
3-5). All patients had enlarged lymph nodes sampled in stations 4, 7 or 10. The mean 
size of the lymph nodes sampled was 24 mm (range 10 - 45mm). The sensitivity of 
EBUS-TBNA for obtaining non-caseating granulomas in patients with sarcoidosis 
was 85% (23/27). The sensitivity of standard bronchoscopic techniques alone was 
significantly lower at 35% (9/26) (p<0.001). Yield per procedure according to stage 
of sarcoidosis is summarised in Table 3. There was no significant difference in 
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diagnostic yield with EBUS-TBNA between stage I and II sarcoidosis. However, the 
sensitivity of standard bronchoscopic techniques was significantly higher in stage II 
(78%) versus stage I (12%) disease (p=0.001). 
In patients with negative EBUS-TBNA, non-caseating granulomas were obtained by 
TBLB of radiologically normal lung parenchyma in one patient and EBB of normal 
appearing endobronchial mucosa in one patient. The sensitivity of combined EBUS-
TBNA and standard bronchoscopic techniques for the diagnosis of sarcoidosis was 
93% (25/27) and was significantly higher than standard bronchoscope techniques 
alone (p<0.0001). Overall diagnostic accuracy for EBUS-TBNA in the cohort was 
88% (35/40) and the combination of EBUS-TBNA with standard bronchoscopic 
techniques had a diagnostic accuracy of 93% (37/40). One patient experienced a 
pneumothorax, requiring overnight admission but not intercostal drainage. 
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Table 3.1 – Characteristics of patients with suspected sarcoidosis undergoing EBUS-
TBNA and bronchoscopy 
 
Age range  19 – 68 
Gender Male 22 
 Female 18 
Ethnicity African or Caribbean 11 
 Asian 2 
 Caucasian 27 
Symptoms Cough 29 
 Fevers 5 
 Weight loss 7 
 Asymptomatic 6 
Lymph node 
stations sampled 
with EBUS-
TBNA 
4R 21 
 4L 3 
 7 35 
 10R 10 
 10L 2 
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Table 3.2: Diagnostic yield of endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA), standard bronchoscopy 
and their combination according to stage of sarcoidosis 
 
 Number of patients with positive diagnostic yield (%) 
EBUS-
TBNA 
Transbronchial 
lung biopsy 
(TBLB) 
Endobronchial 
biopsy (EBB) 
Standard 
bronchoscopy – 
TBLB and EBB 
Combined 
EBUS-TBNA + 
standard 
bronchoscopy 
Stage 1 
sarcoidosis 
(n=18) 
16 (89%) 2 (12%)* 0 (0%)*  2 (12%)* 17 (94%)* 
Stage 2 
sarcoidosis (n=9) 
7 (78%) 6 (67%) 3 (33%) 7 (78%) 8 (89%) 
Overall (n=27) 23 (85%) † 8 (31%) 3 (11%) 9 (35%)* 25 (93%) †† 
 
*One patient with stage I sarcoidosis did not undergo standard bronchoscopy after EBUS-TBNA.† p<0.001 for the comparison of yields 
from EBUS-TBNA versus standard bronchoscopy. †† p<0.0001 for the comparison of yields from combined EBUS-TBNA and 
standard bronchoscopy versus standard bronchoscopy alone. 
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Figure 3.1 
 
L
N 
Needle 
a b 
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Figure 3.1a: Computed tomography with contrast image of enlarged bilateral 
hilar and subcarinal lymphadenopathy due to sarcoidosis. 
Figure 3.1b: Endobronchial ultrasound image demonstrating transbronchial 
needle aspiration of lymph node with a 22 gauge needle. LN – lymph node. 
Figure 3.1c: Non-caseating granuloma (low power, May-Grunwald-Giemsa 
stain) consistent with sarcoidosis obtained via endobronchial ultrasound guided 
transbronchial needle aspiration. 
Figure 3.1d: Multi-nucleate giant cell (high power, May-Grunwald-Giemsa 
stain) obtained via endobronchial ultrasound guided transbronchial needle 
aspiration 
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Suspected sarcoidosis stages I 
and II (n= 40) 
 
EBUS-TBNA + TBLB + 
EBB (n=40)
* 
 
 
Sarcoidosis 
(n=25) 
Lymphoma 
(n=2) 
Tuberculosis 
(n=7) 
Carcinoma 
(n=1) 
No diagnosis 
obtained (n=5) 
Clinical Follow-
up (n=3) 
Mediastinoscopy 
(n=2) 
Reactive 
lymphadenopathy 
(n=1) 
Tuberculosis 
(n=1) 
Reactive 
lymphadenopathy 
(n=1) 
Sarcoidos
is (n=2) 
*
1 patient was unable to undergo standard bronchoscopy after EBUS-TBNA 
 
Figure 3.2: Flowchart of 
patients with suspected 
sarcoidosis 
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3.4 DISCUSSION 
 
In this prospective cohort study of patients with suspected sarcoidosis, combining 
EBUS-TBNA with standard bronchoscopic techniques optimised diagnostic yield 
and resulted in a higher diagnostic accuracy than bronchoscopy alone. Thirty-nine 
out of 40 patients were able to undergo the combined procedure under conscious 
sedation. The current British Thoracic Society guidelines (Bradley et al. 2008) do not 
mention the utility of EBUS-TBNA in the diagnosis of sarcoidosis. However this 
study provides further evidence that EBUS-TBNA is an important minimally 
invasive approach that may be combined with standard bronchoscopy and considered 
a first line investigation in patients with suspected sarcoidosis.  
 
Forty patients with suspected sarcoidosis were enrolled into this study. Of these, 
only 27 were finally diagnosed with sarcoidosis while 8 patients were identified to 
have tuberculosis (Figure 3.2). This discrepancy illustrates the inaccuracy of clinical 
diagnosis and the benefit of obtaining a tissue diagnosis for these patients, 
particularly in tuberculosis endemic areas. This data is in contrast to previous cohort 
reports of patients with suspected sarcoidosis where the disease prevalence was 93% 
– 98% in whom the necessity for pathological diagnosis is questioned. Prior analysis 
of asymptomatic patients with presumed stage I sarcoidosis suggested invasive 
sampling was not required due to the low probability of detecting alternative 
diagnoses (Reich et al. 1998). This paradigm may however not be justified in 
tuberculosis and HIV prevalent regions. 
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A further area of controversy is the use of cytology from lymph node aspirates to 
determine a reliable diagnosis of sarcoidosis. Non-caseating granulomas have been 
observed in mediastinal lymph nodes as a reaction to malignancy or anthracotic 
pigment. However the presence of giant cells is thought to be specific for a true 
granulomatous disorder. Given that non-caseating granulomas may be observed in 
both tuberculosis and sarcoidosis, and Langhans type giant cells, although 
characteristic of tuberculosis, are not always easy to identify, a diagnosis of 
sarcoidosis is often made by exclusion. Additional histological material 
demonstrating non-caseating granulomas from TBLB or EBB add considerable 
weight to a diagnosis of sarcoidosis, whereas microbiological investigations of 
lymph node aspirate or broncho-alveolar lavage may confirm tuberculosis. In all 
cases, the pathological findings should be interpreted within the clinical context. 
 
In this study, the sensitivity of standard bronchoscopic techniques of TBLB and EBB 
for the diagnosis of sarcoidosis was 35%. This is considerably lower than 70% 
previously reported in retrospective series. The operators in the current study were 
highly experienced in TBLB and EBB and an appropriate number of specimens were 
obtained in each case as recommended by current guidelines (Bradley et al. 2008). 
An explanation for the apparent discrepancy is that 67% patients in this cohort had 
radiographic stage I sarcoidosis with enlarged intra-thoracic lymphadenopathy only. 
The prevalence of parenchymal and endobronchial disease in this group of patients is 
lower than in higher radiographic stages resulting in a lower diagnostic yield for 
standard bronchoscopic procedures. A high diagnostic rate from standard 
bronchoscopic techniques was obtained in the 9 patients with stage II disease (78%). 
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In this subgroup there was no statistically significant benefit from the addition of 
EBUS-TBNA although this analysis is underpowered to draw further conclusions.  
 
The sensitivity of EBUS-TBNA in this study (85%) is consistent with previous data. 
To date, the largest published study of patients with suspected sarcoid was 
completed in expert EBUS centres in Japan, Hong Kong and Germany (Wong et al. 
2007). EBUS-TBNA was performed on 65 patients, 61 of whom had sarcoidosis. 
The sensitivity for the procedure was 92%. A recent retrospective study has 
compared EBUS-TBNA, TBLB and BAL in thirty-eight patients (Nakajima et al. 
2009). Of these, 35 patients were diagnosed with sarcoidosis (31 stage I and 4 stage 
II). As observed in the current study, the sensitivity was higher for EBUS-TBNA 
(90.3%) than for TBLB (40%). The authors of the retrospective study did not 
however include EBB and therefore may have underestimated the diagnostic yield 
from bronchoscopy. 
 
Conventional TBNA without EBUS guidance was not employed in this study. 
However, yield from conventional TBNA in practice has been variable and in a 
recent randomised trial the sensitivity of conventional TBNA (using a 19G needle) in 
patients with suspected sarcoidosis and enlarged intra-thoracic lymph nodes was 
53.8% (Tremblay et al. 2009). This was significantly inferior to the yield from 
EBUS-TBNA (83.3%). Therefore the addition of conventional TBNA is unlikely to 
have improved the overall sensitivity. 
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In this study, despite the small sample size, a statistically reliable effect from the 
addition of EBUS-TBNA to standard bronchoscopic techniques was observed. The 
results reflect a single centre experience with a relatively high number of EBUS-
TBNA procedures (>200) performed each year after a learning curve for EBUS-
TBNA was completed. The patients were unselected and consecutive and reflect 
clinical practice. Of note, the additional role of EBUS-TBNA in patients with 
suspected sarcoidosis stages III and IV cannot be extrapolated from these results and 
requires further clarification. Since these radiographic stages are not associated with 
enlarged lymph nodes, it is likely that the benefit of additional EBUS-TBNA 
samples in these patients will be lower.  
 
3.5 CONCLUSION 
 
Combining EBUS-TBNA with standard bronchoscopic techniques is a safe and 
feasible procedure and optimizes the diagnostic yield in patients with pulmonary 
sarcoidosis and enlarged intra-thoracic lymph nodes. EBUS-TBNA in combination 
with standard bronchoscopy may be considered a new first-line investigation in 
patients with suspected sarcoidosis and enlarged intra-thoracic lymphadenopathy.  
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CHAPTER 4: 
THE UTILITY OF ENDOBRONCHIAL ULTRASOUND-
GUIDED TRANSBRONCHIAL NEEDLE ASPIRATION IN 
PATIENTS WITH TUBERCULOUS INTRA-THORACIC 
LYMPHADENOPATHY 
 
4.1 INTRODUCTION 
 
The global threat of tuberculosis (TB) remains undiminished with the World Health 
Organization (WHO) estimating there were 9.4 million incident cases worldwide in 
2009 (World Health Organisation 2010a). The incidence in the UK has risen year on 
year over the last 2 decades, and this trend continued in 2009 with a 4.2% rise. 
Successful chemotherapy requires a combination of drugs for at least six months, but 
this may need to be substantially increased if resistance to the first line agents is 
present. Indeed, the emergence of drug resistant, multi-drug resistant and extremely-
drug resistant (XDR) TB over the last 20 years has emphasised the importance of 
establishing the correct diagnosis and drug susceptibilities of the mycobacterium 
before starting anti-tuberculous therapy(World Health Organisation 2010b). 
While the number of pulmonary tuberculosis cases has fallen in many developed 
countries over recent years the notification of extra pulmonary disease has increased. 
In both the United States and United Kingdom tuberculosis lymphadenitis (TBLA) is 
the commonest extra-pulmonary manifestation amongst all ethnic groups (Fiske et 
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al. 2010). Mediastinal TBLA represented 9% of cases reported in the UK in 
2009(Health Protection Agency 2010) and presents significant diagnostic challenges. 
Clarifying the aetiology of isolated mediastinal lymphadenopathy is essential to 
exclude alternative diagnoses such as lymphoma, carcinoma and sarcoidosis. 
However the lack of specific clinical and radiological features necessitates 
pathological or microbiological diagnosis whenever possible. Mediastinal lymph 
node sampling is commonly performed by conventional transbronchial needle 
aspiration (TBNA), endoscopic ultrasound guided fine needle aspiration or 
mediastinoscopy. 
Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) 
has now emerged as an important tool for the diagnosis of mediastinal and hilar 
lymphadenopathy. In addition to the nodal stations accessible by conventional 
TBNA, EBUS guidance also allows safe aspiration of hilar nodes and nodes less 
than 10mm.  In patients with lung cancer and sarcoidosis, EBUS-TBNA has been 
shown to increase the yield and sensitivity when compared to standard 
bronchoscopic techniques including conventional TBNA (Wallace et al. 2008; 
Tremblay et al. 2009). However, the role of EBUS-TBNA in the diagnosis of 
tuberculous intra-thoracic lymphadenopathy has not been established. This multi-
centre study, for the first time, describes the diagnostic utility of EBUS-TBNA for 
the diagnosis of intra-thoracic tuberculous lymphadenopathy.   
 
4.2 METHODS 
 
4.2.1 Patients 
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Consecutive patients with intra-thoracic lymph node tuberculosis who were referred 
for EBUS-TBNA were included in this study. A final diagnosis of intra-thoracic 
tuberculosis lymphadenitis was confirmed by positive pathology, microbiology or an 
unequivocal clinical and radiological response to anti-tuberculous therapy at least 6 
months after presentation by the referring physician. Patients were excluded if 
sputum or bronchial washings were positive for acid fast bacilli on either smear or 
culture prior to EBUS-TBNA, or if the diagnosis was available from sampling of 
extra-thoracic disease. Demographic data and HIV status were recorded. All patients 
were followed up for at least 6 months. The participating centres were University 
College Hospital (London), St Mary’s Hospital (London), Guy’s and St Thomas’ 
Hospital (London) and Papworth Hospital (Cambridgeshire). Informed consent was 
obtained from each patient prior to undergoing EBUS-TBNA. The observational 
nature of the study meant that ethical approval was not required.   
4.2.2 Intervention 
 
Following contrast-enhanced thoracic computed tomography to assess the size and 
location of the lymphadenopathy, EBUS-TBNA was carried out as an outpatient 
under local anaesthesia and moderate sedation using midazolam and fentanyl. The 
procedure was performed with an echo-bronchoscope (BF-UC160F-OL8 Olympus, 
Tokyo) which allows endoscopic views and simultaneous linear ultrasound of 
mediastinal and hilar structures. The location, number, and size of the intra-thoracic 
lymph nodes were recorded. Vascular structures were confirmed using the colour 
Doppler function. A dedicated aspiration needle (22 or 21 gauge) was then placed in 
the working channel and advanced into the lymph node under ultrasound guidance. 
Once the tip of the needle was visualised in the lymph node, the stylet was 
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withdrawn and suction applied to the needle and the needle was then moved to and 
fro within the lymph node. Two centres employed on-site evaluation of the cell 
content of samples which determined the number of passes. Where on-site evaluation 
was not available, at least 3 passes per lymph node were obtained. Smears were 
prepared directly onto slides for cytological analysis. Samples were also expelled 
directly into formalin for cell block analysis. Needle contents from at least one 
dedicated pass were submitted in saline for microbiological analysis.  The 
microbiological specimens were analyzed by fluorescence microscopy using direct 
auramine stains and Middlebrook 7H9 medium (an element of the BACTEC
TM
 MGIT 
960
TM
 System) was used to culture Mycobacterium spp. 
4.2.3 Assessment of samples 
 
Pathological findings were classified into five grades as documented previously 
(Bezabih, Mariam, & Selassie 2002): Grade I—epithelioid granulomatous reaction 
with caseation; Grade II— epithelioid granulomatous reaction without caseation; 
Grade III—non-granulomatous reaction with necrosis; Grade IV—non-specific; 
Grade V—inadequate sample.  Grades I – III were considered to be consistent with a 
diagnosis of tuberculous intra-thoracic lymphadenitis in the context of clinical 
features, supportive tuberculin skin test (TST) or interferon gamma release assay 
(IGRA) and a clinical response to treatment. Microbiological investigations were 
considered positive for tuberculosis if the smear was positive for acid fast bacilli or 
culture isolated Mycobacterium tuberculosis. 
4.2.4 Statistical analysis 
 
The standard definition for diagnostic sensitivity was employed. Since the 
prevalence of tuberculosis in the cohort was 100%, predictive values were not 
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calculated. Categorical variables were compared using the Chi-squared test. 
Predictors of a positive culture for tuberculosis were modelled using logistic 
regression. Continuous variables were not categorised in the regression analyses. 
Significant variables in univariate analysis (at the 20% level) or those deemed 
clinically important were included in the multivariate model. This study and its 
report conforms to the standards for the reporting of diagnostic accuracy studies 
(STARD) statement (Bossuyt et al. 2003). 
 
4.3 RESULTS 
 
Between 1
st
 January 2008 and 1
st
 February 2010, 156 consecutive patients who 
subsequently received a final diagnosis of intra-thoracic lymph node tuberculosis 
underwent EBUS-TBNA at 4 centres. The median age at the time of the procedure 
was 39 years (range 18 –86 years). There were 80 males (51%). The most common 
clinical symptom was cough in 94 (60%) of the patients. Other presenting symptoms 
included weight loss, cough, haemoptysis and night sweats and are summarised in 
table 4.1. 
At EBUS, mediastinal and hilar lymph nodes ranging in size from 5 to 60 mm 
(median 22 mm) were detected. The sub-carinal lymph node station (station 7) was 
the most common location for EBUS-guided sampling (44% of nodes sampled), 
followed by the right paratracheal lymph node station (4R) (29% of nodes sampled) 
(table 2).  61 patients (39%) had 2 or more nodal stations sampled.   
EBUS-TBNA was diagnostic of tuberculosis in 146 patients (94%, 95% confidence 
interval 88 – 97%).  Pathological findings were consistent with tuberculosis in 134 
91 
 
(86%) patients. 68 (44%) had granulomas with necrosis; 58 (37%) had granulomas 
without necrosis. 8 (5%) had necrosis alone. 19 (12%) patients had lymphocytes 
alone from EBUS-TBNA and in 3 (2%) patients the sample was inadequate for 
pathological assessment. 
Microbiological investigations of EBUS-TBNA yielded a diagnosis of tuberculosis 
in 82 (53%) patients. In 27 (17%) patients smear of the EBUS-guided aspirate was 
positive for acid fast bacilli. Seventy-four (47%) patients had a positive culture for 
Mycobacterium tuberculosis with a median time to positive culture of 16 days (range 
3 – 84 days). In our cohort, 8 (5%) patients were proven to have isoniazid-resistant 
tuberculosis. In 15 (10%) patients, pathology was negative but a firm diagnosis of 
tuberculosis was obtained on Auramine/ Ziehl-Neelsen stain or culture.  
The logistic regression model included age, ethnicity, lymph node size, lymph node 
location, retroviral infection status, abnormal lung parenchyma, number of lymph 
nodes sampled, number of needle passes and lymph node pathology showing 
necrosis. Univariate analysis found that lymph node size > 20mm (P=0.022) was 
associated with an outcome of positive culture from EBUS-TBNA aspirate (Figure 
4.1). In the multivariate analysis (Figure 4.1), the presence of necrosis on EBUS-
TBNA pathology and sampling more than one lymph node may be associated with a 
positive culture in the multivariate regression model (table 4.3). A significant 
interaction between lymph node size and necrosis on pathology was observed with a 
positive culture less likely to occur in larger nodes with necrosis. In 8 (5%) cases the 
EBUS aspirate stained positive for acid fast bacilli, however culture was negative. 
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Ten (6%) patients did not have a specific diagnosis following EBUS-TBNA. Of 
these, 4 underwent mediastinoscopy which confirmed the diagnosis of tuberculosis 
in all cases, while 6 patients received empirical anti-tuberculous therapy (figure 4.2). 
One patient undergoing EBUS-TBNA experienced a serious complication 
necessitating inpatient admission. The patient was a 32 year old man of south Asian 
origin in whom a 35mm right paratracheal lymph node was aspirated under EBUS 
guidance. Four uncomplicated passes into the lymph node were made and the 
procedure yielded necrotising granulomas which was also positive for acid fast 
bacilli on Ziehl-Neelsen staining. Anti-tuberculous therapy was initiated. However, 
two days after the procedure, the patient presented with sepsis and blood cultures 
were positive for a beta-haemolytic group G streptococcus. The patient improved 
with appropriate antibiotics and was discharged on the 8th day post-procedure 
without further complications. The episode was ascribed to insertion of the 
bronchoscope itself rather than performance of TBNA, as previously described 
(Steinfort, Johnson, & Irving 2010).   
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Table 4.1: Baseline characteristics of patients with tuberculous intra-thoracic 
lymphadenopathy 
 
Total number of patients 156 
Male 80 (51%) 
Median age (range) 39 (18 – 86) 
Ethnicity: 
                            African 
                            Caucasian 
                            Caribbean 
                            South Asian 
                            East Asian 
                            Other 
 
47 (30%) 
25 (16%) 
6 (4%) 
56 (36%) 
12 (8%) 
10 (6%) 
Presenting symptoms: 
 
                              Fever / night sweats 
                              Weight loss 
                              Cough 
                              Haemoptysis 
                              No symptoms 
 
 
76 (49%) 
72 (46%) 
94 (60%) 
12 (77%) 
34 (22%) 
Abnormal lung parenchyma on CT 54 (35%) 
HIV positive 17 (11%) 
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Table 4.2: Results for endobronchial ultrasound guided transbronchial needle 
aspiration of 220 lymph nodes in 156 patients with intra-thoracic tuberculous 
lymphadenopathy according to lymph node location 
 
Lymph node 
station 
Number of nodes 
sampled at EBUS-
TBNA 
Number of nodes 
from which 
pathological grades 
I-III were obtained 
Number of nodes 
from which 
positive culture 
for tuberculosis 
was obtained 
2R 3 3 0 
2L 1 1 0 
4R 63 54 27 
4L 13 11 7 
7 96 87 53 
10R 28 26 10 
10L 13 10 5 
11R 1 1 1 
11L 2 2 1 
 
* According to Mountain-Dresler Lymph node map
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Table 4.3: Univariate and multivariate analyses of factors to predict positive culture 
of Mycobacterium tuberculosis in patients undergoing EBUS-TBNA. 
 
Covariate Unadjusted 
Odds ratio of 
positive 
culture 
Univariate 
P value 
Adjusted Odds 
ratio of positive 
culture (95% 
CI) 
Multi-
variate P 
value 
Age 0.993 0.487   
African or Asian 1.382 0.410   
LN >20mm 0.457 0.019 0.905 (0.361 – 
2.264) 
0.832 
Station 7 lymph 
node 
1.051 0.879   
HIV positive 1.281 0.631   
Abnormal lung 
parenchyma 
1.170 0.641   
Multiple lymph 
nodes sampled 
1.731 0.097 1.921 (0.965 – 
3.823) 
0.063 
Number of 
needle passes 
1.276 0.079   
Pathology 
showing 
necrosis (grades 
I or III*) 
1.138 0.689 2.254 (0.870 – 
5.839) 
0.094 
LN > 20mm * 
Necrosis - 
interaction 
  0.292 (0.075 – 
1.128) 
0.074 
 
*Grade I - epithelioid granulomatous reaction with caseation; Grade III - -
granulomatous reaction with necrosis 
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Figure 4.1: STATA output of univariate and multivariate logistic regression analysis. 
Outcome refers to a positive culture of Mycobacterium tuberculosis from EBUS-
TBNA aspirate. 
 
  
97 
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Figure 4.1 cont. Mulitvariate regression analysis with interaction term between 
presence of necrosis and lymph node size 
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156 patients with tuberculous intra-
thoracic lymphadenitis underwent 
EBUS-TBNA 
Grade I—
Granulomas with 
caseation (n= 68) 
Grade II— 
Granulomas 
without caseation 
(n=58) 
Grade III—non-
granulomatous 
reaction with 
necrosis (n=8) 
Grade IV—lymphocytes 
only (n=19) and Grade V – 
inadequate sample (n=3) 
Culture positive 
for M.tb (n=37) 
Culture 
negative (n=10) 
Culture positive 
for M.tb (n=20) 
 
Culture positive 
for M.tb (n=5) 
 
Culture positive 
for M.tb (n=12) 
 
Mediastinoscopy 
(n=4) 
Clinical 
Follow-up 
(n=6) 
All patients responded to anti-tuberculous therapy 
Figure 4.2: Flowchart of patients 
with intra-thoracic lymph node 
tuberculosis undergoing EBUS-
TBNA. M.tb = Mycobacterium 
tuberculosis 
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4.4 DISCUSSION 
 
This is the first study to assess the utility of EBUS-TBNA in the diagnosis of 
tuberculous intra-thoracic lymphadenopathy and demonstrates a sensitivity of 94% 
for the technique in 156 patients, with one complication observed. In 74 (47%) 
patients a positive culture of Mycobacterium tuberculosis was obtained.  
In patients with isolated mediastinal lymphadenopathy due to tuberculosis, 
traditional techniques of bronchoscopy and sputum culture have a low yield for 
positive culture(Codecasa et al. 1998). Mediastinoscopy may be employed but 
requires general anaesthesia, carries a morbidity of 1-2% and also has the 
disadvantage that posterior subcarinal and hilar nodes are inaccessible. Recently, 
endoscopic ultrasound guided fine needle aspiration (EUS-FNA) of tuberculous 
mediastinal lymphadenopathy has been described (Puri et a. 2010; Song et al. 2010). 
In these studies, diagnostic yield was 90% - 93%. However, EUS-FNA does not 
allow access to the right paratracheal and hilar lymph node stations which are 
commonly involved in tuberculosis (Codecasa, Besozzi, De, Miradoli, Sabolla, & 
Tagliaferri 1998) and accounted for 47% of the nodal stations sampled in this study. 
EBUS-TBNA now provides an important alternative in patients with tuberculous 
intra-thoracic lymphadenopathy. The procedure is well tolerated in the outpatient 
setting, provides access to the mediastinal and hilar lymph node locations commonly 
involved in tuberculosis and also allows bronchial washings to be performed at the 
same procedure. Successful isolation of an organism allows susceptibility testing, 
which is an increasingly necessary clinical need in the UK, as elsewhere,  given the 
prevalence of isoniazid-resistant and multidrug resistant disease (Health Protection 
Agency 2010).  Prior to the advent of EBUS-TBNA many of these patients would 
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have received empirical anti-tuberculous therapy. However, demonstration of a 
resistant organism (over 10% of the culture-positive patients in this cohort) 
significantly alters the anti-tuberculous regimen and duration of treatment and sub-
optimal treatment may induce selection of further drug resistant strains. In addition it 
is well recognised that intra-thoracic TBLA may not alter radiologically on 
successful treatment and in fact a significant proportion may paradoxically increase 
during treatment. In this setting, a firm microbiological diagnosis avoids the risk of 
inappropriate antimicrobial escalation, but instead allows consideration of the use of 
anti-inflammatory treatments.  
The culture rate of 47% observed in this study is similar to culture rates from lymph 
node sampling observed with other modalities. In a study of 29 patients with intra-
thoracic TBLA who underwent mediastinoscopy, 14 (48%) patients had a positive 
culture for Mycobacterium tuberculosis (Farrow et al. 1985). Bilaceroglu et al(2004) 
report a culture rate of 26% (17/63) performing TBNA without EBUS, while in a 
study of EUS, culture rate was 21% (Song et al. 2010). Gupta and colleagues (1993) 
obtained a positive culture for tuberculosis in 49% of lymph node fine needle 
aspirates. Gulati et al (2000) demonstrated that tuberculosis was cultured in 7 out of 
26 patients undergoing USS guided percutaneous mediastinal lymph node biopsies. 
These low culture rates are likely to represent the heterogeneity in bacillary load of 
intra-thoracic tuberculous lymph nodes and the yield obtained with EBUS is 
comparable with these other modalities. The mean time to culture was 16 days 
(range 3 to 84). One centre extended liquid mycobacterial culture beyond 6 weeks’ 
incubation, and identified 3 additional isolates. Further investigation into the value of 
extended culture and of the potential application of rapid molecular techniques, such 
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as the GeneXpert MTB platform (Boehme et al. 2010), is warranted to try to further 
increase sensitivity. 
The logistic regression model demonstrated that those EBUS procedures which 
obtained necrotic granulomas or necrosis alone were more likely to have a positive 
culture for tuberculosis. It may be postulated that the bacillary load in these lymph 
nodes is higher in order to cause necrosis and therefore the organism in these patients 
is more likely to be cultured. As has been previously demonstrated in patients with 
sarcoidosis undergoing conventional TBNA (Trisolini et al. 2008), sampling more 
than one lymph node station increases the diagnostic yield. Although many patients 
were observed to have matted and hypoechoic lymph nodes on the endobronchial 
ultrasound views, the significance of these findings was not assessed. 
Seventeen patients included in the study were infected with the human 
immunodeficiency virus (HIV) and culture was positive in 6 of these patients. A 
previous report has demonstrated that EBUS-TBNA may diagnose non-tuberculous 
mycobacterial disease in a patient with acquired immune deficiency syndrome 
(Steinfort et al. 2009). Further data is required on the utility of EBUS-TBNA in HIV 
infected individuals. 
Data from systematic review of patients with non-small cell lung cancer undergoing 
EBUS-TBNA indicate that EBUS-TBNA is a safe procedure with minimal 
complications (Gu et al. 2009). In this report we describe one complication of 
symptomatic bacteraemia following EBUS-TBNA of necrotic mediastinal 
lymphadenopathy. Von Bartheld and colleagues (2010)  have described the 
formation of a mediastinal – oesophageal fistula in a patient following EUS-FNA 
with a 22 gauge needle of a heterogeneous subcarinal gland. In addition, there has 
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also been a report of mediastinitis following EUS guided aspiration of necrotic 
subcarinal lymph node in a patient with non-small cell lung cancer (Aerts et al. 
2008). It may be postulated that the risk of infectious complications may be 
increased in patients undergoing aspiration of large necrotic lymph nodes and further 
safety data is required in this patient group. 
Limitations of the current study are recognised. Tuberculosis has a high endemic rate 
in our predominantly London based population with an incidence of 44.3 per 
100,000 per year(Health Protection Agency 2010). In addition, the centres included 
in the study have considerable experience with EBUS-TBNA and so the results may 
not be applicable to other areas. The retrospective nature of this study prevented the 
inclusion of patients with isolated mediastinal lymphadenopathy and therefore it is 
not possible to determine the disease prevalence of tuberculosis in our population 
undergoing EBUS-TBNA. In this study, the finding of granulomas without caseation 
along with supporting clinical evidence and response to therapy was considered to be 
consistent with a final diagnosis of tuberculosis. Although a positive tuberculin skin 
test or interferon gamma release assay adds weight to the diagnosis of tuberculosis, it 
is possible that these investigations may still be positive in patients with sarcoidosis 
from populations such as ours with a moderately high incidence of tuberculosis.  
However even allowing for this, it should be noted that in the group with non-
caseating granulomas, 20 of the 58 cases in this cytological criteria were culture 
positive (in addition to clinical criteria of improvement on treatment) - hence 
indicating that this pathological finding is in itself still compatible with active 
tuberculosis.  
In conclusion, EBUS-TBNA is a safe and effective first line investigation in patients 
with tuberculous intra-thoracic lymphadenopathy.    
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CHAPTER 5:  
ENDOBRONCHIAL ULTRASOUND-GUIDED 
TRANSBRONCHIAL NEEDLE ASPIRATION FOR THE 
DIAGNOSIS OF INTRA-THORACIC LYMPHADENOPATHY 
IN PATIENTS WITH EXTRA-THORACIC MALIGNANCY 
 
5.1 INTRODUCTION 
 
Mediastinal lymphadenopathy is a common finding in patients with extra-thoracic 
malignancies and is a frequent diagnostic dilemma for respiratory physicians and 
oncologists. Enlarged mediastinal nodes are often discovered at the time of initial 
staging, when the demonstration of mediastinal metastases may significantly alter 
treatment and prognosis. Alternatively mediastinal lymphadenopathy may be 
discovered after treatment and require pathological evaluation in order to exclude or 
confirm disease recurrence. 
Prior to the advent of endobronchial ultrasound guided transbronchial needle 
aspiration (EBUS-TBNA), sampling of intra-thoracic lymphadenopathy was most 
commonly performed by mediastinoscopy or endoscopic ultrasound guided fine 
needle aspiration (EUS-FNA). However, mediastinoscopy is associated with a 1% 
complication rate (Lemaire et al. 2006) and requirement for general anaesthesia, 
while EUS-FNA does not allow access to the right paratracheal and hilar lymph 
nodes. EBUS-TBNA allows sampling of paratracheal, subcarinal and hilar 
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lymphadenopathy under sedation in the outpatient setting. The technique has a role 
in the diagnosis and staging of lung cancer with a sensitivity of over 90%, even early 
in the learning process. Prospective data is now available on the utility of EBUS-
TBNA in the diagnosis of sarcoidosis (Tremblay et al. 2009) and the previous 
chapter has also demonstrated a high diagnostic yield in patients with tuberculous 
lymphadenopathy. Limited data however exists on the role of EBUS-TBNA in the 
diagnosis of extra-thoracic malignancies (Tournoy et al. 2011).   This large multi-
centre study, describes the diagnostic utility of EBUS-TBNA for the clarification of 
intra-thoracic lymphadenopathy in patients with extra-thoracic malignancy. 
 
5.2 METHODS 
 
5.2.1 Patients 
 
Consecutive patients with an active or previous diagnosis of extra-thoracic 
malignancy and enlarged intra-thoracic lymphadenopathy who underwent EBUS-
TBNA between 1
st
 January 2007 and 1
st
 December 2010 were included. Patients 
were suspected to have intra-thoracic lymph node metastases on the basis of CT or 
PET-CT findings. The participating centres were University College London 
Hospital, Papworth Hospital Cambridge, University Hospitals Birmingham, 
University Hospital of North Tees, and Lancashire Teaching Hospitals, Preston. The 
retrospective observational design of the study meant that ethical approval was not 
required. 
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5.2.2 Intervention 
 
EBUS-TBNA was performed with a dedicated linear echo-endoscope (Olympus BF-
UC160F-OL8) under moderate sedation with intravenous midazolam and fentanyl or 
midazolam alone. Systematic assessment of all EBUS accessible lymph nodes was 
made. Vascular structures were avoided using the Doppler function. Under direct 
ultrasound guidance the lymph node was then aspirated using either a 21 gauge or 22 
gauge needle. Samples were expelled both, onto glass slides where air dried smears 
were made for cytology and also into liquid fixative suitable for cell block 
preparations. In cases where core biopsies were obtained for histology, these were 
placed directly into formalin. The appropriate immunohistochemical staining with 
antibodies to the cytokeratins, thyroid transcription factor-1, prostate-specific 
antigen, oestrogen and progesterone receptors and neuroendocrine markers, was 
utilised when required. 
 
5.2.3 Analysis 
 
Standard definitions of sensitivity, negative predictive value and diagnostic accuracy 
were employed. Positive malignant findings on EBUS-TBNA were not confirmed 
and specificity was assumed to be 100%. Non-malignant findings at EBUS-TBNA 
were subject to surgical confirmation or at least 6 months radiological and clinical 
follow-up. Predictors of malignant lymphadenopathy were modelled using logistic 
regression. Continuous variables were not categorised in the regression analyses. 
Significant variables in univariate analysis (at the 10% level) or those deemed 
clinically important were included in the multivariate model. Analysis was carried 
out with STATA version 10 (Stata corporation). This study conforms to the 
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standards for the reporting of diagnostic accuracy studies (STARD) initiative 
(Bossuyt et al. 2003). 
 
5.3 RESULTS 
 
All 161 patients successfully underwent EBUS-TBNA and no complications were 
observed. The median age of the patients was 64 (range 19 – 86). The most common 
extra-thoracic malignancies observed were breast, colorectal and oesophageal 
carcinomas. The patient characteristics are summarised in Table 5.1.  
The median size of lymph nodes seen at EBUS-TBNA was 25 (range 6 – 48) mm 
and each node underwent a median of 4 passes (range 2 – 6).  One hundred and 
ninety-six nodes were sampled in 160 patients, with no samples taken in one patient. 
The subcarinal or right paratracheal lymph node stations were the site of aspiration 
in 100 (62%) of patients. Twenty-eight (17%) patients had hilar lymph nodes 
sampled only. The sensitivity, negative predictive value (NPV) for malignancy and 
overall accuracy for EBUS-TBNA was 87%, 73% and 88% respectively. The final 
diagnosis was unknown in 6 patients. If we assume that the intra-thoracic lymph 
nodes in these patients harboured extra-thoracic malignancy (undiagnosed by EBUS-
TBNA) the sensitivity, NPV and accuracy are 78%, 61% and 84%. Overall, 110 
(68%) of the patients in the study were known to have had malignant intra-thoracic 
lymphadenopathy. EBUS-TBNA did not obtain a diagnosis in 13 patients with 
metastases to intra-thoracic nodes from an extra-thoracic malignancy. Four patients 
had breast cancer, 1 bladder cancer, 1 renal cell carcinoma, 1 seminoma, 1 
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leiomyosarcoma, 3 melanoma, 1 head and neck carcinoma and 1 patient had 
lymphoma. 
In 14 (9%) patients EBUS-TBNA demonstrated granulomas alone and the final 
diagnosis in each of these patients was sarcoidosis. Of the 51 cases, in which EBUS-
TBNA did not provide a malignant or alternative diagnosis, surgery was performed 
in 9 (18%) and a median of 15 months clinical and radiological follow-up was 
employed in the remainder (Figure 5.1).  
Univariate analysis of lymph node size, number of passes per node and number of 
lymph nodes sampled revealed there was a statistically significant association 
between lymph node size and presence of metastatic lymphadenopathy (P=0.03). In 
the logistic regression multivariate model, lymph node size remained significantly 
associated with malignant lymphadenopathy (OR 1.04 (95% confidence interval 1.00 
– 1.08). This implies that for every increase in lymph node size of 1mm the 
probability of the lymph node being malignant increases by 4%. Univariate analysis 
demonstrated there was no association between lymph node size and yield from 
EBUS-TBNA (P=0.279) (Figure 5.2). 
Of the 71 patients with extra-thoracic malignancy diagnosed by EBUS-TBNA, 
morphological appearances alone were sufficient in 17 (24%). 
Immunohistochemistry was successfully performed in 54 (76%) patients whose 
EBUS-TBNA had diagnosed malignancy, elucidating the primary origin of the 
tumour (Figure 5.3).  
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Table 5.1: Characteristics of patients with extra-thoracic malignancy 
Total number of patients 161 
Male 73 (45%) 
Median age (range) 64 (19 – 86) 
Median lymph node size 
(mm, range) 
25 (6 – 48) 
Extra-thoracic malignancy 
primary site 
 
Breast 40 
Colorectal 25 
Oesophagus 13 
Melanoma 12 
Head and Neck 11 
Renal cell 10 
Prostate 9 
Bladder 8 
Lymphoma 7 
Ovarian 5 
Sarcoma 4 
Testis 3 
Cervix 3 
Stomach 3 
Endometrial 2 
Penis 2 
Teratoma, Anus, Vulva, 
Schwannoma 
1 each 
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161 patients with extra-
thoracic malignancy and 
intra-thoracic 
lymphadenopathy 
EBUS-TBNA 
(n=161) 
 
Metastasis from 
extra-thoracic 
malignancy 
(n=71) 
Sarcoidosis 
(n=14) 
Reactive lymph 
node (n=42) 
Inadequate or 
no sample 
(n=9) 
Carcinoma of 
unknown 
primary (n=5) 
Mediastinoscopy (n=9) and / or 6 months clinical follow-up 
Sarcoidosis 
(n=15) 
Reactive 
lymph 
node 
(n=25) 
Metastasis from 
extra-thoracic 
malignancy 
(n=13) 
Figure 5.1: Flowchart of 
patients with extra-thoracic 
malignancy 
New lung 
cancer (n=20) 
New lung 
cancer 
(n=1) 
Tuberculosis 
(n=1) 
Unknown 
(n=6) 
Bronchogenic 
cyst (n=3) 
Fungal 
infection 
(n=1) 
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Figure 5.2: STATA output of univariate and multivariate regression analyses in 
patients undergoing EBUS-TBNA with extra-thoracic malignancy 
 
Univariate analyses: 
 
 
 
Multivariate analysis: 
 
  
                                                                              
lymphnodes~e     1.041615   .0199353     2.13   0.033     1.003266    1.081429
                                                                              
finaldiagn~s   Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -100.97493                       Pseudo R2       =     0.0232
                                                  Prob > chi2     =     0.0284
                                                  LR chi2(1)      =       4.81
Logistic regression                               Number of obs   =        161
. logistic  finaldiagnosis  lymphnodesize
                                                                              
lymphnodes~e     1.019304   .0180036     1.08   0.279     .9846218    1.055209
                                                                              
ebuspathol~y   Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -107.59558                       Pseudo R2       =     0.0055
                                                  Prob > chi2     =     0.2753
                                                  LR chi2(1)      =       1.19
Logistic regression                               Number of obs   =        161
. logistic  ebuspathology  lymphnodesize
                                                                              
numberofln~s     1.178568   .3710299     0.52   0.602     .6358937    2.184364
                                                                              
ebuspathol~y   Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -108.05158                       Pseudo R2       =     0.0013
                                                  Prob > chi2     =     0.5980
                                                  LR chi2(1)      =       0.28
Logistic regression                               Number of obs   =        161
. logistic  ebuspathology  numberoflnstations
                                                                              
numberofln~s     1.085326   .3508359     0.25   0.800      .575978    2.045099
lymphnodes~e     1.041662   .0199049     2.14   0.033     1.003371    1.081414
                                                                              
finaldiagn~s   Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood =  -100.9425                       Pseudo R2       =     0.0236
                                                  Prob > chi2     =     0.0875
                                                  LR chi2(2)      =       4.87
Logistic regression                               Number of obs   =        161
. logistic  finaldiagnosis  lymphnodesize  numberoflnstations
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Figure 5.3: EBUS-TBNA samples demonstrating metastatic breast cancer. A)  FNA smear shows malignant cells (MGG) B) cell block 
preparation contains numerous malignant cells (H&E) C) TTF-1 negative staining D) CK7 positive staining E) CK20 negative staining F) ER 
staining negative. EBUS-TBNA: endobronchial ultrasound guided transbronchial needle aspiration; MGG: May Grunwald Giemsa stain; H&E: 
hematoxylin and eosin; TTF-1: thyroid transcription factor-1; CK: cytokeratin; ER: estrogen receptor. 
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5.4 DISCUSSION 
 
This multi-centre study of 161 patients is the largest to date to demonstrate the role 
of EBUS-TBNA in the diagnosis of intra-thoracic lymphadenopathy in patients with 
extra-thoracic malignancy. EBUS-TBNA demonstrated a sensitivity of 87% with an 
overall diagnostic accuracy of 88% and therefore is an important alternative to other 
techniques for the diagnosis of intra-thoracic lymphadenopathy in patients with 
extra-thoracic malignancy.  
Clarification of mediastinal lymphadenopathy in the context of a known or suspected 
extra-thoracic malignancy is a common scenario faced by physicians and may have 
profound effects on the patient’s treatment and prognosis. Although mediastinoscopy 
is considered the gold standard investigation in this clinical scenario, 
mediastinoscopy is associated with risks due to general anaesthesia, a serious 
complication rate of 1% and increased healthcare costs compared to minimally 
invasive techniques. Standard cervical mediastinoscopy also only provides access to 
the paratracheal and anterior subcarinal lymph nodes. Evidence of the utility of 
alternatives to mediastinoscopy in this patient group is beginning to emerge.  A 
recent report of conventional TBNA in 5 patients with extra-thoracic malignancy 
(Bruno et al. 2010) showed that the procedure is able to provide suitable material for 
the diagnosis of extra-thoracic malignancy. A large study of 75 patients undergoing 
endoscopic ultrasound guided fine needle aspiration (EUS-FNA) demonstrated a 
sensitivity of 86% (Peric et al. 2010), while Tournoy and colleagues (2011) also 
showed a sensitivity of 85% for EBUS-TBNA in 61 patients with malignant intra-
thoracic lymphadenopathy(Tournoy, Govaerts, Malfait, & Dooms 2011).  
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In this study of 161 patients with suspected metastases from extra-thoracic 
malignancy, only 84 (52%) had a final diagnosis of intra-thoracic lymph node 
metastases, highlighting the importance of pathological confirmation in this clinical 
scenario. The negative predictive value obtained in this cohort was low at 73%, 
emphasising the need for further investigation if EBUS-TBNA did not yield a 
malignant or other specific diagnosis.  
Of note in this study, EBUS-TBNA demonstrated non-caseating granulomas in 14 
cases, in all of whom a sarcoid-like reaction was the final diagnosis. Previous studies 
of granulomas in mediastinal lymph nodes in patients with early stage non-small cell 
lung cancer have suggested that this finding reliably excludes malignancy and 
suggested that clinical follow-up rather than further invasive sampling may be 
justified in this context (Steinfort & Irving 2009). The statement that the presence of 
granulomas may reliably exclude malignancy is questionable.  The coexistence of 
granulomas and malignant cells in metastatic lymph nodes has been described 
(Trisolini, Cancellieri, & Patelli 2009) and, although we did not encounter this 
phenomenon in any of our patients initially diagnosed with sarcoid on EBUS TBNA, 
we would recommend further investigation when granulomas only are observed in 
EBUS-TBNA and the suspicion of malignancy remains.    
Limitations of the current study are recognised. The retrospective nature means that 
only patients who were clinically selected for EBUS-TBNA were included. 
Although consecutive patients were included to minimise this bias, the 
characteristics of patients who were directly referred for mediastinoscopy outside of 
the study are unknown. The multi-centre collaboration strengthens conclusions about 
the generalisability of the data, however, due to differing pathology practices, 
standardised immunohistochemistry protocols were not followed.   
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In conclusion, pathological evaluation is important for diagnosis and staging of 
patients with extra-thoracic malignancy and suspected mediastinal or hilar lymph 
node metastases. EBUS-TBNA is a safe and sensitive technique and may be 
considered a first line investigation in these patients. 
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CHAPTER 6:  
ENDOBRONCHIAL ULTRASOUND-GUIDED 
TRANSBRONCHIAL NEEDLE ASPIRATION PREVENTS 
MEDIASTINOSCOPIES IN PATIENTS WITH ISOLATED 
MEDIASTINAL LYMPHADENOPATHY 
 
6.1 INTRODUCTION 
 
Isolated mediastinal lymphadenopathy is a common presentation to respiratory 
physicians. Final diagnoses often include sarcoidosis, tuberculosis, lymphoma and 
metastatic carcinoma. However, symptoms are often non-specific and fevers, night 
sweats and weight loss may be a common feature of each diagnosis. A pathological 
and microbiological diagnosis is therefore commonly obtained to differentiate these 
conditions and guide further management. 
Mediastinoscopy has traditionally been considered the gold-standard for lymph node 
sampling in these patients. Previous retrospective studies have demonstrated a high 
diagnostic yield for the procedure in this patient group with few complications 
Lemaire et al. 2006; Porte et al 1998). However, mediastinoscopy requires general 
anaesthesia, only allows access to the paratracheal and anterior subcarinal lymph 
nodes and in many cases requires an inpatient stay. Patients are left with a visible 
scar above the suprasternal notch which may be a cosmetic issue in young people. 
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Although complications from mediastinoscopy are rare they may be catastrophic and 
include vocal cord palsy, innominate vein damage and even death (Porte et al. 1998).  
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) 
was developed for the mediastinal staging of lung cancer and studies have 
demonstrated that it has a similar sensitivity to mediastinoscopy for detecting 
mediastinal metastases from non-small cell lung cancer. In the only prospective 
direct comparison of EBUS-TBNA and mediastinoscopy to date in patients with 
suspected lung cancer (Ernst et al. 2008), EBUS-TBNA demonstrated a significantly 
superior sensitivity (91% vs 78%, P=0.007). Data have now emerged on the utility of 
EBUS-TBNA in the diagnosis of benign mediastinal lymph nodes (Tremblay et al. 
2009), lymphoma (Marshall et al. 2011) and extra-thoracic malignancy (Tournoy et 
al. 2011). However, given concerns about smaller biopsy sizes with EBUS-TBNA 
and inherent selection bias of retrospective studies, it is unknown whether EBUS-
TBNA can replace mediastinoscopy as a first investigation in patients with isoIated 
mediastinal lymphadenopathy (IML). In this prospective multi-centre clinical trial, 
the aim was to determine whether EBUS-TBNA could be utilised as an alternative 
initial procedure in consecutive patients presenting with IML requiring pathological 
evaluation and also to describe the economic consequences of this strategy. 
 
6.2 METHODS 
 
6.2.1 Trial design 
 
This was a multi-centre single arm prospective clinical trial of EBUS-TBNA in 
patients with isolated mediastinal lymphadenopathy. If EBUS-TBNA did not give a 
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definitive diagnosis, patients underwent mediastinoscopy. In order to clarify whether 
patients included in this study reflected patients previously referred for 
mediastinoscopy, data was also collected on 68 patients who underwent 
mediastinoscopy between 2007 and 2008, prior to the introduction of the EBUS-
TBNA service.  Although a randomised trial of EBUS-TBNA versus 
mediastinoscopy was originally planned, we anticipated difficulty with recruitment if 
all patients were not allowed to undergo EBUS-TBNA. The trial protocol was 
approved by the Moorfields and Whittington Research Ethics Committee (reference 
09/H0721/23). The trial was registered as REMEDY (clinical trial of EBUS-TBNA 
in patients with isolated mediastinal lymphadenopathy) on  www.clinicaltrials.gov as 
NCT00932854. 
 
6.2.2 Participants 
 
Consecutive patients with undiagnosed isolated mediastinal lymphadenopathy on CT 
or PET-CT who were referred for mediastinoscopy were approached for trial entry 
between July 2009 and April 2011. The participating centres were University 
College London Hospital, Whittington Hospital, North Middlesex University 
Hospital, Barnet General Hospital and Princess Alexandra Hospital. Patients with 
anterior mediastinal lymphadenopathy only, with a known lung cancer, without 
informed consent or absolute contra-indications to EBUS-TBNA or mediastinoscopy 
were all excluded from the trial. 
 
6.2.3 Intervention 
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All patients were scheduled to undergo EBUS-TBNA as an initial procedure. The 
technique for EBUS-TBNA has been previously described (Chapter 3). Briefly, the 
procedure is conducted in the outpatient setting and patients receive intravenous 
sedation with midazolam and fentanyl in addition to topical lidocaine. A dedicated 
linear echoendoscope (Olympus BF-UC160F-OL8) was used in all cases and a 
systematic assessment of hilar and mediastinal lymph nodes was made. Under 
ultrasound guidance mediastinal and/or hilar lymph nodes were punctured with a 
dedicated 21-gauge or 22-gauge needle and suction was applied.  Samples were 
transferred onto glass slides and also directly into liquid fixative for cell block 
processing. Any cores of tissue were placed into formalin.  The site and number of 
lymph nodes punctured as well as the number of passes were at the operator’s 
discretion. On-site evaluation of samples was not employed. Immunohistochemistry 
was performed as required, however flow cytometry was not used. The pathologists 
were blinded to the fact that the patient was in a clinical trial and were provided with 
clinical information, reflecting routine clinical practice.  
Pathological and microbiological results were reviewed in a multi-disciplinary team 
(MDT) setting including radiologists, respiratory physicians, thoracic surgeons and 
pathologists. If a diagnosis agreed by the MDT was not obtained from EBUS-
TBNA, then the patient underwent mediastinoscopy. Cervical mediastinoscopy was 
performed under general anesthesia via an incision above the suprasternal notch and 
lymph node stations 2, 4 and 7 were sampled. Any overnight inpatient stay was 
determined by the responsible surgeon. 
In cases where EBUS-TBNA and mediastinoscopy failed to show a definitive 
diagnosis, the participant underwent serial imaging and clinical follow-up for at least 
6 months duration. 
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6.2.4 Endpoints 
 
The co-primary outcomes were the proportion of mediastinoscopies saved and 
healthcare costs compared to a strategy where all patients undergo mediastinoscopy. 
Other endpoints were the sensitivity, negative predictive value (NPV) and diagnostic 
accuracy of EBUS-TBNA in patients with isolated mediastinal lymphadenopathy. 
Complications of EBUS-TBNA were recorded if bleeding exceeded 10mls or 
peripheral oxygen saturations were recorded below 90%. Length of inpatient stay 
was also prospectively documented.  
 
6.2.5 Economic analysis 
 
The incremental cost of the EBUS-TBNA strategy (where negative EBUS-TBNA is 
followed by mediastinoscopy) versus mediastinoscopy alone in patients with IML 
was calculated from the perspective of the NHS. The analysis was based on a 
decision tree model (Figure 6.1). Patients with IML who received EBUS-TBNA 
either received a diagnosis or did not. In the case of the latter, they underwent 
mediastinoscopy, and if that failed to produce a diagnosis they received clinical 
follow-up until a diagnosis was available. They then received treatment depending 
on their diagnosis. Patients in the mediastinoscopy alone strategy either received a 
diagnosis from this procedure or not, and in the latter case received clinical follow-
up until a diagnosis was available. We assume that treatment and treatment outcomes 
following diagnosis were the same irrespective of the method of diagnosis, and 
therefore treatment costs are omitted from the incremental analysis. Since treatment 
outcomes were the same, the two strategies were equally effective, and therefore the 
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economic evaluation is a cost-minimisation analysis; hence the EBUS-TBNA 
strategy represents good value for money to the NHS if it is less costly than the 
mediastinoscopy strategy.  
In the model, the proportion of patients receiving EBUS-TBNA, mediastinoscopy 
and clinical follow-up for each strategy was obtained from the prospective trial. Unit 
costs were taken from manufacturers’ prices and local hospital costs (see Table 6.1 
for details of the cost-breakdown of the EBUS-TBNA procedure). Because all costs 
occurred within one year discounting was unnecessary. We investigated the 
sensitivity of the results to the cost of the EBUS-TBNA procedure, varying it 
between £503 (the 2010-11 NHS tariff for a flexible bronchoscopy) and £5259 (the 
2010-11 NHS tariff for mediastinoscopy with complications) for the analysis. 
 
6.2.6 Sample Size 
 
It was assumed that an incremental cost of £500 per patient would be acceptable if 
EBUS-TBNA could reduce the number of mediastinoscopies by 60%. This supposes 
that 40% of patients would undergo both EBUS-TBNA and mediastinoscopy. A total 
of 75 patients were required to detect a mean difference of £500 in cost assuming an 
80% power and 2.5% significance level (since the Bonferroni correction is applied to 
adjust for multiple significance testing). The sample size is also sufficient to give the 
trial adequate power to assess whether the proportion of patients undergoing 
mediastinoscopy is reduced by 60%, assuming the same power and significance 
level.   
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Figure 6.1: Decision tree model of patients with isolated mediastinal lymphadenopathy. Data is from the REMEDY trial. 
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Table 6.1: Estimated cost of the EBUS-TBNA procedure to the NHS, assuming 250 
cases per year and 3 cases per session 
 
Resource Cost per 
year (£) 
Cost per 
procedure 
(£) 
Capital costs of 2 EBUS echoendoscopes 
(£140,000 spread over 5 years) 
28,000 112 
EBUS-TBNA needle 43,750 175 
Maintenance contract 9000 36 
2 Consultants for 2.5 sessions per week 50,000 200 
2 Nurses, 1 health care assistant, 1 recovery 
nurse per session 
68,750 275 
Sterilisation 13,750 55 
Pathology 36,250 145 
Administration 10,000 40 
Overheads (endoscopy suite, portering, 
facilities, drug costs) and Indirect costs 
86,000 344 
Total cost of EBUS-TBNA 345,500 1382 
 
  
124 
 
6.2.7 Statistical methods 
 
Demographic and clinical characteristics of the study population were summarised 
using mean, standard deviation, median, or counts and percentages, depending on 
their type and distribution. A one sample z test was used to determine if there was a 
significant reduction in mediastinoscopies due to EBUS-TBNA. The one sample t-
test was used to investigate whether the strategy of EBUS-TBNA initially (followed 
by mediastinoscopy if negative) differs significantly in cost from that associated with 
mediastinoscopy alone. Test accuracy of EBUS-TBNA and mediastinoscopy was 
calculated using the sensitivity and NPV with 95% binomial confidence intervals. 
Specificity of EBUS-TBNA and mediastinoscopy samples was assumed to be 100%. 
Statistical calculations have been performed using STATA version 10 (Statcorp., 
USA). The design, conduct, analysis and report of this study conform to the Standard 
of Reporting Diagnostic Accuracy Guidelines (Bossuyt et al. 2003). 
 
6.3 RESULTS 
 
Seventy-seven patients were recruited during the study period with a median age of 
42 years. The total number recruited exceeded the required sample size as several 
patients had consented to enter the trial at different sites on the final day of 
rectuitment. The most common diagnosis was sarcoidosis and their characteristics 
are summarized in Table 6.2.  The table also includes the characteristics and final 
diagnoses of patients undergoing mediastinoscopy only between 2007 and 2008. 
Patients in the prospective trial and historical controls had similar age and symptom 
distributions.  
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EBUS-TBNA prevented 87% of mediastinoscopies (97.5% CI 78 – 96%) but failed 
to provide a diagnosis in 10 patients (figure 6.2, page 132). All 10 patients proceeded 
to mediastinoscopy.  Mediastinoscopy provided a specific diagnosis in 7 cases while 
the remaining 3 patients had further clinical and radiological follow-up of at least 6 
months duration. There were no losses to follow-up and all patients were included in 
the analysis. The final diagnosis was correctly determined by EBUS-TBNA in 67 
cases giving an overall diagnostic sensitivity of 92% (95% confidence interval 83 – 
95%). NPV was 40% (95% CI 12 – 74%) and diagnostic accuracy of 92% (95% CI 
84 – 97%). EBUS-TBNA successfully diagnosed sarcoidosis in 32 (94%) out of 34 
patients with the condition (Table 6.3a, page 129). Twenty-eight patients in the trial 
had a final diagnosis of tuberculosis and EBUS-TBNA provided pathological 
evidence of tuberculosis in 26 (93%) and cultured Mycobacterium tuberculosis in 11 
(40%) cases. Two patients were diagnosed with Hodgkin’s lymphoma following 
EBUS-TBNA. A further patient with lymphoma was not definitively diagnosed by 
EBUS-TBNA and required mediastinoscopy to confirm the diagnosis. 
No major complications from EBUS-TBNA were observed. Four patients 
experienced transient hypoxia and 1 patient had self-limiting bleeding. These 
complications did not result in early termination of the procedure in any case and all 
procedures were day cases. The median number of passes per lymph node, the 
frequency of lymph node stations sampled and diagnostic yield of EBUS-TBNA is 
shown in Table 6.3b (page 130). The ten patients undergoing mediastinoscopy (after 
negative EBUS-TBNA) accumulated a total of 15 inpatient nights and no serious 
complications were observed.   
In the retrospective study of mediastinoscopy in patients with isolated mediastinal 
lymphadenopathy, mediastinoscopy provided a specific diagnosis in 53 patients out 
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of 68 patients. In the 15 patients with no specific diagnosis, the final diagnosis was 
sarcoidosis in 4, adenocarcinoma in 1 and reactive lymphadenopathy in the 
remainder. The sensitivity of mediastinoscopy in this retrospective cohort was 92% 
(95 CI 81% - 97%).  
The mean cost of EBUS-TBNA procedure per patient was £1382 (Table 6.1). The 
standard price for mediastinoscopy is £3228 according to the 2010-11 NHS payment 
by results tariff. In the base case analysis, the mean cost per patient of the EBUS-
TBNA strategy was £1822; for the mediastinoscopy only strategy the cost was 
£3268 (Table 6.4). Hence the incremental cost per patient of the EBUS-TBNA 
strategy versus the mediastinoscopy strategy was –£1446. Therefore, the EBUS-
TBNA strategy was significantly cheaper than mediastinoscopy strategy. A 
univariate threshold sensitivity analysis which varied the potential cost of EBUS-
TBNA demonstrated that under the conditions of the trial, the EBUS-TBNA strategy 
was less costly than the mediastinoscopy strategy if the cost per EBUS-TBNA 
procedure was less than £2828 (Figure 6.3, page 133). 
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Table 6.2: Clinical characteristics of patients with isolated mediastinal 
lymphadenopathy 
 
 EBUS-TBNA (n=77) Mediastinoscopy 
only (n=68) 
Age 
     < 30 
     30 – 49 
     50 – 69 
     >69 
     Median (range) 
 
15 (19%) 
34 (44%) 
16 (21%)) 
12 (16%) 
42 (17 – 79) 
 
3 (4%) 
25 (37%) 
29 (43%) 
11 (16%) 
53 (25 – 85) 
Gender 
     Male 
     Female 
 
45 (58%) 
32 (42%) 
 
38 (56%) 
30 (44%) 
Ethnicity 
     Caucasian 
     Asian 
     African 
     Caribbean 
     Other 
 
25 (32%) 
29 (38%) 
15 (19%) 
6 (8%) 
2 (3%) 
 
36 (53%) 
22 (32%) 
9 (13%) 
0 (0%) 
1 (1%) 
Symptoms 
     Cough 
     Dyspnoea 
     Weight loss 
     Fevers / night sweats 
     Chest pain 
     Other 
     None 
     
 
27 (35%) 
11 (14%) 
13 (17%) 
13 (17%) 
3 (4%) 
2 (3%) 
8 (10%) 
 
31 (46%) 
8 (12%) 
8 (12%) 
5 (7%) 
10 (15%) 
2 (3%) 
4 (6%) 
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Table 6.2 continued: Clinical characteristics of patients with isolated mediastinal 
lymphadenopathy 
 
 EBUS-TBNA (n=77) Mediastinoscopy 
only (n=68) 
 
Final Diagnosis 
 
     Sarcoidosis Stage 1 
 
     Sarcoidosis Stage 2 
 
     Tuberculosis 
 
     Lymphoma 
 
     Extra-thoracic 
malignancy 
 
     Lung cancer 
 
     Reactive 
lymphadenopathy 
 
 
 
31 (40%) 
 
3 (4%) 
 
28 (36%) 
 
3 (4%) 
 
4 (5%) 
 
                                     
4 (5%) 
 
4 (5%) 
 
 
 
 
31 (46%) 
 
2 (3%) 
 
17 (25%) 
 
5 (7%) 
 
2 (3%) 
 
                              
1 (1%) 
 
10 (15%) 
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Table 6.3a: Diagnoses obtained by EBUS-TBNA in the REMEDY trial 
 
 Number of diagnoses 
obtained by EBUS-TBNA 
 
Sensitivity 
Sarcoidosis Stage 1 29 94% 
Sarcoidosis Stage 2 3 100% 
Tuberculosis 26 93% 
Lymphoma 2 66% 
Extra-thoracic malignancy 4 100% 
Non-small cell lung cancer 3 75% 
Overall 67 92% 
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Table 6.3b: Results of EBUS-TBNA in 77 patients with isolated mediastinal 
lymphadenopathy 
 
Lymph node 
station 
Number of 
nodes sampled 
(%) 
Mean lymph 
node size 
(mm) 
Median 
number of 
passes 
Sensitivity 
4R 21 25 5 90% 
4L 1 35 5 100% 
7 66 26 5 92% 
10R 1 15 3 100% 
Total 99 23 4 92% 
 
  
131 
 
Table 6.4: Costs of different strategies for the investigation of patients with isolated mediastinal lymphadenopathy 
 
 Parameter value  Costs 
 EBUS 
strategy 
Mediastinoscopy 
strategy 
 
Unit 
cost 
EBUS 
strategy 
Mediastinoscopy 
strategy 
Difference 
EBUS-TBNA 1.00 0 £1382 £1382 0  
Mediastinoscopy 0.13 1.00 £3228 £420 £3228  
Clinical Follow-
up 
0.04 0.08 £500 20 40  
Total cost    £1822 £3268 £1446 
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Figure 6.2: Flowchart of patients in the REMEDY trial 
 
  
Consecutive patients with 
isolated mediastinal 
lymphadenopathy (n=77) 
EBUS-TBNA (n=77) 
No specific diagnosis 
(n=10) 
Diagnosis made 
(n=67) 
29 Sarcoidosis Stage 1 
3 Sarcoidosis Stage 2 
26 Tuberculosis 
2 Lymphoma 
4 Extra-thoracic 
malignancy 
3 NSCLC 
 
N 
Mediastinoscopy (n=10) 
No specific diagnosis 
(n=4) Diagnosis made (n=6) 
2 Sarcoidosis Stage 1 
2 Tuberculosis 
1 Lymphoma 
1 NSCLC 
 
 
 
Diagnosis made (n=4) 
4 Lymph node 
hyperplasia 
    Clinical and 
radiological follow-up 
(n=4) 
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Figure 6.3: Univariate threshold sensitivity analysis. Threshold sensitivity analysis demonstrating that the cost of mediastinoscopy alone is more 
expensive than a strategy of EBUS-TBNA (followed by mediastinoscopy if EBUS-TBNA is negative) as long as EBUS-TBNA costs less than 
£2828 (red dashed line). Above this threshold cost for EBUS-TBNA, mediastinoscopy alone is the less costly strategy. The best estimate cost of 
EBUS is £1382 (purple dashed line). 
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6.4 DISCUSSION 
 
This is the first prospective clinical trial to demonstrate the utility and cost-savings 
of using EBUS-TBNA as an initial investigation for patients with IML requiring 
pathological diagnosis. The study demonstrates that EBUS-TBNA is a highly 
effective diagnostic modality and can prevent 87% of mediastinoscopies in this 
scenario. The negative predictive value however is low at 40% and therefore 
mediastinoscopy is recommended after negative EBUS-TBNA, which is an 
important consideration when obtaining consent from patients for the procedure.  
Considerable evidence is now available on the efficacy of EBUS-TBNA in patients 
with lung cancer (McComb et al. 2011). Data is also expanding on the effectiveness 
of EBUS-TBNA in patients with mediastinal sarcoidosis (Navani et al. 2011a), 
tuberculosis (Navani et al. 2011b), lymphoma (Marshall et al. 2011) and extra-
thoracic malignancy (Tournoy et al. 2011). However, much of the data is from 
retrospective cohort studies and therefore subject to selection bias. In particular, in 
many of the studies, patients referred for mediastinoscopy were excluded and 
therefore their characteristics are unknown.  In addition, in prior studies, many 
patients undergoing EBUS-TBNA would not have been otherwise referred for 
mediastinoscopy. Therefore, previous inferences on mediastinoscopies prevented are 
prone to bias. For example in Yasufuku and colleagues’ large retrospective report of 
patients with undiagnosed mediastinal masses (Yasufuku et al. 2011), the authors 
concluded that EBUS-TBNA can spare more invasive procedures but it is not clear 
that the patients would have been subjected to the more invasive procedures in the 
absence of EBUS-TBNA. In the current prospective trial, only patients who were 
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referred for mediastinoscopy were included and were similar to historical controls 
undergoing mediastinoscopy, minimizing this bias as much as possible. 
The diagnosis of lymphoma by EBUS-TBNA is an area of controversy since the 
management of lymphoma often depends on pathological subtype and grade and 
EBUS-TBNA obtains smaller specimens than mediastinoscopy.  EBUS-TBNA may 
be particularly useful for the mediastinal staging of lymphoma and in the diagnosis 
of lymphoma recurrence, however its role for primary diagnosis is currently under 
debate. In one study of EBUS-TBNA in patients with lymphoma, EBUS had a 
sensitivity of 76% and 19% of the diagnosed patients still required a further invasive 
procedure (Steinfort et al. 2010a). In this trial of 77 consecutive patients, only 3 
patients had a lymphoma. EBUS-TBNA provided a conclusive diagnosis in 1 patient 
and prevented mediastinoscopy in another (who went on to have the diagnosis 
confirmed by bone marrow biopsy). The low prevalence of lymphoma in this typical 
cohort of patients further highlights that EBUS-TBNA is a good initial test for 
patients with IML.  
EBUS-TBNA was diagnostic of tuberculosis in 26 out of 28 cases in this study. Of 
these, 11 (40%) were culture positive and 1 isolate of Mycobacterium tuberculosis 
were found to be resistant to isoniazid. This is consistent with the larger multi-centre 
cohort of patient with mediastinal lymph node tuberculosis (Chapter 4) which 
demonstrated an overall diagnostic sensitivity of 94% in 156 patients and culture rate 
of 47%. The emergence of drug resistant tuberculosis emphasises the importance of 
sampling MLNs in this scenario and also the utility of EBUS-TBNA in this group of 
patients. In some cases however, diagnostic difficulty remains in distinguishing 
sarcoid from tuberculosis as non-caseating granulomas obtained from EBUS-TBNA 
may also be consistent with tuberculosis. The merit of PCR based tests on samples 
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obtained from EBUS-TBNA is currently under evaluation. The advent of 
miniforceps and transbronchial needle forceps may help to improve diagnostic yield 
further in patients with suspected mediastinal lymphoma or tuberculosis (Herth et al. 
2011). 
This study is the first health economic analysis of EBUS-TBNA in patients with 
IML. The cost of EBUS-TBNA to the NHS in this trial was estimated at £1382 per 
procedure. This is slightly higher than the costs of EBUS-TBNA estimated in 
Singapore (Ang et al. 2010) of SGD 2623 (£1337) and the US (Harewood et al. 
2010) of $1711 (£1051). A decision tree analysis in patients with lung cancer from 
an Australian perspective (Steinfort et al. 2010b) employed a mean cost of EBUS-
TBNA of $1361(£905). The current NICE guidance on lung cancer utilises a cost of 
£1252 per EBUS-TBNA (Medford et al. 2009).  If we used these lower costs per 
procedure then the cost savings achieved by the EBUS-TBNA strategy would 
increase by a small amount. The estimate of the cost to the NHS of EBUS-TBNA of 
£1382 per procedure (detailed in Table 6.1) is based on a model of 2 lists per week 
and 3 cases per list resulting in approximately 250 cases per year. This necessitates 2 
dedicated endobronchial ultrasound scopes and a single processor which have been 
factored into the costings as capital costs.  
In the current analysis a cost-minimisation approach was considered the most 
appropriate as the same final diagnosis, treatment and treatment outcomes would 
have been reached regardless of whether EBUS-TBNA or mediastinoscopy were 
employed as the initial procedure. In addition, complications from EBUS-TBNA and 
mediastinoscopy were not observed or included in this study; this is possibly a 
conservative assumption. A systematic review of studies of EBUS-TBNA in patients 
with lung cancer up to 2008 (Gu et al. 2009) has demonstrated that the procedure is 
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very safe with only 2 complications recorded in 1299 procedures (1 patient with a 
pneumothorax and 1 patient with hypoxia). In a large retrospective single-centre 
study of 2145 patients  undergoing mediastinoscopy the complication rate was 1% 
which comprised of 1 death, 7 haemorrhages, 2 tracheal injuries, 2 pneumothoraces 
and 12 patients with vocal cord dysfunction (Lemaire et al. 2006). The low rate of 
complications was not included in the decision tree model but in view of reported 
complication rates in the literature which are higher for mediastinoscopy, their 
inclusion would have further favoured the EBUS-TBNA strategy.  
Limitations of the study are acknowledged. EBUS-TBNA was performed in a 
tertiary centre with a high volume of procedures carried out by physicians with 
expertise in the procedure. The reporting pathologists also have considerable 
experience in the interpretation of EBUS-TBNA specimens. The sensitivity obtained 
and proportion of mediastinoscopies prevented in this study therefore may not be 
immediately reproducible in other centres. The trial excluded patients with anterior 
mediastinal lymphadenopathy (inaccessible by EBUS-TBNA) and therefore the 
results cannot be applied to these patients. Although the cost of EBUS-TBNA to the 
NHS has been approximated, sensitivity analysis has been carried out and the effect 
has been reported for a wide range of potential EBUS-TBNA costs.  
In conclusion, EBUS-TBNA is a safe, highly sensitive and cost-saving initial 
investigation in patients with IML being referred for mediastinoscopy. The low 
negative predictive value of EBUS-TBNA in this setting indicates that 
mediastinoscopy should be performed in cases of negative EBUS-TBNA. 
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CHAPTER 7:  
SUITABILITY OF ENDOBRONCHIAL ULTRASOUND-
GUIDED TRANSBRONCHIAL NEEDLE ASPIRATION 
SPECIMENS FOR THE SUBTYPING AND GENOTYPING OF 
NON-SMALL CELL LUNG CANCER 
 
7.1 INTRODUCTION 
 
Traditionally, the pathology of lung cancer has been divided into non-small cell lung 
cancer (NSCLC) and small cell lung cancer, reflecting the different tumour biology 
and treatments. In recent years, it has become necessary to further subdivide NSCLC 
and subtyping and genotyping of NSCLC is now central to treatment decisions for 
patients with advanced NSCLC. Late phase clinical trials have provided 3 major 
observations that certain treatment agents only have efficacy or safety in particular 
subtypes or genotypes of NSCLC. First, a large randomised non-inferiority trial of 
Pemetrexed and Cisplatin in 1725 patients with NSCLC (Scagliotti et al. 2008) 
demonstrated that Pemetrexed is only of benefit in patients with non-squamous 
histology, while in patients with squamous subtype Pemetrexed was inferior to the 
standard treatment of Cisplatin and Gemcitabine.  This has been reflected in 
guidance from the National Institute of Health and Clinical Excellence (NICE) 
which has recommended pemetrexed as a first line treatment for patients with 
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adenocarcinoma or large cell carcinoma in September 2009 (National Institute of 
Health and Clinical Excellence 2009).  
 
Second, a randomised phase II trial of bevacizumab plus carboplatin and paclitaxel 
versus carboplatin and paclitaxel alone revealed that fatal pulmonary haemorrhage 
was significantly higher in patients with squamous subtype of NSCLC (Johnson et 
al. 2004). Consequently, bevacizumab is contra-indicated in patients with squamous 
cell lung cancer (SQCC). Third, phase III randomised trials in East Asia have 
demonstrated that the tyrosine kinase inhibitors only have improved progression-free 
survival (PFS) in patients with NSCLC harbouring an activating EGFR mutation. In 
patients without an EGFR mutation, standard chemotherapy may offer superior PFS 
(Mok et al. 2009;Zhou et al. 2011) . Further targeted agents in patients with specific 
cancer genotypes are set to emerge (Kwak et al. 2010).  
Coupled with the emergence of personalised therapies for advanced NSCLC has 
been the rapid expansion of endobronchial ultrasound guided transbronchial needle 
aspiration (EBUS-TBNA) which allows sampling of mediastinal and hilar 
lymphadenopathy under direct vision. The technique employs a 21 or 22 gauge 
needle and therefore obtains smaller samples than biopsy via mediastinoscopy. 
Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) 
was initially developed for the nodal staging of lung cancer. However, it is now 
commonly used as an initial investigation in patients with suspected NSCLC after 
computed tomography scan as it may provide a tissue diagnosis and accurate nodal 
staging in a single investigation (Navani, Spiro, & Janes 2009). However, given the 
concern regarding the smaller samples obtained it is unknown whether aspirates 
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from EBUS-TBNA in routine practice provide sufficient material to allow subtyping 
and genotyping of NSCLC in order to guide treatment. We therefore conducted a 
large pragmatic multi-centre study to clarify whether samples from EBUS-TBNA 
were suitable for subtyping of NSCLC and EGFR mutation testing.          
7.2 METHODS 
 
7.2.1 Patients and EBUS-TBNA samples 
 
Patients included in this retrospective study were known or suspected to have 
NSCLC and underwent EBUS-TBNA between January 2009 and March 2011 across 
5 centres in the UK. The participating centres were University College London 
Hospital, University Hospital Birmingham, University Hospital of North Tees, 
Lancashire Teaching Hospital and Papworth Hospital, Cambridge. Patient 
demographic data was collected and included age, gender and ethnicity. Information 
on the EBUS-TBNA procedure regarding the lymph stations and the size of lymph 
nodes sampled was also documented. Following systematic assessment of the 
mediastinal and hilar lymph node stations, the target lymph node was aspirated under 
direct ultrasound vision using a dedicated EBUS-TBNA needle (22 or 21 gauge). 
Three to 5 passes per lymph node were made. Rapid on-site evaluation of samples 
was not employed. The samples obtained were expelled from the needle using the 
stylet and placed into liquid fixative for cell-block processing. Needle contents were 
also flushed with saline into the liquid fixative. The specimen was centrifuged to 
form a pellet, suspended in agar, fixed in neutral buffered formalin and processed as 
a cell block from which a single hematotoxylin and eosin (H&E) stained section was 
cut. Further sections were cut and used for immunohistochemical staining as 
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required (Wallace et al. 2007). When cores of tissue were obtained at EBUS-TBNA 
these were placed directly into formalin.  
7.2.2 Pathological and molecular techniques 
 
Interpretation of the EBUS-TBNA specimens was carried out by the locally 
reporting pathologist and there was no centralised reporting. Classification of 
NSCLC was based upon morphological appearances (H&E stain) according to the 
criteria summarised in Table 7.1. Immunostaining was performed if the sample was 
sufficient and clinically indicated (Figure 71a-d). Antibodies to cytokeratins 5/6 
(CK5/6) and p63 were deemed to be consistent with squamous cell carcinoma 
(Kaufmann et al. 2001;Khayyata et al. 2009). Antibodies to Thyroid transcription 
factor 1 (TTF-1) were also employed and TTF-1 is known to be expressed in 
approximately 75% of lung adenocarcinomas (Stenhouse et al. 2004;Yatabe, 
Mitsudomi, & Takahashi 2002).  
The decision to submit the sample for EGFR mutation testing was made following 
discussion by the multi-disciplinary team. EGFR mutations were detected using 
DNA sequencing techniques and patients were considered to be positive for EGFR 
mutation if 1 of 29 EGFR mutations was detected by polymerase chain reaction 
based assays (Figure 7.1e). Four centres employed the commercially available 
amplification refractory mutation system (ARMS) kit (Qiagen) which is able to 
detect an EGFR mutation in samples which contain 1% tumour. The remaining 
centre employed a matrix-assisted laser desorption/ionization mass spectroscopy 
system for detecting EGFR mutations (Sequenom MassARRAY). 
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7.2.3 Endpoints and statistical analysis 
 
The primary endpoint of the study was the proportion of patients with NSCLC 
undergoing EBUS-TBNA in whom it was not possible to subtype the lung cancer 
and therefore were classified as NSCLC not otherwise specified (NSCLC-NOS). The 
co-primary endpoint was the proportion of samples that were not suitable for EGFR 
testing as determined by the local testing centre. The rate of NSCLC-NOS were 
determined according to age, lymph node location (hilar versus mediastinal) and size 
(greater or less than 1cm in short-axis), pathological differentiation and whether 
immunohistochemistry was carried out in univariate and multivariate analyses. The 
unit of analysis was the patient. 
Each patient was followed up for at least 6 months duration and each EBUS-TBNA 
procedure was therefore classified as a true positive, true negative or false negative 
result. False positive results from EBUS-TBNA were assumed not to occur.  
Standard definitions for the calculation of the sensitivity and negative predictive 
value of EBUS-TBNA (secondary endpoints) in patients with NSCLC were applied.  
Proportions were compared using the Chi-squared test. Predictors of NSCLC-NOS 
were modelled using logistic regression. Covariates demonstrated to be significant at 
the 20% level on Univariate analysis were entered into the multivariate model. All 
statistical calculations were carried out using STATA version 10 (Statacorp., USA). 
Ethical approval was not required given the observational nature of the study. All 
results were fully disclosed to the patients and also discussed in multi-disciplinary 
team meetings in order to determine the treatment strategies. 
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Table 7.1: Morphological criteria used on EBUS-TBNA samples for differentiating 
between adenocarcinoma and squamous cell lung carcinoma. Data from Sturgis et al. 
(2000). 
 
 Adenocarcinoma Squamous Cell 
Carcinoma 
Background Cell debris, foamy 
macrophages 
Necrosis 
Cell distribution Small aggregates Individually dispersed 
Architecture Glandular, acinar, 
papillary 
Solid, trabecular 
Cell group Morulae Pearl formations 
Cell membrane Poorly defined Well defined 
Cytoplasm Scanty, vacuolated Large, dense, keratinized 
Nuclei Round-oval, lightly 
stained 
Irregular, hyperchromatic 
Nucleoli Prominent (well 
differentiated) 
Inconspicuous 
(keratinized) 
Prominent (non-
keratinized) 
Nuclear pseudoinclusions Present Absent 
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Figure 7.1a: EBUS-TBNA smear demonstrating adenocarcinoma (May–Grunwald-
Giemsa stain). 
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Figure 7.1b: Cell block obtained from EBUS-TBNA demonstrating adenocarcinoma 
(H&E stain) 
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Figure 7.1c: Adenocarcinoma from EBUS-TBNA cell block positive for TTF-1, 
confirming lung origin 
TTF-1; thyroid transcription factor -1 
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Figure 7.1d: EBUS-TBNA cell block demonstrating adenocarcinoma to be ERCC1 
positive, suggesting resistance to platinum-based chemotherapies 
ERCC1: excision repair cross-complementing group 1 
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Figure 7.1e: Real-time polymerase chain reaction plot (RT-PCR) showing exon 19 deletion in the Epidermal Growth Factor Receptor gene. 
DNA is extracted from EBUS-TBNA specimens and the mutations are detected by real-time PCR amplification and hybridisation using 
fluorescently labelled probes. There is RT-PCR amplification of EGFR control (blue arrow) and exon 19 deletion (red arrow). The exogenous 
control is the green line. 
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7.3 RESULTS 
 
Between 2009 and 2011, 615 patients with known or suspected NSCLC underwent 
EBUS-TBNA at 5 UK centres. Three-hundred and fifty-five (58%) were male and 
the median age of patients with NSCLC was 69 (range 35 – 88) years. Baseline 
characteristics are summarised in Table 7.2 (page 156). Two-hundred and fifty-eight 
patients had more than 1 lymph node sampled and in total 893 lymph nodes were 
aspirated. The size and location of lymph nodes sampled and the diagnostic yield are 
shown in Table 7.3 (page 157).  
The pathological subtypes of NSCLC diagnosed by EBUS-TBNA are shown in 
Figure 7.2 (page 152). In total, 478 had a final diagnosis of NSCLC in intra-thoracic 
lymph nodes. The number of patients with a final diagnosis by EBUS-TBNA of 
NSCLC – NOS (the primary endpoint) was 86 (21%, 95% CI 18% - 26%). 250 
(62%) patients had their EBUS-TBNA specimens submitted for immunostaining and 
this was possible in 233 (93%, 95% CI 89% - 96%).  In univariate analysis, there 
was no association between NSCLC-NOS and age, lymph node size, lymph node 
location, number of lymph nodes aspirated and pathological differentiation. 
However, a highly significant relationship was seen on univariate and multivariate 
analysis (Figure 7.3i-viii, page 153-5) between immunohistochemistry not 
performed and the final diagnosis of NSCLC-NOS (Table 7.4, page 158). The 
multivariate model also included pathological differentiation. When immunostaining 
was possible, the risk of the NSCLC tumour being unclassified was halved in the 
multivariate analysis (OR 0.50, 95% CI 0.28 – 0.88, P=0.016).   
Three hundred and eighty-one patients had lymph nodes aspirated that were greater 
than 1cm in short axis. Of these, 281 had NSCLC diagnosed by EBUS-TBNA and 
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the number of patients diagnosed with NSCLC –NOS was 46 (16% 95% CI 11% – 
19%) in this subgroup. In the 54 patients with recorded lymph node size less than or 
equal to 1cm in short axis, the prevalence of malignancy was 61% (33 patients) and 
the number of patients diagnosed with NSCLC-NOS was 3 (9%, 95% CI 2 – 24%). 
In 180 patients the lymph node size was not recorded. There was no statistically 
significant difference (P=0.60) in the NOS-NSCLC rate in nodes greater or less than 
1cm in short axis. 458 patients had sampling with a 22 gauge needle while the larger 
21 gauge needle was used in the remainder and was associated with a NSCLC-NOS 
rate of 22% and 10% respectively (P=0.40). 
Ninety-three (22%) patients who underwent EBUS-TBNA had EGFR mutation 
analysis requested on the sample. Of these, 47 were adenocarcinoma, 18 had 
squamous cell carcinoma, 9 had large cell carcinoma and 19 had NSCLC-NOS. 
EGFR mutation analysis was possible (the co-primary endpoint) in 84 (90%, 95% CI 
82% – 95%) cases and 5 (5%) patients with EGFR mutations were identified. Of the 
5 patients who had an EGFR mutation, all were Caucasian and had adenocarcinoma. 
The median age of these patients was 58 years (range 53 – 68) and 4 (80%) were 
female.  Two out of the 5 EBUS-TBNA samples which had an EGFR mutation 
EBUS-TBNA were also noted to stain for TTF-1.   
Overall, EBUS-TBNA had a sensitivity of 88% (95% CI 85% - 91%), negative 
predictive value of 71% (95% CI 64% - 77%) and diagnostic accuracy of 91% (95% 
CI 88% - 93%). Four hundred and twenty-two  patients had NSCLC diagnosed by 
EBUS-TBNA. Fifty-six patients had a false negative EBUS procedure. In each of 
these cases lymphoid cells only were aspirated and subsequent surgery, 
mediastinoscopy or clinical follow-up confirmed malignancy (Figure 7.2, page 152). 
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None of the 32 specimens in whom granulomas were aspirated were proven to be 
false negative results. 
The sensitivity from aspiration of hilar lymph nodes (stations 10 and 11) was 78% 
(95% CI 67% - 87%) and was significantly inferior to the sensitivity from 
mediastinal lymph nodes (88%, 95% CI 84% - 91%, P=0.049). The median size of 
hilar lymph nodes was 15mm (range 7 – 40). 
Sensitivity in patients with lymph nodes ≤1cm in short-axis was 61% (95% CI 44% - 
75%), and significantly lower than the sensitivity of 90% (95% CI 87% - 93%, 
P<0.001) in nodes >1cm.  There was no interaction between lymph node location 
and size. 
One patient’s EBUS procedure resulted in a death. The patient was an 81 year old 
female who presented with stage IV adenocarcinoma of the lung. The EBUS-TBNA 
procedure was uncomplicated and the patient was discharged home after the 
procedure with normal vital observations. Twenty-four hours later the patient was 
admitted to hospital with clinical features of severe pneumonia and sepsis. Group A 
Streptococcus was isolated from blood cultures and also from a throat swab. The 
patient deteriorated from sepsis and respiratory failure and died within 48 hours of 
admission. The scenario was attributed to the carriage of organisms by the EBUS 
scope from the pharynx into the lungs. No other complications were reported. 
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Patients with suspected or 
known NSCLC underwent 
EBUS-TBNA (n=615) 
Squamous Cell 
Carcinoma (n=112) 
Large cell 
carcinoma 
(n=23) 
 
Adenocarcinoma 
(n=105) 
Mixed 
(n=3) 
IHC performed 
(n=43) 
Ck5/6 positive (n=35) 
IHC performed (n=92) 
TTF-1 positive (n=65) 
EGFR mutation 
testing performed 
(n=49) 
EGFR mutation (n=5) 
56 NSCLC 
subsequently 
diagnosed by 
mediastinoscopy 
(n=7), at surgery 
(n=6), by EUS (n=1) 
or by clinical follow-
up (n=42) 
Granulomas (n=32),   
Lymphoid Cells only 
(n=179), inadequate 
(n=9) 
NSCLC  
NOS 
(n=89) 
Figure 7.2: Flowchart 
of patients 
Other 
(n=63) 
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Figure 7.3: STATA output of univariate and multivariate analyses to predict 
occurrence of NSCLC-NOS from EBUS-TBNA specimens 
(i) No relationship between NOS rate and age (P=0.93) 
 
(ii) No relationship between NOS rate and lymph node location (mediastinal vs hilar 
lymph nodes) 
 
 
(iii) No relationship between number of lymph nodes sampled and NOS rate 
 
 
                                                                              
         age     .9989435   .0126495    -0.08   0.933      .974456    1.024046
                                                                              
    cytology   Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -192.99876                       Pseudo R2       =     0.0000
                                                  Prob > chi2     =     0.9335
                                                  LR chi2(1)      =       0.01
Logistic regression                               Number of obs   =        332
. logistic  cytology  age
                                                                              
lymphnodel~1     1.556467   .5404004     1.27   0.203     .7881439    3.073792
                                                                              
    cytology   Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -192.21845                       Pseudo R2       =     0.0041
                                                  Prob > chi2     =     0.2106
                                                  LR chi2(1)      =       1.57
Logistic regression                               Number of obs   =        332
. logistic cytology  lymphnodelocation1
                                                                              
numberofly~d     1.095411   .2368968     0.42   0.673     .7169584    1.673634
                                                                              
    cytology   Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood =  -192.9139                       Pseudo R2       =     0.0005
                                                  Prob > chi2     =     0.6742
                                                  LR chi2(1)      =       0.18
Logistic regression                               Number of obs   =        332
. logistic cytology  numberoflymphnodessampled
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(iv) No relationship between NOS rate and size of largest lymph node sampled 
 
 
(v). Non-significant relationship between NOS rate and pathological differentiation 
(P=0.089) 
Patients with a poorly or undifferentiated tumour have 1.7 times the odds of their 
NSCLC being undifferentiated 
 
 
(vi) Highly significant relationship between NOS rate and lack of 
immunohistochemistry 
 
                                                                              
sizeoflarg~m     1.002251     .02334     0.10   0.923     .9575334    1.049056
                                                                              
    cytology   Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -114.87328                       Pseudo R2       =     0.0000
                                                  Prob > chi2     =     0.9231
                                                  LR chi2(1)      =       0.01
Logistic regression                               Number of obs   =        213
. logistic  cytology sizeoflargestnodesampledmm
                                                                              
pathologic~n     1.666418   .5007746     1.70   0.089     .9246762    3.003158
                                                                              
    cytology   Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -191.60293                       Pseudo R2       =     0.0073
                                                  Prob > chi2     =     0.0943
                                                  LR chi2(1)      =       2.80
Logistic regression                               Number of obs   =        332
. logistic  cytology pathologicaldifferentiation
                                                                              
immunohist~y     .4675082   .1338022    -2.66   0.008     .2667921    .8192294
                                                                              
    cytology   Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -189.20649                       Pseudo R2       =     0.0197
                                                  Prob > chi2     =     0.0059
                                                  LR chi2(1)      =       7.59
Logistic regression                               Number of obs   =        332
. logistic  cytology immunohistochemistry
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(vii) Raw data showing relationship between NOS rate (cytology=1) and presence of 
immunochemistry 
 
 
(viii) In a multivariate model that also included pathological differentiation, 
immunohistochemistry retained its significant association with NOS rate.  
 
  
     Total         219        113         332 
                                             
         1          69         20          89 
         0         150         93         243 
                                             
  Cytology           0          1       Total
             Immunohistochemistry
. tab  cytology immunohistochemistry
                                                                              
immunohist~y     .4963152    .144514    -2.41   0.016     .2804852    .8782239
pathologic~n     1.435791    .441307     1.18   0.239     .7860761    2.622515
                                                                              
    cytology   Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -188.52805                       Pseudo R2       =     0.0232
                                                  Prob > chi2     =     0.0114
                                                  LR chi2(2)      =       8.95
Logistic regression                               Number of obs   =        332
. logistic  cytology  pathologicaldifferentiation  immunohistochemistry
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Table 7.2: Baseline characteristics of 615 patients with suspected lung cancer who 
underwent EBUS-TBNA 
 
 Number (%) 
Gender 
          Male 
          Female 
 
355 (58%) 
260 (42%) 
Age 
          <50 
          50 – 75 
          >75 
 
34 (6%) 
437 (71%) 
144 (23%) 
Smoking 
          Current 
          Former 
          Never or <10 pack years 
 
161 (26%) 
406 (66%) 
48 (8%) 
Ethnicity 
          Caucasian 
          South Asian 
          East Asian 
          African 
          Caribbean 
          Other 
          Unknown 
 
546 (89%) 
9 (1%) 
1 (0%) 
0 (0%) 
0 (0%) 
0 (0%) 
59 (10%) 
Total 615 
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Table 7.3: Lymph node stations sampled in 615 patients undergoing EBUS-TBNA 
Lymph 
node 
station 
 
Number 
of nodes 
sampled 
Mean 
size of 
lymph 
node 
(mm) 
Prevalence 
of NSCLC 
Sensitivity Negative 
Predictive 
Value 
Diagnostic 
accuracy 
2R 
 
12 18 56% 80% 80% 89% 
2L 
 
1 20 100% 100% N/A 100% 
3P 
 
2 18 0% N/A 100% 100% 
4R 
 
225 21 86% 90% 62% 91% 
4L 
 
72 18 72% 75% 61% 82% 
7 
 
361 22 74% 89% 77% 92% 
10R 
 
87 17 71% 100% 100% 100% 
10L 
 
44 18 78% 94% 83% 96% 
11R 
 
16 15 93% 85% 33% 86% 
11L 
 
4 13 100% 50% 0% 50% 
Overall 
 
824 21 78% 88% 72% 91% 
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Table 7.4: Univariate and multivariate analyses of factors to predict NSCLC-NOS in 
patients undergoing EBUS-TBNA. On the basis of univariate results, only 
pathological differentiation and performance of immunohistochemstry 
 
Covariate Unadjusted 
OR of 
NSCLC-
NOS 
Univariate P 
value 
Adjusted 
OR of 
NSCLC-
NOS 
Multivariate 
P value 
Age 0.99 0.93   
Lymph node location 1.55 0.20   
Lymph node size 1.0 0.92   
Pathological 
differentiation 
1.66 0.09 1.44 0.24 
Immunohistochemistry 
performed 
0.47 0.008 0.50 0.016 
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7.4 DISCUSSION 
 
While the sophistication of patient selection for treatment has increased, the size of 
lung cancer samples to obtain that information has reduced. The challenge for the 
lung cancer multi-disciplinary team is therefore to optimise diagnostic specimens 
and staging, while also supplying sufficient information to guide oncological 
therapy. Since at least 75% of patients have inoperable disease, this information to 
guide treatment algorithms must often be obtained from small histology or cytology 
specimens. 
EBUS-TBNA is an important investigation for the diagnosis of mediastinal and hilar 
lymphadenopathy in patients with lung cancer. It has been recommended as an initial 
investigation by NICE (2011) in patients with enlarged mediastinal lymph nodes as 
it may provide an inoperable disease stage and a pathological diagnosis in a single 
investigation. This large multi-centre pragmatic implementation study demonstrates 
that routine samples from EBUS-TBNA are able to provide sufficient information to 
allow subtyping in 79% and genotyping in 90% of patients with NSCLC. 
The proportion of patients with NSCLC in whom EBUS-TBNA diagnosed NSCLC-
NOS in this multi-centre study was 21%. This is consistent with data from 
alternative biopsy techniques. An analysis of the California Cancer Registry of 
175,298 patients diagnosed with lung cancer between 1989 and 2006 demonstrated a 
NSCLC-NOS rate of 22.1% (Ou & Zell 2009). The rate of NSCLC-NOS was higher 
in the patients who had a cytological diagnosis alone (37%). The National Lung 
Cancer Audit (NLCA) recently published data on 37,637 patients diagnosed with 
lung cancer in Great Britain and Northern Ireland in 2009 (NHS Information Centre 
2011). These patients underwent diagnosis and staging of lung cancer in a real world 
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setting in England and Wales and the audit demonstrated an overall NSCLC-NOS 
rate of 30.5%. The improved rate of NSCLC-NOS in EBUS-TBNA samples does 
not entirely reflect a change in pathological assessment with a drive to lower NOS 
rate since part of the EBUS cohort was also carried out in 2009. It does highlight that 
EBUS-TBNA samples at the very least are as good as other sample acquisition 
techniques for subtypying, such as bronchoscopy and CT guided biopsy.  EBUS-
TBNA is also able to sample central parenchymal lung lesions that would otherwise 
not be accessible without a considerably more invasive approach (Tournoy et al. 
2009). Therefore increased application of EBUS-TBNA may improve the rates of 
histological confirmation in patients with NSCLC, which currently stand at a mean 
of 75.6% in the NLCA (NHS Information Centre 2011).   
Previous studies have shown that samples from cytology are valid when compared to 
subsequent larger samples. Indeed, the morphologic features that distinguish 
squamous cell carcinoma (predominantly keratinized cytoplasm and intercellular 
bridges) from adenocarcinoma (mucin vacuoles and gland formation) span less than 
the 250-μm inner diameter of a 25-gauge fine needle (Fischer et al. 2011). In a recent 
retrospective study of 48 patients (Wallace & Rassl 2011), cell block samples from 
EBUS-TBNA were compared to histological specimens obtained by alternative 
procedures such as bronchoscopy and CT guided biopsy. All subtypes diagnosed by 
EBUS-TBNA were validated by histological samples. When immunohistochemistry 
was performed on cell blocks, there were six cases diagnosed with NSCLC-NOS on 
EBUS-TBNA samples which were diagnosed with a specific cell type on alternative 
histological samples (3 adenocarcinomas, 2 squamous cell carcinomas and 1 large 
cell undifferentiated carcinoma).  A further study of 101 individuals demonstrated a 
93% concordance between small biopsy and cytology specimens (Sigel et al. 2011). 
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As in this study, lack of supporting immunohistochemistry contributed to 
unclassified cytology cases. In another report, 158 (85%) cases of NSCLC were 
typed by cytology and 28 (15%) were classified as NSCLC-NOS (Nizzoli et al. 
2011). Utilising histological specimens from the same patients, 183 (98%) of cases 
were subtyped by histology and only 3 (2%) cases were classified as NSCLC-NOS.  
There was 88% concordance between cytological and histological typing. The 
available data therefore confirm that cytological specimens are reliable for subtyping 
with no false positive results from cytological subtyping observed and that use of 
immunohistochemistry can reduce the NSCLC-NOS rate. 
Immunohistochemistry profiles do not feature in the diagnostic criteria for squamous 
cell or adenocarcinoma in the current WHO classification of NSCLCs which is based 
on resected surgical specimens (Travis WD 2004). However when morphological 
criteria are unable to distinguish subtypes in smaller samples, a panel of antibodies 
including TTF-1, p63 and CK5/6 as well as a mucin stain has been recommended in 
order to minimise the rate of NSCLC tumour that remain unclassified and to make 
the key distinction between squamous and non-squamous subtypes (Nicholson et al. 
2010). The current large pragmatic study shows that samples obtained by EBUS-
TBNA are suitable for this approach from any accessible lymph node station and 
even when sampling lymph nodes less than 1cm in size.  
The EGFR-tyrosine kinase inhibitors erlotinib and gefitinib have become established 
as first-line treatments for patients with advanced lung cancer that harbour an EGFR 
mutation. Current European Society of Medical Oncology guidelines recommend 
that all never or former light smokers (<15 packs per year) or patients with non-
squamous histology should be tested for EGFR mutation status regardless of 
performance status (Felip et al. 2011). Cytological samples in alcohol based fixatives 
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may preserve nucleic acids better than formalin (Vincek et al. 2003) and molecular 
profiling of cytology samples has been shown to be reliable when compared with 
histological samples from the same patient (van Eijk et al. 2011). In this study, 
EGFR mutation testing was requested in 93 patients and the test was possible and 
deemed reliable in 84 (90%) cases. In the remaining cases, there was insufficient 
tumour sample to perform the investigation. Five patients with an EGFR mutation 
were observed out of 49 with adenocarcinoma. Previous studies have assessed the 
utility of EBUS-TBNA samples for EGFR testing with variable results. In one study 
EGFR mutation testing was possible in 27 out of 35 patients (77%) undergoing EUS-
FNA or EBUS-TBNA (Schuurbiers et al. 2010). Another study of 36 patients in 
Spain undergoing EBUS-TBNA suggested EGFR mutation analysis was feasible in 
26 cases (Garcia-Olive et al. 2010). Billah demonstrated that 96% of specimens from 
EBUS-TBNA in a US cancer centre were able to undergo EGFR mutation testing 
(Billah et al. 2011). Similarly high rates of reliable EGFR mutation testing of EBUS-
TBNA samples have been observed by Nakajima and colleagues (2007;Nakajima et 
al. 2011). A recent study, in which cell blocks were prepared from 128 lung cancer 
cytology specimens, demonstrated that molecular analysis was possible in 98% of 
specimens (Rekhtman et al. 2011). The low prevalence of EGFR mutation in patients 
with adenocarcinoma (10%) in our study reflects the predominantly Caucasian 
smoking population.  
It is widely accepted that NSCLC may contain areas of mixed adenocarcinoma, large 
and squamous cell carcinoma. Up to 25% of small cell carcinomas are thought to 
contain areas of NSCLC differentiation (Anraku & Waddell 2006). This pathological 
heterogeneity implies that smaller cytological samples may not be representative of 
the entire lesion. Another area of controversy that is currently developing in NSCLC 
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is that of genetic tumour heterogeneity. Conflicting evidence exists. Three studies 
comparing EGFR mutation status in primary tumour and local lymph node 
metastases demonstrated significant discrepancies between the sites (Park et al. 
2009;Schmid et al. 2009;Sun et al. 2011). However a recent study showed that when 
highly sensitive techniques for mutation detection are employed, no discordant 
mutation patterns were detected among 77 paired primary and metastatic tumours 
(Yatabe, Matsuo, & Mitsudomi 2011). These authors suggested that weak EGFR 
mutation signals in an area without EGFR amplification may not reach the threshold 
of detection because of the mixture with normal cells resulting in 
pseudoheterogeneity. The authors concluded that true genetic heterogeneity is rare 
(Yatabe, Matsuo, & Mitsudomi 2011). This latter view would support EGFR 
mutation status being assessed in the most accessible tissue only, rather than multiple 
sites being sampled. 
This study confirms the high yield from EBUS-TBNA of detecting malignancy in 
intra-thoracic lymph nodes in a real world setting. A sensitivity of 88% in 615 
patients was observed (disease prevalence of 78%) which is similar to a sensitivity of 
93% observed in a meta-analysis of 1299 patients (Gu et al. 2009). This study 
contains the first reported death attributed to EBUS-TBNA. The complication may 
be attributed to the process of introducing pharyngeal micro-organisms into the 
lower respiratory tract. The patient was elderly and immunosuppressed due to widely 
metastatic malignancy and succumbed to sepsis within 72 hours of the procedure. 
 The large number of patients included in this study renders subgroup analyses 
powerful. Hilar lymph nodes and lymph nodes less than 1cm were noted to have 
lower sensitivities than mediastinal nodes and nodes greater than 1cm respectively. 
This may be due to the increased technical difficulty of sampling hilar and smaller 
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lymph nodes. However, when hilar or small lymph nodes were sampled successfully, 
the samples were still suitable for NSCLC sub-typing and EGFR mutation analysis.  
Limitations of this study are recognised. Pathological samples in this study did not 
undergo central review, however this reflects the pragmatic nature of the study and 
results in strong external validity. The centres included in the study carry out a high 
volume of EBUS-TBNA procedures with  experienced operators and pathologists. A 
final issue is that not all negative EBUS-TBNA cases underwent mediastinoscopy. 
All patients did however undergo at least 6 months clinical follow-up to allow a 
clinical diagnosis to be made. 
Recent guidance has suggested a novel algorithm for the diagnosis of 
adenocarcinoma in small biopsies and cytological samples (Travis et al. 2011). In 
patients with positive cytology and classic morphology for adenocarcinoma or 
squamous cell carcinoma no further markers are required and those with 
adenocarcinoma can be submitted directly for EGFR mutation testing. Samples 
which are classified as NSCLC-NOS on morphology are recommended to undergo a 
panel of immunohistochemistry that includes one squamous cell carcinoma marker 
and one adenocarcinoma marker +/- mucin staining. If the NSCLC tumour still 
remains unclassified then molecular analysis is still recommended.  This multi-centre 
study clearly demonstrates that samples from EBUS-TBNA obtained in routine 
practice are suitable for entry into this new diagnostic algorithm and provides further 
impetus for the use of EBUS-TBNA as an initial diagnostic procedure in patients 
with suspected lung cancer. 
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CHAPTER 8:  
THE LUNG-BOOST TRIAL – A PRAGMATIC 
RANDOMISED CONTROLLED TRIAL OF ENDOBRONCHIAL 
ULTRASOUND-GUIDED TRANSBRONCHIAL NEEDLE 
ASPIRATION AS AN INITIAL INVESTIGATION IN PATIENTS 
WITH SUSPECTED LUNG CANCER 
 
8.1 INTRODUCTION 
 
Lung cancer remains one of the most challenging of all the malignant diseases. There 
are 1.35 million new cases diagnosed each year and lung cancer is the biggest killer 
of men and women who die of any cancer across the world (Parkin et al. 2005). Lung 
cancer in never smokers has risen to be included in the top ten causes of death from 
cancer in the Western World; yet smoking, the primary cause for 85% of sufferers, is 
being met with variably successful smoking cessation programmes across the globe. 
Smoking, especially amongst young women continues to rise.  
The clinical staging of non-small cell lung cancer (NSCLC) is a critical process that 
determines treatment options and guides prognosis. This is currently best achieved 
via a multi-disciplinary approach involving surgical, respiratory, oncology and 
radiology input. In patients with NSCLC who are fit for surgery and have no 
166 
evidence of extra-thoracic spread, the disease status of the mediastinal lymph nodes 
(MLN) is used to differentiate operable from inoperable candidates. Patients with no 
clinical evidence of MLN metastases are eligible for surgery while those with 
clinically detected N2 or N3 disease are referred for multi-modality treatment. 
Several invasive and non-invasive techniques are available to diagnose and stage 
lung cancer. Patients commonly undergo a computed tomography (CT) scan of the 
thorax and upper abdomen. Approximately 50% of patients present with metastatic 
disease evident outside the thorax and in these patients a biopsy from the most 
convenient location by the least invasive modality allows management of the patient. 
However, in patients with intra-thoracic disease (stages I – IIIA) only on initial 
presenting CT scan, the diagnostic and staging algorithm is more complex. A biopsy 
of the primary lesion is commonly undertaken by bronchoscopy or CT guided biopsy 
before attention turns to nodal staging. CT and PET-CT scanning of mediastinal 
nodes are associated with significant problems of sensitivity in nodes <1cm in short 
axis and specificity in lymph nodes >1cm in short axis. Therefore, unless the patient 
has all mediastinal lymph nodes <1cm in short axis which are negative on PET-CT 
scan, current guidelines recommend invasive mediastinal sampling.  
The complete diagnosis and staging of patients with intra-thoracic disease therefore 
usually requires several procedures, often taking several weeks, which is a time of 
anxiety for patient. A further consideration is that the current approach to 
mediastinal staging of NSCLC (CT, PET-CT, mediastinoscopy) can result in 
inaccurate nodal staging in 25% of operable patients (Navani et al. 2010). This is 
unsurprising when we consider that the results of meta-analyses have calculated the 
sensitivity for the detection of mediastinal metastases by CT scan as 51%, by PET-
CT as 74% and mediastinoscopy as 78% (Silvestri et al. 2007).    
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Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is 
a newer technique that allows minimally invasive sampling of all intra-thoracic 
lymph nodes adjacent to the bronchial tree. A pooled analysis of 1299 patients with 
known or suspected NSCLC undergoing EBUS-TBNA demonstrated that the 
procedure had a sensitivity of 90% for the detection of nodal metastases (Gu et al. 
2009). At the time of trial inception, guidelines recommended EBUS-TBNA as an 
alternative to mediastinoscopy in patients who required invasive mediastinal 
sampling after PET-CT scan.  
We aimed to investigate whether EBUS-TBNA could be utilised as an initial 
investigation in patients with suspected lung cancer. Since the procedure was able to 
provide a tissue diagnosis and an inoperable disease stage in a single investigation, 
we hypothesised that EBUS-TBNA as a first test would reduce the time to treatment 
decision by reducing the number of investigations and outpatient appointments 
required in patients with suspected lung cancer. It was recognised that patients with 
N2 disease evident from EBUS-TBNA may remain candidates for radical treatment 
with chemo-radiotherapy, continuous hyperfractionated accelerated radiotherapy 
(CHART) or surgery and so would still require PET-CT scanning for definitive 
systemic staging. Therefore we conducted a pragmatic, multi-centre randomised 
controlled trial to test the hypothesis that EBUS-TBNA as an initial investigation 
after staging CT scan would reduce the time to treatment decision for patients with 
suspected lung cancer.  
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8.2 METHODS 
 
8.2.1 Patients 
 
Patients with suspected stage I – IIIA lung cancer on the basis of CT scan of the 
neck, thorax and upper abdomen were eligible for trial entry.  Patients were at least 
18 years of age and fit enough to undergo thoracotomy and lung resection. Exclusion 
criteria were significant concurrent malignancy and contra-indication to EBUS-
TBNA or mediastinoscopy. Patients with evidence of extra-thoracic malignancy, 
supraclavicular lymphadenopathy or pleural effusion were also excluded.  
This investigator initiated trial was approved by the ethics committees of the 6 
participating centres (University College London Hospital, Whittington Hospital, 
North Middlesex University Hospital, Princess Alexandra Hospital, Barnet General 
Hospital and Nottingham Hospital). The Lung-BOOST trial was registered on 
clinicaltrials.gov as NCT00652769. 
 
8.2.2 Study design 
 
Participants were randomly assigned (1:1) to either conventional diagnosis and 
staging (CDS) or EBUS-TBNA as an initial investigation followed by conventional 
diagnosis and staging techniques as required (EBUS-CDS). Telephone 
randomisation using permuted blocks of four generated by computer was employed. 
Randomisation was stratified according to the presence of mediastinal lymph nodes 
>1cm in short axis and recruiting centre. Following the informed consent process by 
the investigator, randomisation was carried out by research assistants telephoning the 
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randomisation line at the North London Cancer Research Network office. The 
random allocation sequence was concealed from participants and investigators until 
the interventions were assigned. Due to the nature of the intervention and the 
pragmatic nature of the trial, blinding of participants and investigators was not 
possible. Data was collected on paper case record forms (Appendix 1) and entered 
(using double data-entry) by an independent data clerk onto a secured trial database 
on a dedicated trial computer. 
 
8.2.3 Conventional diagnosis and staging 
 
Participants allocated to conventional diagnosis and staging (CDS) underwent 
investigations as determined by the multidisciplinary team. A suggested algorithm 
for CDS was provided in the trial protocol based on best available evidence and 
published guidelines (Figure 8.1). Patients were recommended to undergo CT guided 
biopsy or bronchoscopy depending upon whether the primary lesion was peripheral 
or central. Conventional transbronchial needle aspiration was utilised at the 
operator’s discretion. If the patient was a candidate for radical treatment, a PET-CT 
scan was recommended. Mediastinoscopy was advised if the presence of FDG avid 
lymph nodes precluded a radical treatment option. Invasive mediastinal sampling 
was also recommended in the trial protocol if any mediastinal lymph node was > 
1cm in short axis and its result would alter management. However, the protocol did 
not mandate any specific investigations (other than the exclusion of EBUS-TBNA) 
and all investigations and their order, including the need for PET-CT scan and 
mediastinoscopy, were determined by the multi-disciplinary team. 
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8.2.4 Endobronchial Ultrasound 
 
Patients randomised to the EBUS-TBNA arm of the trial underwent EBUS-TBNA as 
an initial procedure after staging CT scan. The procedure was performed in the 
outpatient setting under sedation with midazolam and fentanyl. Topical lidocaine 
was applied for local anaesthesia. EBUS-TBNA was performed with a dedicated 
bronchoscope with linear ultrasound integrated into the distal end (BF-UC160F-OL; 
Olympus, Tokyo). A systematic examination of all mediastinal and hilar lymph node 
stations was made. Nodes that were highlighted to be suspicious of metastasis on CT 
scan due to size or location were sampled and labelled according to the Mountain – 
Dressler (1997) lymph node map. If no abnormal nodes were identified, aspirates 
were taken using a 22 or 21-gauge needle from a lymph node station that is most 
likely to drain the primary lesion. Standard videobronchoscopy was permitted as an 
additional investigation at the same sitting at the operator’s discretion. Endosopic 
ultrasound guided fine needle aspiration (EUS-FNA) was permitted as an alternative 
to EBUS-TBNA if a target lesion was not amenable to EBUS-TBNA. Three to 5 
passes per lymph node were made. Rapid on-site evaluation of samples was not 
performed. Specimens obtained were smeared onto slides and also spun down for 
cell block analysis. Any cores obtained were transferred directly into formalin and 
subsequent histolopathological examination. Samples from EBUS-TBNA underwent 
routine laboratory processing. Results from EBUS-TBNA were discussed in multi-
disciplinary team meetings in the referring hospitals and further investigations were 
requested as required. A suggested investigative pathway was provided in the trial 
protocol but not mandated (Figure 8.2). 
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8.2.5 Treatment after diagnosis and staging 
 
In the event of mediastinal metastases being identified by clinical staging 
procedures, patients were referred for multi-modality therapy. This included 
palliative chemotherapy, palliative radiotherapy, radical radiotherapy, CHART or 
combined (concurrent or sequential) chemo-radiotherapy. When mediastinal 
metastases were not identified, patients were referred for surgery or radical 
radiotherapy. A PET-CT was recommended in all cases prior to a decision to treat 
with radical intent.   
 
8.2.6 Endpoints 
 
The primary endpoint was the time from first outpatient appointment to treatment 
decision, after completion of diagnosis and staging procedures. The sensitivity, 
negative predictive value and diagnostic accuracy of EBUS-TBNA were also 
calculated. Pre-specified secondary endpoints were (i) the health care costs of 
diagnosing and staging lung cancer (ii) the number of investigations and outpatient 
visits a patient required to be diagnosed and staged with lung cancer (iii) the 
proportion of lung cancer patients that are diagnosed and staged with a single test 
after CT scan (iv) the number of PET-CT scans and mediastinoscopies, (v) the 
number of futile thoracotomies. A futile or unnecessary thoracotomy was defined as 
either an exploratory (open and shut) thoracotomy, unexpected pT4 disease, 
unexpected mediastinal nodal metastases (pN2 or pN3), death within 1 year after 
surgery or evidence of disease recurrence within 1 year of surgery. The rate of 
complications due to diagnostic and staging techniques were also documented.   
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 8.2.7 Economic Analysis 
 
The incremental cost of the strategy of EBUS-TBNA as an initial investigation 
versus conventional diagnosis and staging in patients with suspected lung cancer was 
calculated from the perspective of the NHS. The analysis was based on data from the 
trial only up until the point of treatment decision. Unit costs were taken from NHS 
tariffs or local hospital costs. Estimation of the cost of EBUS-TBNA has been 
previously described (Table 6.1). Because all costs per patient occurred within one 
year, discounting was unnecessary. The sensitivity of the results to the cost of the 
EBUS-TBNA procedure was calculated, varying it between £503 (the 2010-11 NHS 
tariff for a flexible bronchoscopy) and £5259 (the 2010-11 NHS tariff for 
mediastinoscopy with complications).  
 
8.2.8 Statistical Analysis 
 
For the analysis of the primary endpoint (time to treatment decision), the Kaplan 
Meier method was utilised on a complete-case intention-to-treat basis. Standard 
definitions of sensitivity for the detection of nodal metastases were employed. The 
final diagnosis of nodal staging was determined by clinical follow-up and positive 
pathology from EBUS-TBNA, conventional TBNA, EUS-FNA, mediastinoscopy or 
mediastinal lymph node dissection. It was agreed with the ethics committee that 
malignant diagnoses from techniques that generate pathological specimens did not 
require further verification. 
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A sample size of at least 168 was initially planned to give 99% power, on the basis 
that patients in the CDS arm of the trial would require 3 investigations and a median 
time to treatment of 30 days, while patients in the EBUS-TBNA arm would require a 
single investigation and a median of 14 days. The trial was closed on the 1
st
 July 
2011 due to funding expiry at which point 133 patients had been recruited, giving the 
trial 95% power to detect a difference if one existed (Table 8.1).  
The Fisher exact test was used for the analysis of categorical data, while unpaired t 
tests were used to compare groups of continuous normally distributed variables. All 
tests performed were 2-sided and 5% was taken as the cut-off for statistical 
significance. Statistical analyses were performed using STATA version 10 
(Statacorp., USA). This trial report conforms to CONSORT guidance and is 
registered on www.clinicatrials.gov  as NCT00652769. 
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Patient with 
suspected lung 
cancer 
Staging CT scan of 
neck, thorax, upper 
abdomen and first 
OPA 
Bronchoscopy or 
CT-guided biopsy 
Intra-thoracic disease only 
Multimodality 
treatment 
MDT and 
2
nd
 OPA 
Not candidate for 
radical treatment 
PET or CT-PET 
scan  
MDT and 3
rd
  OPA 
Mediastinum PET 
negative and 
mediastinal nodes 
<1cm 
Surgery with 
curative 
intent 
N2/3 positive on PET 
scan or mediastinal 
nodes > 1cm 
Mediastinoscopy 
No N2/3 
disease 
N2/3 disease 
confirmed 
Candidate for 
radical treatment 
Figure 8.1: 
Conventional 
diagnostic and 
staging  pathway 
for lung cancer. 
Adapted from 
NICE and ACCP 
guidelines. 
Blue boxes 
represent 
procedures, tests 
and outpatient 
appointments 
necessary for 
diagnosis and 
staging. Red 
boxes represent 
outcome. 
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Staging CT scan of 
neck, thorax, upper 
abdomen and first 
OPA 
Multimodality 
treatment 
Disease confined to thorax only  
Endobronchial ultrasound-guided 
mediastinal aspiration 
MDT and 2
nd
 OPA 
N2/3 disease 
confirmed 
Negative mediastinum on 
EBUS/EUS 
PET scan then MDT 
and 3
rd
 OPA 
Mediastinum PET 
neg and mediastinal 
nodes <1cm 
Surgery with 
curative 
intent 
N2/3 positive on PET scan or 
mediastinal nodes > 1cm 
Mediastinoscopy 
No N2/3 
disease 
N2/3 disease 
confirmed 
Patient with suspected 
lung cancer 
Figure 8.2: Novel 
pathway for lung 
cancer diagnosis 
and staging with  
EBUS-TBNA as 
an initial test after 
CT scan 
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Table 8.1: Sample size estimation with varying power but static type 1 error and 
clinical assumptions 
 
Time to treatment decision    
Conventional 
diagnosis and 
staging 
EBUS-TBNA Power Type 1 error Sample size 
66% of patients 
within 30 days 
and 33% within 
14 days 
66% of patients 
within 14 days 
and 33% within 
30 days 
80% 5% 82 
66% of patients 
within 30 days 
and 33% within 
14 days 
66% of patients 
within 30 days 
and 33% within 
14 days 
90% 5% 104 
66% of patients 
within 30 days 
and 33% within 
14 days 
66% of patients 
within 30 days 
and 33% within 
14 days 
95% 5% 126 
66% of patients 
within 30 days 
and 33% within 
14 days 
66% of patients 
within 30 days 
and 33% within 
14 days 
99% 5% 170 
 
  
177 
8.3 RESULTS 
 
Between June 2008 and July 2011, 133 patients with suspected lung cancer were 
randomised, 67 to conventional diagnosis and staging and 66 to initial EBUS-TBNA. 
One patient (previously randomised to the control arm) withdrew consent before any 
further investigations were carried out. Both groups were well balanced for all major 
clinical characteristics (Table 8.2, page 183). 
 
8.3.1 Conventional Diagnosis and Staging arm 
 
In the 66 patients who underwent CDS, 49 patients underwent bronchoscopy, 5 of 
whom had a conventional TBNA; 29 had CT guided biopsy, 50 had a PET-CT scan, 
2 had a bone scan and 8 patients a mediastinoscopy (Figure 8.3a, page 193). Four 
patients crossed over and underwent EBUS-TBNA at the request of the multi-
disciplinary team meeting. One patient in the CDS arm of the trial had both EUS-
FNA and EBUS-TBNA. Other investigations included MRI of the neck, ultrasound 
of the liver, CT of the brain, video-assisted thoracoscopic surgical lung biopsy and 
repeat bronchoscopy. The final diagnosis (Table 8.3, page 184) was NSCLC in 50 
patients (21 adenocarcinoma, 21 squamous cell carcinoma, 3 large cell carcinoma, 2 
adenosquamous and 3 not otherwise specified). Seven patients had a small cell lung 
cancer. Further final diagnoses were metastatic melanoma in 2, metastatic breast 
cancer in 1, folded lung in 1, tuberculosis in 1 and bacterial infection in 4 patients. 
The total number of investigations in the 66 patients in the conventional diagnosis 
and staging arm was 158 (Table 8.4). Mediastinal metastases (representing N2 or N3 
disease) were found by clinical staging techniques in 37 (56%) patients. Seventeen 
patients (26%) underwent thoracotomy with mediastinal lymph node dissection.  
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Four of these patients did not have NSCLC. Clinically unsuspected nodal disease 
was not found on pathological staging in any patients and 3 patients had an open and 
shut thoracotomy due to unsuspected T4 disease (Table 8.5, page 186). 
 
8.3.2 EBUS-TBNA initial staging arm 
 
EBUS-TBNA was performed in 64 patients and detected mediastinal nodal 
metastases in 37 (59%).  Two patients had EUS-FNA as their initial investigation 
and 1 patient with N2 disease was identified using this technique. Five patients 
required CT guided biopsy and 33 patients had a PET-CT and 7 underwent 
mediastinoscopy. One patient had a video-assisted thoracoscopic surgical lung 
biopsy. Two patients had mediastinal metastases detected by mediastinoscopy so that 
overall mediastinal metastases were diagnosed by clinical staging techniques in 40 
(61%) patients. The total number of investigations in 66 patients who underwent 
EBUS-TBNA as an initial test was 112. The final diagnosis was NSCLC in 46 
patients (26 adenocarcinoma, 17 squamous cell carcinoma, 1 large cell carcinoma, 1 
adenosquamous and 1 not otherwise specified). Four patients had small cell lung 
cancer. The final diagnosis was metastatic prostate cancer in 1, metastatic breast 
cancer in 1, folded lung in 2, tuberculosis in 2, lung abscess in 1 and bacterial 
infection in 9 patients.  Seventeen patients (26%) without evidence of mediastinal 
nodal metastases underwent thoracotomy and mediastinal lymph node dissection. 
Three patients were found not to have NSCLC and surprise mediastinal metastases 
were found in 1 patient at pathological staging. No patients had an open and shut 
thoracotomy.  
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8.3.3 Primary Endpoint 
 
Using a complete-case intention-to-treat analysis (Figure 8.3b), the median time to 
treatment decision in the conventional diagnosis and staging arm of the trial was 29 
days, compared to a median of 14 days in the EBUS arm. Using Kaplan Meier 
analysis (Figure 8.4), the hazard ratio was 2.02 (95% CI 1.419 – 2.884, P<0.0001). 
Therefore patients in the EBUS-CDS arm of the trial were likely to reach a treatment 
decision twice as fast as patients in the conventional diagnosis and staging arm.  
 
8.3.4 Secondary Endpoints 
 
The number of PET scans in the EBUS-TBNA arm was significantly reduced 
compared to the number in the conventional diagnosis and staging arm. There was 
no difference in the number of mediastinoscopies in each arm. The mean number of 
investigations per patient in the conventional diagnosis and staging arm and EBUS-
TBNA arm were 2.39 and 1.70 respectively (P<0.0001). Twelve percent of patients 
were diagnosed and staged with a single investigation using the conventional 
strategy while 45% (P<0.0001) required an EBUS-TBNA or EUS-FNA as their sole 
investigation in the EBUS-CDS arm of the trial.  
Analysis of unnecessary thoractomoies is preliminary since not all patients have 
undergone 1 year of follow-up. Using our a priori definition, unnecessary 
thoracotomies occurred in 8 (62%) patients out of 13 undergoing surgery in the CDS 
arm and in 6 out of 14 (43%, P=0.269) patients in the EBUS+CDS arm (Table 5). In 
an exploratory analysis, if we exclude patients who only had disease recurrence 
within 12 months of surgery, the unnecessary thoracotomy rate was higher in the 
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CDS arm (46%) compared to the EBUS-CDS arm (14%, P=0.10). The primary and 
secondary endpoints are summarised in Table (Table 8.6). 
 
8.3.5 Performance characteristics of endoscopic investigations 
 
Results of the 64 patients who underwent EBUS-TBNA are shown in Table 8.7. The 
median size of lymph nodes sampled was 12 mm and lymph node stations 4R (right 
paratracheal) and 7 (subcarinal) were the most commonly sampled. The sensitivity of 
EBUS-TBNA was 92% (95% CI 78% – 98%). The negative predictive value of 
EBUS-TBNA was 90% (95% CI 72% – 97%) and diagnostic accuracy was 95% 
(95% CI 86% - 99%). 
Two patients underwent EUS-FNA, both of station 5 lymph nodes in the EBUS-CDS 
arm of the trial. The procedure yielded a malignant diagnosis in one case. In the CDS 
arm of the study, 5 patients underwent conventional TBNA. In two patients there 
was a benign final diagnosis and in 1 patient conventional TBNA provided a 
diagnosis of squamous cell diagnosis. In the remaining 2 patients undergoing 
conventional TBNA, a negative procedure was followed by a mediastinoscopy that 
demonstrated mediastinal metastases. 
The accuracy of nodal staging is shown in Table 8.8 (page 189). In patients who 
underwent routine EBUS-TBNA (or EUS-FNA), one patient had the nodal staging 
underestimated (cN0, pN2). In the CDS arm 5 patients had the nodal stage 
underestimated. However, in each of these cases, the pathological nodal status was 
N1 (when the clinical stage was N0) and therefore may not have affected the 
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decision to operate. The proportion of inaccurate nodal staging was 38% in the CDS 
arm and 7% in the EBUS-CDS arm (P=0.077). 
 
8.3.6 Patient treatments  
 
Patient treatments are summarised in Table 8.9 (page 190) according to the arm of 
the trial. There were significantly more patients undergoing chemotherapy in the 
EBUS-CDS arm (50%) compared to the CDS arm (28%, P=0.028). The number of 
patients with lung cancer submitted for treatment with radical intent was not 
significantly different between the groups with 23 (40%) in the CDS arm of the trial 
and 17 (34%) in the EBUS-CDS arm of the trial (P=0.429). Fewer patients in the 
EBUS-CDS arm of the trial received palliative radiotherapy or supportive care only 
but this did not reach statistical significance (Table 8.9). 
 
8.3.7 Economic evaluation 
 
The cost of diagnostic and staging procedures is shown in Table 8.10. Using the base 
case assumptions, the mean cost per patient of the CDS arm was £2970.61 while the 
mean costs per patient in the EBUS-CDS arm was £2965.78 giving a small non-
significant difference of £4.83 in favour of the EBUS-CDS arm. Univariate threshold 
sensitivity analysis (which varied the potential cost of EBUS-TBNA) demonstrated 
that under the conditions of the trial, the EBUS-CDS strategy was less costly than 
the CDS strategy if the cost of EBUS-TBNA was less than £1387 (Figure 8.5, page 
196). 
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8.3.8 Adverse events 
 
Adverse events from diagnosis and staging were rare and are summarised in Table 
8.11 (page 192). One patient in each arm of the trial had a pneumothorax, with the 
patient in the CDS arm of the trial requiring intercostal drainage and inpatient 
admission.   
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Table 8.2: Baseline clinical characteristics in the Lung-BOOST trial 
 Conventional diagnosis 
and staging (n=66) 
 
EBUS-TBNA diagnosis 
and staging (n=66) 
Age: mean (range) in 
years 
67 (44 – 88) 69 (40 – 87) 
Gender 
                Male  
                Female 
 
46 (70%) 
20 (30%) 
 
43 (65%) 
23 (35%) 
Ethnicity 
               Caucasian 
               Asian  
               African 
               Caribbean 
               Other 
 
59 
2 
2 
2 
1 
 
51 
6 
4 
3 
2 
Performance Status 0 or 1: 
number (%) 
57 (86%) 60 (90%) 
Pack year smoking 
history: mean (range) 
42 (0 – 110) 43 (0 - 138) 
FEV1: mean (SD) in litres 1.9 (1.0 – 3.6) 1.9 (1.1 – 3.8) 
Mediastinal lymph node 
≥10mm in short axis                 
                Yes                 
                No 
 
                                         
42 (64%) 
24 (36%) 
 
                                               
39 (59%) 
27 (41%) 
Clinical Nodal Staging on 
initial CT scan 
cN0 
cN1 
cN2 
cN3 
 
                                        
20 (30%) 
9 (14%) 
33 (50%) 
4 (6%) 
 
                                       
21 (32%) 
6 (9%) 
34 (52%) 
5 (8%) 
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Table 8.3: Final diagnosis according to arm of study 
 
 Conventional diagnosis 
and staging (n=66) 
 
EBUS-TBNA diagnosis 
and staging (n=66) 
Non-small Cell Lung Cancer 
             Adenocarcinoma 
             Squamous Cell 
             Large Cell 
             Adenosquamous 
            Not otherwise 
specified 
50 (76%) 
21 (42%) 
21 (42%) 
3 (6%) 
2 (4%) 
3 (6%) 
46 (70%) 
26 (57%) 
17 (37%) 
1 (2%) 
1 (2%) 
1 (2%) 
Small Cell Lung Cancer 7 (11%) 4 (6%) 
Extra-thoracic Malignancy 3 (5%) 2 (3%) 
Benign lesion 6 (9%) 14 (21%) 
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Table 8.4: Investigations and outpatient appointments for all patients 
 
 Conventional 
diagnosis and 
staging (n=66) 
EBUS-TBNA 
diagnosis and 
staging (n=66) 
P value 
For all patients (n=132) 
Number of patients 
diagnosed and 
staged with a single 
investigation 
8 30 <0.0001 
Number of PET 
scans (%) 
50 33 0.0037 
Number of 
mediastinoscopies 
(%) 
8 7 NS (P=1.000) 
Total number of 
investigations after 
CT scan until 
treatment decision 
(mean and SD of 
tests per patient) 
158 (mean 2.394 
SD 0.828) 
112 (mean 1.697 
SD 0.828) 
<0.0001 
Number of 
outpatient 
appointments to 
treatment decision 
(mean per patient) 
178 (mean 2.7 SD 
1.069) 
103 (mean 1.561 
SD 1.066) 
<0.0001 
Total number of 
inpatient days 
during diagnosis and 
staging for all 6 
patients (range) 
28 (0 – 5) 
0.424 SD 0.857 
17 (0 – 3) 
0.258 SD 0.846 
NS (P=0.2648) 
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Table 8.5: Diagnostic performance of each arm in the Lung-BOOST trial 
 Standard techniques 
of conventional 
TBNA, PET-CT 
scanning and 
mediastinoscopy* 
(n=66) 
EBUS-
TBNA** 
(n==66) 
P value 
Diagnosis of lung cancer 57 50 NS 
(P=0.18) 
Prevalence of N2/N3 
disease (%) 
39 patients (68%) 44 patients 
(67%) 
 
Sensitivity for detecting 
mediastinal metastases 
100% 98%  
Number of patients with 
lung cancer undergoing 
radical treatment 
          Surgery 
          Radical Radiotherapy 
          Chemo-Radiotherapy 
23 (40%) 
 
13 
5 
5 
17 (34%) 
 
14 
2 
1 
 
Unnecessary 
thoracotomies*** 
         Total 
         pN2 
         pT4 
         pM1a 
         Death within 12 
months of surgery                                                                
         Recurrence within 12 
months of surgery 
 
                                  
8 (62%) 
0 
3 
1 
2 
                                         
2 
 
                         
6 (43%) 
1 
0 
1 
0 
                              
4 
 
 
               
NS 
(P=0.269) 
*investigations were agreed at multi-disciplinary team discussion 
** If EBUS-TBNA was negative, subsequent investigations were determined by the 
multi-disciplinary team 
*** median follow-up of 20 months  
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Table 8.6: Summary of primary and secondary endpoints (intention-to-treat analysis) 
 
 Conventional 
diagnosis and 
staging (n=66) 
EBUS-TBNA 
diagnosis and 
staging (n=66) 
P value 
Primary endpoint 
Median time to 
treatment decision 
29 days 14 days <0.0001 
Pre-specified Secondary endpoints 
Healthcare costs of 
diagnosis and 
staging (£ per 
patient) 
2970.61 2965.78 NS 
Mean number of 
investigations per 
patient for diagnosis 
and staging 
2.394 1.697 <0.0001 
Mean number of 
outpatient 
appointments per 
patient 
2.706 1.561 <0.0001 
Proportion of 
patients diagnosed 
and staged with a 
single investigation 
8 (12%) 30 (45%) <0.0001 
Number of PET-CT 
scans 
50 33 0.0037 
Mediastinoscopies 8 7 NS (P=1.000) 
Unneccesary 
thoracotomies 
8 6 NS (P=0.269) 
188 
Table 8.7: Performance characteristics of EBUS-TBNA in the Lung-BOOST trial 
 
Total number of patients who underwent 
EBUS-TBNA 
64 
Number of patient with mediastinal 
nodes ≥1cm on CT scan 
39 
Median size of lymph nodes sampled 
(mm) 
12 (range 4 – 45) 
Lymph node station sampled 
     2R  
     4R 
     2L 
     4L 
     7 
     10R 
     10L 
 
1 
26 
1 
5 
23 
7 
1 
Median number of passes per node 
(range) 
3 (2 – 6) 
Sensitivity of EBUS-TBNA (TP/TP+FN) 92% (35/38) 
Negative Predictive Value of EBUS-
TBNA (TN/TN+FN) 
90% (26/29) 
Diagnostic accuracy of EBUS-TBNA 
(TP+TN/n) 
95% (61/64) 
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Table 8.8: Accuracy of clinical T and N staging in 27 patients who underwent 
pathological staging. Shaded rows represent categories of clinical under-staging 
 
 Conventional 
diagnosis and 
staging (n=13) 
EBUS-TBNA 
diagnosis and 
staging (n=14) 
P value 
cN0, pN0 8 12  
cN0, pN1 5 0  
cN0, pN2 0 1  
cN1, pN1 0 1  
cN1, pN2-3 0 0  
cN1, pN0 0 0  
cT1-3, pT3 10 13  
cT1-3, pT4 3 1  
Inaccurate N Stage 5 (38%) 1 (7%) 0.077 
Inaccurate T stage 3 (23%) 1 (7&) NS (P=0.326) 
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Table 8.9: Treatment modalities according to arm of trial in patients with lung cancer 
 
 Conventional 
diagnosis and 
staging (n=57) 
EBUS-TBNA 
diagnosis and 
staging (n=50) 
P value 
Surgery 13 (23%) 14 (28%) NS (P=0.656) 
Radical 
radiotherapy 
5 (9%) 2 (4%) NS (P=0.445) 
Chemo-
radiotherapy 
5 (9%) 1 (2%) NS (P=0.211) 
Chemotherapy 16 (28%) 25 (50%) P=0.028 
Palliative 
radiotherapy 
12 (21%) 5 (10%) NS (P=0.184) 
Supportive care 
only 
6 (11%) 3 (6%) NS (P=0.498) 
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Table 8.10: Mean costs per patient of the randomised strategies for the diagnosis and 
staging of lung cancer. *Data from Lung-BOOST trial. Unit cost is estimated for 
EBUS-TBNA. Other unit costs are from the 2010-11 NHS Tariff. All costs are 
measured in 2010-11 £UK. 
 Parameter value 
(proportion of 
patients)* 
 Mean cost per patient; UK£ 
 Conven-
tional 
diagnosis 
and 
staging 
EBUS-
TBNA 
diagnosi
s and 
staging 
Unit 
cost 
Conven-
tional 
diagnosis 
and 
staging 
EBUS-
TBNA 
diagnosis 
and 
staging 
Difference 
EBUS-TBNA 
0.076 0.970 1382 104.70 1340.54  
EUS-FNA 0 0.030 800 0 24  
Bronchoscopy 0.667 0.030 503 335.30 15.24  
Conventional 
TBNA 
0.076 0 100 7.58 0  
CT guided biopsy 0.439 0.076 450 197.55 34.20  
PET-CT scan 0.758 0.500 1695 1284.09 847.5  
Mediastinoscopy 0.121 0.106 3228 361.58 316.38  
Bone scan 0.030 0 258 7.82 0  
Other major 
surgical biopsy 
0.045 0.015 2983 135.59 45.20  
Inpatient days 0.333 0.258 500 166.50 129.00  
Outpatient 
appointments 
2.70 1.56 137 369.9 213.72  
Total cost per 
patient 
   2970.61 2965.78 -4.83 
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Table 8.11: Adverse events. One patient had a pneumothorax requiring an intercostal 
drain and inpatient admission. 
 
 Conventional diagnosis 
and staging (n=66) 
EBUS-TBNA diagnosis 
and staging (n=66) 
Related to EBUS-TBNA None None 
Related to CT guided 
biopsy 
1 Pneumothorax (chest 
drain required) 
1 Pneumothorax (no chest 
drain required) 
Related to bronchoscopy None None 
Related to 
mediastinoscopy 
None None 
Inpatient days related to 
complications 
2 None 
Other None None 
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Eligible patients with 
intra-thoracic disease only 
on staging CT scan 
(n=133) 
Randomisation: stratified 
per centre and mediastinal 
nodes ≥1cm (n=132) 
PET-CT scan (n=33) 
PET-CT scan (n=48) 
Randomised to 
conventional diagnosis 
and staging (n=66) 
Initial investigation 
      Bronchoscopy (n=44) 
      CT guided biopsy (n=14) 
      Conventional TBNA (n=5) 
      Mediastinoscopy (n=1) 
      PET-CT scan (n=2) 
 
 
Randomised to EBUS-
TBNA as initial 
investigation (n=66) 
Initial investigation 
      EBUS-TBNA (n=64) 
      EUS-FNA (n=2) 
 
 
cN0 – 1 
NSCLC 
(n=24) 
cN2 – 3 
NSCLC 
(n=26) 
Further investigations 
      Mediastinoscopy (n=7) 
      CT guided biopsy (n=5) 
      Other (n=1) 
Further investigations 
      CT guided biopsy (n=15) 
      Mediastinoscopy (n=7) 
      Other (n=22) 
Multi-modality 
treatment n=23) 
Lung cancer 
surgery (n=14) 
cN0 – 1 
NSCLC 
(n=19) 
cN2 – 3 
NSCLC 
(n=27) 
1 patient withdrew 
consent 
50 patients with NSCLC 
Figure 8.3a: Lung-
BOOST trial flowchart 
46 patients with NSCLC 
Lung cancer 
surgery (n=13) 
Multi-modality 
treatment (n=22) 
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Figure 8.3b: CONSORT diagram 
 
 
Analysed (n=66 
Allocated to CDS 
(n=67) 
 
Received allocated 
intervention (n=66) 
 
Did not receive 
allocated intervention  
(n=1; withdrew 
consent) 
Lost to follow-up 
(n=0) 
Discontinued 
ntervention (n=0) 
Allocated to EBUS+ 
CDS (n=66) 
 
Received allocated 
intervention (n=66) 
 
Did not receive 
allocated intervention 
(n=0) 
Analysed  (n=66) 
Allocation 
Analysis 
Follow-Up 
Randomized (n=133) 
Stratified for Centre 
and Mediastinal lymph 
node ≥ 10mm 
Enrollment 
Lost to follow-up 
(n=0) 
Discontinued 
intervention (n=0) 
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Figure 8.4: Kaplan-Meier graph of time to treatment decision in each arm of the trial 
(complete case intention to treat analysis).   
 
 
 
 
CDS – conventional diagnosis and staging; EBUS-CDS – endobronchial ultrasound 
followed by conventional diagnosis and staging. 
 
 
Cox analysis: 
0
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                                                  LR chi2(1)      =     15.03
Time at risk    =         3714
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No. of subjects =          130                     Number of obs   =       130
Cox regression -- Breslow method for ties
Iteration 0:   log likelihood = -505.09279
Refining estimates:
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Figure 8.5: Univariate threshold sensitivity analysis. The costs of the strategy of 
EBUS-TBNA as an initial investigation minus conventional diagnosis and staging is 
plotted according to different estimates of the cost of EBUS-TBNA. At the best 
estimate for the cost of EBUS-TBNA of £1382, the EBUS strategy is approximately 
cost-neutral. The cost of conventional diagnosis and staging is higher than that for 
the EBUS strategy as long as EBUS-TBNA costs are less than £1387. 
 
 
 
  
Cost of 
(CDS – 
EBUS-
CDS) 
strategies 
(UK£) 
Best estimate of 
cost of EBUS-
TBNA 
Cost of EBUS-TBNA (UK£) 
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8.4 DISCUSSION 
 
This is the first randomised controlled trial of EBUS-TBNA in patients with 
suspected lung cancer and shows that routine use of EBUS-TBNA as an initial test 
after staging CT scan results in a faster treatment decision and utilises fewer 
investigations and outpatient appointments. 
EBUS-TBNA has become an important investigation for patients with lung cancer. 
However, much of the data demonstrating its utility is based on case series, many of 
which are retrospective. These cohort studies suffer with problems of selection bias 
and a further problem with the early EBUS-TBNA literature was that much of the 
data was from a few expert centres. The randomised design of the current study 
minimises the risk of selection bias as EBUS-TBNA operators were unable to 
choose patients for the procedure. Despite this, the sensitivity of EBUS-TBNA in the 
study remained high at 92% (95% CI 78% – 98%).  
Randomised trials of lung cancer staging techniques are rare but provide the highest 
quality evidence on which to base diagnostic algorithms. The outcome of futile or 
unnecessary thoracotomies has been used as a surrogate for accuracy of staging, 
since less accurate staging would result in a higher proportion of futile 
thoracotomies. Trials of PET and PET-CT demonstrated that PET-CT was able to 
prevent 1 in 5 futile thoracotomies. Preliminary results of a trial of routine EUS-
FNA also suggested that futile thoracotomies could be prevented, however this trial 
did not routinely employ PET-CT. The recent ASTER trial (Annema et al. 2010) 
suggested that combining EBUS, EUS and mediastinoscopy (when EBUS/EUS was 
negative) could prevent 1 in 7 unnecessary thoracotomies. However, in the ASTER 
study, the relative individual diagnostic merits of EBUS-TBNA and EUS-FNA were 
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not explored and it is unclear if both procedures need to be routinely performed to 
obtain this benefit. The definition and concept of futile thoracotomies is 
controversial. The current Lung-BOOST trial incorporated death or recurrence 
within 12 months as part of the definition; however the ASTER trial only included 
death or recurrence within 3 months. This may in part explain the high rate of futile 
thoracotomies in the trial (63% and 43% in the CDS and EBUS-CDS arms 
respectively). A statistically significant benefit of EBUS-TBNA in reducing the 
number of unnecessary thoracotomies was not seen in this trial and this may 
represent low power of the analysis of this secondary endpoint and also the relatively 
short length of follow-up (median 20 months). 
The primary endpoint of the Lung-BOOST trial was time to treatment decision and 
the trial demonstrated that routine and upfront use of EBUS-TBNA in the diagnostic 
pathway can reduce the median time to treatment decision from 29 days to 14 days. 
UK government initiatives in the NHS Cancer Plan have mandated since 2005 that 
patients have a treatment decision by 31 days from referral and a further maximum 
of 31 days between decision to treat and receiving treatment. The time that patients 
spend undergoing diagnostic and staging investigations is a time of great anxiety for 
patients and emphasised by the fact the median survival for all patients with lung 
cancer remains poor at 6.2 months. Therefore, the primary outcome measure in this 
trial of time to treatment decision is of great importance to patients and the multi-
disciplinary teams charged with their care. The trial demonstrates that EBUS-TBNA 
can provide a diagnosis and inoperable disease stage in 45% of patients so that they 
require no further investigation before a treatment decision can be made. It is 
recognised that many patients diagnosed with N2 disease by EBUS-TBNA will still 
require further investigations, including PET-CT scan if combination chemo-
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radiotherapy is being considered, However in this pragmatic trial PET-CT was only 
necessary in 19% of patients after a positive EBUS-TBNA. Routine use of EBUS-
TBNA was able to reduce time to treatment decision primarily by reducing the 
number of outpatient appointments and investigations (particularly PET-CT scans). 
Despite the reduction in investigations and outpatient attendances, overall costs of 
diagnosis and staging were similar in the two arms. This is due to the current high 
estimated cost of EBUS-TBNA which may fall in the future as the technology is 
adopted by more centres. A sensitivity analysis demonstrated that if the cost of 
EBUS-TBNA was below £1387, the EBUS-CDS strategy would be cost saving. Of 
considerable interest is the fact that significantly more patients in the EBUS-TBNA 
arm had a treatment decision of chemotherapy. Longer term follow-up will 
determine whether this will translate into a survival benefit.  
In addition to the short length of follow-up of the trial (which closed to recruitment 
on the 1
st
 July 2011), other limitations are recognised.  The pragmatic nature of the 
trial meant that a consistent diagnostic and staging algorithm was not observed 
across the trial centres. However, this design for the study (which was carried out at 
2 teaching hospitals and 4 district general hospitals), gives the results strong external 
validity and potential for reproducibility, which may not be possible with some of 
the other lung cancer staging randomised trials. A reflection of the pragmatic nature 
of the trial is that only 8 patients in the CDS arm of the trial and 7 patients in the 
EBUS-CDS arm of the trial underwent mediastinoscopy. This is a considerably 
smaller proportion of patients than in other randomised trials such as ASTER and 
Fischer et al. (2009). The high accuracy of nodal staging in this trial justified the 
approach of the multi-disciplinary teams. A final limitation is that the economic 
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analysis in this trial has not taken into account treatment decisions and survival and 
therefore requires further analysis when longer follow-up is available in the future.  
In conclusion, when EBUS-TBNA is utilised as an initial investigation in patients 
with suspected stage I – IIIA lung cancer on CT scan, the time to treatment decision 
is reduced, with fewer PET-CT scans and outpatient appointments when compared to 
a conventional diagnostic and staging strategy. 
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CHAPTER 9: SUMMARY 
 
This thesis has examined the role of EBUS-TBNA in patients with mediastinal 
lymphadenopathy. It has demonstrated that EBUS-TBNA has wide applications in 
patients with mediastinal lymphadenopathy. Data on the learning curve for EBUS-
TBNA using CUSUM analysis suggests that approximately 20 procedures are 
required for training in the procedure. This will however require confirmation from 
other centres before formal guidance on the procedure can be issued. 
In patients with suspected sarcoidosis, a prospective study (Chapter 3) has 
demonstrated that combining the standard bronchoscopic procedures of 
transbronchial biopsy and endobronchial biopsy with EBUS-TBNA may 
significantly improve the diagnostic yield of bronchoscopy. The data suggested that 
transbronchial lung biopsy and EBUS-TBNA were complementary techniques with 
diagnoses being made with the bronchoscopic techniques in patients with a negative 
EBUS-TBNA and vice versa.  The data showed that combining the procedures in 
one sitting was safe and efficacious. 
Patients with mediastinal lymphadenopathy due to tuberculosis may significantly 
benefit from EBUS-TBNA (Chapter 4). EBUS-TBNA can provide evidence of 
tuberculosis in 94% (95% CI 88% - 97%) of cases and be able to provide a positive 
culture in 47% of patients which may alter the drug regimen, given the rising 
incidence of drug-resistant cases. Data from this chapter may therefore significantly 
influence the management internationally of patients with mediastinal lymph node 
tuberculosis. 
202 
Patients with extra-thoracic malignancies often develop mediastinal 
lymphadenopathy. There is a clinical conundrum of whether this lymphadenopathy 
is due to the malignancy or another disease process. In the 161 patients included in 
this study, 68% had a final diagnosis of malignant intra-thoracic lymphadenopathy, 
highlighting the importance of sampling these nodes and not just assuming they are 
due to metastatic spread. When the lymph nodes were due to extra-thoracic 
malignancy, EBUS-TBNA was able to diagnose them in 87% of cases. 
Chapter 6 is the first prospective study of EBUS-TBNA in consecutive patients with 
isolated mediastinal lymphadenopathy in patients who otherwise would have been 
referred for mediastinoscopy. Eight-seven percent (97.5% CI 78 – 96%) of 
mediastinoscopies were prevented. These data strongly support the routine use of  
EBUS-TBNA as an alternative to mediastinoscopy in patients with isolated 
mediastinal lymphadenopathy. However, if EBUS-TBNA does not provide a 
definitive diagnosis, mediastinoscopy should still be recommended, given the low 
negative predictive value of EBUS-TBNA in this setting.    
The management of advanced non-small cell lung cancer has undergone significant 
changes in the last few years, such that a diagnosis of non-small cell lung cancer 
alone is no longer sufficient to guide a treatment plan. The subtyping and genotyping 
of non-small cell lung cancer is now important for patient management. Chapter 7 
shows that specimens from EBUS-TBNA in routine practice can be used for 
differentiation of squamous from non-squamous lung cancer and the at EGFR 
mutation testing is also possible. Finally, the thesis also reports on the Lung-BOOST 
trial – a pragmatic randomised controlled trial of EBUS-TBNA as a first 
investigation in patients with suspected lung cancer. EBUS-TBNA is able to provide 
an inoperable disease stage in a single investigation and also sufficient tissue to 
203 
guide clinical practice. Data from the randomised trial shows that patients 
undergoing EBUS-TBNA as an initial investigation reach a treatment decision in a 
median of 14 days, compared to 29 days with conventional diagnosis and staging. 
Economic analysis shows that this significant improvement in time to treatment 
decision comes at no extra cost to the NHS and that if the price of EBUS-TBNA was 
below £1387, then the initial EBUS-TBNA strategy would be cost-saving. This is 
the first randomised data of EBUS-TBNA and despite the lack of selection bias, a 
high sensitivity of EBUS-TBNA was maintained. The procedure is also a very safe 
with complication rates that are similar to standard bronchoscopy. Data from this 
thesis provides a strong evidence base for the utility of EBUS-TBNA in current 
respiratory medicine.  
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Endobronchial Ultrasound for the 
diagnosis of Mediastinal 
Lymphadenopathy  
A clinical trial of endobronchial ultrasound and mediastinoscopy for the 
diagnosis of mediastinal lymphadenopathy 
 
GENERAL PROTOCOL INFORMATION 
 
This document describes the trial and provides information about its 
background, rationale and procedures for entering and managing 
patients. Every care was taken in its drafting, but corrections or 
amendments may be necessary.  
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Section 1: Background 
 
1.1 Mediastinal lymphadenopathy: the importance of tissue diagnosis 
 
Mediastinal lymphadenopathy refers to the enlargement of lymph nodes within the 
mediastinum and determining the diagnosis of mediastinal lymphadenopathy is a 
common problem faced by respiratory physicians. The differential diagnosis of 
enlarged mediastinal lymph nodes (MLN) includes neoplasm, granulomatous 
disease, infection and reactive hyperplasia. Neoplastic causes are most commonly 
metastatic lung cancer, lymphoma or metastatic disease from the oesophagus, breast, 
kidney or head and neck. Sarcoidosis and tuberculosis result in granulomatous 
lymphadenopathy. Fungal infections such as histoplasmosis and coccidiodomycosis 
may also cause enlarged MLNs. Rarer causes of mediastinal lymphadenopathy 
include Castleman’s disease, angioimmunoblastic lymphadenopathy, chronic 
berylliosis, Wegener’s granulomatosis and chronic mediastinitis. 
 
In UK practice, the most common causes of mediastinal lymphadenopathy are 
sarcoidosis, metastatic lung cancer, tuberculosis and lymphoma. These four 
important conditions have vastly different treatments and prognoses. Moreover their 
symptoms are often non-specific. Fevers, night sweats and weight loss may be a 
common feature of each diagnosis and does not help with their differentiation. 
Therefore, a tissue diagnosis of mediastinal lymphadenopathy is critical to allow 
patient management. 
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1.2 Mediastinal Lymph Node Map: American Thoracic Society classification 
 
 
From Mountain and Dresler. The regional lymph node map: Chest 1997.
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1.3 Techniques for diagnosing mediastinal lymphadenopathy 
 
Chest radiograph 
On the chest radiograph, the ease with which MLN enlargement can be recognized 
depends on the particular location.  Enlargement of the right upper paratracheal 
nodes causes uniform or lobular widening of the right paratracheal stripe, and an 
increase in density of the superior vena cava of which the border may become 
convex to the lung. Enlarged right lower paratracheal nodes push the azygos vein 
laterally increasing the diameter of the combined opacities of both node and azygos 
arch. Aorto-pulmonary nodes may cause a bulge in the angle between the aortic arch 
and the main pulmonary artery. If they are substantially enlarged, the left upper 
paratracheal nodes induce mediastinal widening. The radiographic features of 
subcarinal node enlargement include the displacement of the azygo-oesophageal line 
that becomes convex to the lung, an increased opacity of the subcarinal space on the 
posteroanterior film and a lack of visibility of the external surface of the medial wall 
of the intermediate bronchus. Enlargement of the anterior mediastinal nodes may be 
substantial to be visible on the chest films. In such case, mediastinal widening is 
frequently bilateral and lobulated in outline. The radiographic signs of enlargement 
of hilar lymph nodes are hilar enlargement, or a rounded mass in a portion of the 
hilum.  
 
Computed Tomography 
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Lymph node enlargement is defined on the basis of a short-axis node diameter 
exceeding 1 cm. A coalescence of enlarged nodes suggests infection, granulomatous 
disease or malignancy. Diffuse mediastinal involvement is more typical of 
lymphoma, large cell undifferentiated carcinoma and acute or chronic mediastinitis. 
Computed Tomography (CT) can also be used to define the density of lymph nodes. 
Enlarged nodes may be calcified, or low in density and necrotic in appearance or can 
enhance following intravenous injection of contrast media. Low attenuation lymph 
nodes after administration of contrast media, with or without rim enhancement 
typically reflect the presence of necrosis. This finding is commonly seen in patients 
with tuberculosis, metastatic carcinoma and lymphoma. Post-contrast enhancement 
of enlarged hilar and MLNs may suggest Castlemans disease, angioimmunoblastic 
lymphadenopathy or vascular metastases in particular from renal cell carcinoma. 
This feature of enhancement may also be found in sarcoidosis and tuberculous 
lymphadenopathy. Therefore, CT appearances are insufficiently specific to allow a 
definitive diagnosis and pathological diagnosis remains necessary. CT does however 
provide accurate anatomical information and acts as a road-map for further 
investigations. 
 
Positron Emission Tomography 
PET enables detection of MLNs with abnormally high functional activity (e.g. 
tumour metastases), a feature that CT lacks. Because of this advantage and because 
of the limitations of using size criteria with CT to diagnose malignant MLNs,  PET 
has superior sensitivity, specificity and accuracy in diagnosing mediastinal 
metastases as compared with CT and chest roentograms. However, inflammatory 
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mediastinal lymph nodes especially due to tuberculosis or sarcoid may also be 
positive on PET scanning.  
The most commonly utilized radiotracer in PET is 18-fluorodeoxyglucose (18FDG), 
which detects foci of abnormally high glucose metabolism. The standardized uptake 
value (SUV), the measure of metabolic activity detected by PET, is directly related 
to the degree of metabolic activity within a tissue focus or within an organ and in the 
context of non-small cell lung cancer provides predictive information regarding 
treatment response and survival. The maximum SUV (maxSUV) in a region of 
interest (ROI) has been adopted as an approach to characterize metabolically active 
lesions. The formula for the 
SUV is: 
SUV =   mean ROI activity (MBq/mL)   
  dose (MBq)/Body weight (kg) 
 
The SUV is therefore normalized by body weight. Traditionally, clinicians and 
radiologists have designated a maxSUV of 2.5 as the upper limit of normal in an 
attempt to minimize the chance of false-negative results.  
This rationale has been best studied in patients with non-small cell lung cancer 
(NSCLC)
1
. Despite its superiority over CT for detecting mediastinal disease in 
NSCLC and a high negative predictive value, PET and integrated PET-CT have 
several distinct limitations. First, any metabolically active tissue may generate a 
positive PET signal. In patients with NSCLC, 25% of PET positive mediastinal 
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lesions are false positives
2
. Therefore, current guidelines mandate that PET positive 
mediastinal (and extra-thoracic lesions) require biopsy confirmation before curative 
treatment is excluded. Second, the sensitivity of PET for detecting tumour metastasis 
varies depending on the lymph node’s size and location within the mediastinum. The 
American College of Chest Physicians guidelines suggest that all MLNs greater than 
1cm in short axis should be pathologically assessed
3
, regardless of FDG uptake. 
Although PET has excellent sensitivity (80—99%) in detecting metastasis to 
American Thoracic Society MLN stations 4R, 4L, 10R, and 10L (Fig. 1), its 
sensitivity at other MLN stations (e.g., stations 5, 6, 7,8R, and 8L) is poor (29—
60%)
4
. 
 
Scientific data on the role of PET or integrated PET-CT in sarcoidosis is limited. 
One study suggested that the sensitivity of PET in detecting sarcoid was high for 
radiographic stages II and III (where enlarged MLNs are a feature) and may predict 
disease activity and reponse to treatment. However, specificity remains low. 
SUVmax values between 2 and 15 have been reported in MLNs due to sarcoid
5
 and 
therefore FDG avid mediastinal lymph nodes are non-specific and require 
pathological diagnosis.  
 
Functional imaging with 18-FDG PET and integrated PET-CT increase the 
sensitivity and specificity of lymphoma assessment and may also predict outcome 
and direct future therapies. Once again, however there are no specific appearances on 
PET images that will preclude the need for pathological diagnosis. Active 
tuberculosis (TB) infection including asymptomatic and extra-pulmonary disease 
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may be detected with FDG-PET/CT. It may also be a useful tool in the assessment of 
latent TB, to exclude active disease prior to treatment. PET/CT has the potential for 
monitoring response to anti-tuberculosis treatment. Metabolic response may also 
indicate clinical response and guide duration of anti-mycobacterial therapy
6
. 
 
Despite advances in imaging techniques, pathological confirmation of mediastinal 
lymphadenopathy remains mandatory.  
 
Conventional transbronchial needle aspiration 
During standard bronchoscopy, a dedicated transbronchial aspiration needle is 
introduced into the biopsy channel and blindly punctures the bronchial wall allowing 
the mediastinal lymph node to be aspirated. This is most accurately done for 
enlarged lymph nodes in the subcarinal area but lower paratracheal and hilar lymph 
nodes can also be sampled
7
. A positive result from trans-bronchial needle aspiration 
(TBNA) may obviate the need for further invasive tests. However, a meta-analysis of 
patients undergoing TBNA in patient with lung cancer and enlarged MLNs showed a 
pooled sensitivity that was low at 39%, with a FN rate of 28%, when the prevalence 
of mediastinal metastases was 34%
8
.  
 
One study has examined the utility of conventional TBNA for the diagnosis of 
isolated MLN
9
. TBNA procedures were performed using a flexible bronchoscope 
and a 22-gauge Wang needle in 60 consecutive patients with isolated MLN. A 
diagnosis was reached in 45 of 60 patients (75%). Diagnoses included tuberculosis 
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(n=21), sarcoidosis (n=21), carcinoma (n=15), and lymphoma (n=3). TBNA had 
high sensitivity for TB, but diagnosed 1 case (out of 3) of lymphoma
10
.  
 
Several other studies have examined the role of conventional TBNA in patients with 
MLN due to suspected sarcoid and tuberculosis. They have found similar 
sensitivities of the procedure (75 – 79%)11;12. However, overall, the relatively low 
diagnostic yield and high negative predictive value mean that TBNA is poorly 
utilized
13
 and further tests are commonly necessary in the event of a non-diagnostic 
or negative sample. 
 
Endoscopic Ultrasound 
Endoscopic ultrasound guided fine needle aspiration (EUS-FNA) of mediastinal 
lymphadenopathy has been available for over a decade
14
. Under conscious sedation, 
an endoscope is placed in the esophagus and an integrated linear ultrasound probe 
allows visualization of the mediastinum. Aspiration with a 22-guage needle is 
performed through the wall of the esophagus under direct vision.  
 
Due to the anatomical location of the esophagus, EUS-FNA is able to sample 
mediastinal lymph nodes in stations 2L, 4L, 5, 7, 8 and 9 and also the celiac axis 
nodes. Samples obtained by EUS-FNA with a 22-guage needle are suitable for 
cytopathological analysis. Occasionally core samples are obtained by EUS-FNA and 
may be sent for histopathological investigation. Core tissue samples may be more 
reliably obtained using a 19-guage trucut needle. This method requires that the 
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mediastinal lymph node be at least 2cm in the direction of the biopsy. Adding trucut 
biopsy to fine needle aspiration improves the diagnostic accuracy and the adequacy 
of sampling. 
 
Cohort studies have clearly demonstrated the utility of EUS-FNA in the mediastinal 
staging of NSCLC
15
 and data is now emerging on the utility of EUS for the diagnosis 
of sarcoid
16
. Currently, there are no reports on its value in patients with MLNs due to 
tuberculosis or lymphoma.  
 
Although EUS-FNA is a promising tool for the diagnosis of isolated MLNs, there 
are several restrictions. EUS cannot sample right-sided or hilar lymph nodes stations 
and these areas are commonly involved in patients with sarcoidosis and tuberculosis 
(particularly 4R). In addition, EUS does not allow visualization of the endobronchial 
tree which may provide additional diagnostic information in patients with 
granulomatous diseases. The equipment and skilled personnel are also not widely 
available and this has meant that EUS (like conventional TBNA) is underutilized for 
the diagnosis of isolated MLN.  
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1.3.1 Mediastinoscopy for the diagnosis of mediastinal lymphadenopathy 
 
Cervical mediastinoscopy is currently considered the best investigation for the 
diagnosis of mediastinal lymphadenopathy. The procedure is performed under 
general anaesthesia and provides access to the upper and lower paratracheal lymph 
nodes and occasionally the anterior subcarinal station. Although rare, complications 
do occur. One percent of patients experience complications including haemorrhage, 
vocal cord dysfunction, tracheal injury and pneumothorax
17
. Mortality rate is 
considered to be 0.1%, usually from damage to major vessels intra-operatively.  
 
The largest published series to date of mediastinoscopy examined 2145 procedures 
over a nine year period in a single centre. In patients with lung cancer, their false 
negative rate was 5.5% when the disease prevalence was 23.5% and most patients 
received an accurate pathological diagnosis
18
.  
 
A recent study of 47 patients with isolated MLN examined the diagnostic yield of 
mediastinoscopy and compared it to the clinical diagnosis
19
. The sensitivity and 
specificity of the pre-operative clinical diagnosis was 87% and 78% respectively. 1 
patient with suspected tuberculosis was revealed to have lymphoma on biopsy. Five 
out of the 12 patients with a pre-operative diagnosis of malignancy had a final 
diagnosis of sarcoidosis. Nine cases of isolated MLN were identified incidentally. Of 
these, 7 had tuberculosis, 1 sarcoid and 1 non-small cell lung cancer. All but one 
patient had a definitive diagnosis reached at mediastinoscopy. 
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Another large study of mediastinoscopy of the diagnosis of MLN, prospectively 
evaluated 271 patients with isolated MLN and 127 patients with a pulmonary or hilar 
lesion of unknown aetiology
20
. Overall there were 17 false negative results (4.3%). 
The sensitivity of mediastinoscopy in patients with isolated MLN was 96% and in 
patients with a pulmonary or hilar lesion the sensitivity was 92%. Interestingly, 76% 
of the samples were performed in the right latero-tracheal lymph node station (4R), 
with 12.5% from the subcarinal lymph node station (7) and 7.8% in the left 
laterotracheal lymph node station (4R). There were no deaths and morbidity was low 
(2.25%). Importantly, mediastinoscopy altered the pre-operative suspected diagnosis 
in 74 patients (18.5%)
21
. 
 
Mediastinoscopy therefore offers a sensitive and safe technique for the diagnosis of 
mediastinal lymphadenopathy and is currently considered the gold standard 
investigation. However, several limitations of the procedure must be recognised. 
First, standard cervical mediastinoscopy does not allow complete access to the 
mediastinum. In particular, posterior subcarinal nodes (7), the aorto-pulmonary 
window (5,6) and inferior lymph node station are inaccessible to the standard 
technique (8,9). Also, general anaesthesia is required and overnight inpatient stay is 
still necessary in the UK for the majority of patients. These latter considerations in 
addition to surgical time are responsible for high healthcare costs associated with the 
procedure. The current NHS tariff for mediastinoscopy is £2157
22
. 
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1.4  Endobronchial Ultrasound guided Transbronchial Needle 
Aspiration (EBUS-TBNA) 
 
EBUS-TBNA, using a linear echoendoscope,  was first described in 2003
23
. The 
procedure allows TBNA with a 22-guage needle under real-time ultrasound 
guidance. This progress in technology allows the pulmonologist and thoracic 
surgeon for the first time to sample the majority of the mediastinum in a minimally 
invasive manner with high sensitivity. Lymph nodes stations 1, 2, 3, 4, 7, 10 and 11 
are readily accessible, representing an increased range compared to standard 
mediastinoscopy. EBUS-TBNA routinely provides samples from the posterior sub-
carinal space and hilar areas that are out of reach of cervical mediastinoscopy.  
 
Data now exists that confirms the theoretical benefit of real-time linear EBUS-
TBNA over the blind conventional method. A single centre study from the US 
prospectively examined 138 consecutive patients with suspected or proven lung 
cancer
24;25
. Each patient sequentially underwent blind TBNA, EBUS-TBNA (and 
EUS-FNA) and 30% of patients in the cohort had mediastinal metastases. The study 
demonstrated that linear real-time EBUS-TBNA had a significantly superior 
sensitivity for detecting mediastinal disease than standard TBNA (69% vs 36%)
26
. 
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The use of EBUS-TBNA  has been recommended for the mediastinal staging of non-
small cell lung cancer in enlarged PET positive nodes in American
27
 and European 
guidelines
28
. To date, however, it’s published use in the diagnosis of sarcoid is 
limited to under 200 patients
29-31
. There are no reports of its diagnostic properties in 
TB and a just single cohort study of 11 patients with lymphoma out of whom a 
diagnosis was reached in 10 with EBUS-TBNA
32
.  
 
One of the limitations of EBUS-TBNA is the fact that only a 22G needle is currently 
available. This generally provides cytological samples only which may make the 
diagnosis of lymphoma less reliable. However, a newer 21G needle will be available 
in the near future and mini-forceps have already been employed in one small study 
with encouraging results
33
. An important limitation of EBUS is the false negative 
rate of 20% observed with the technique. Therefore all negative samples, that do not 
provide a definitive diagnosis, should be investigated further with a surgical 
approach
34
.  
 
1.4.1  Advantages of EBUS-TBNA 
 
EBUS has several important advantages over the other techniques for the diagnosis 
of MLNs. It is a minimally invasive approach that is routinely performed in an 
ambulatory care setting and only requires conscious sedation. EBUS also allows 
access to almost the entire mediastinum (except for the aorto-pulmonary LN stations 
5,6 and the inferior LNs 8,9), representing a wider range of LN sampling than 
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mediastinoscopy. In particular bilateral hilar and posterior subcarinal nodes are 
easily sampled with EBUS but are out of the reach of standard cervical 
mediastinoscopy. 
 
A further benefit of the bronchoscopic approach for the diagnosis of MLNs is that 
the complimentary techniques of transbronchial biopsy, endobronchial biopsy and 
broncho-alveolar lavage may be employed at the same sitting to maximise diagnostic 
yield. These bronchoscopic techniques are standard procedures for the diagnosis of 
sarcoid and in isolation have a sensitivity of 75%
35
. Bronchoscopy with washings / 
broncho-alveolar lavage also has a role in the diagnosis of tuberculosis but is of 
limited value in the diagnosis of lymphoma. Finally, there have been no major 
reported adverse events with EBUS-TBNA.  
 
 
1.5 Why is a trial needed? 
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The role of EBUS-TBNA for the diagnosis of unselected MLN has not been 
evaluated. EBUS-TBNA does however have several distinct theoretical advantages 
over mediastinoscopy for the diagnosis of MLN. We therefore plan to investigate 
whether EBUS-TBNA, followed by mediastinoscopy if EBUS-TBNA is negative, is 
an efficacious and cost-effective strategy for the diagnosis of mediastinal 
lymphadenopathy. 
 
In addition, current published data is from cohorts which are subject to selection bias 
and therefore do not adequately describe to the clinician, which patients should be 
referred for EBUS-TBNA. We aim to include consecutive patients with undiagnosed 
MLN and therefore avoid selection bias.  
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Section 2 Trial Design 
 
2.1 Hypothesis 
 
In the diagnosis of mediastinal lymphadenopathy, EBUS-TBNA and bronchoscopy 
will reduce the number of mediastinoscopies and result in healthcare cost savings.  
 
2.2 Objectives 
 
The trial is designed to investigate 
1. Whether EBUS-TBNA can reduce the number of necessary 
mediastinoscopies and inpatient days for patients with  mediastinal 
lymphadenopathy 
2. The sensitivity and negative predictive value of EBUS-TBNA (after CT scan) 
for the diagnosis of mediastinal lymphadenopathy 
3. The diagnostic accuracy of EBUS-TBNA for unselected patients with 
mediastinal lymphadenopathy 
4. Whether EBUS-TBNA is a cost-effective technique for the diagnosis of 
mediastinal lymphadenopathy 
5. The prevalence of malignancy in unselected patients with mediastinal 
lymphadenopathy 
 
2.3 Single-arm trial 
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This study will conform to the Standards for Reporting of Diagnostic Accuracy 
statement
36
; therefore the trial will ensure that these standards in study design are 
met at the outset. 
 
This is a single arm trial to evaluate the effectiveness and cost-effectiveness of 
EBUS-TBNA in reducing the number of mediastinoscopies, which is considered the 
gold standard investigation.  Comparison of the outcomes (proportion of patients 
undergoing mediastinoscopy and associated cost) will be made with patients who 
have all undergone mediastinoscopy. Since the proportion of patients in the control 
arm to undergo mediastinoscopy is already known (100%), a control arm is not 
required. 
 
2.4 Bias 
Consecutive patients will be recruited and therefore selection bias will be avoided. 
Pathologists with experience in examining samples from MLNs will report the 
pathology with knowledge of the clinical scenario, which closely reflects clinical 
practice. However, they will be blinded to the fact that patient is in a clinical trial, 
minimising observer bias. Due to the difference in the samples produced from 
EBUS-TBNA (cytology) and mediastinoscopy (histology) it is not possible to blind 
the pathologists to the procedure employed. 
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Section 3 Trial entry 
 
3.1 Recruitment 
Consecutive patients with undiagnosed MLN will be recruited from several sites. 
The centres in the study will be University College London Hospital, Medical 
University South Carolina, Whittington Hospital, North Middlesex and and Barnet 
Hospitals. Patients with undiagnosed MLN referred to thoracic physicians or 
surgeons will be considered for trial entry.  
 
3.2  Patient selection 
 
3.2.1    Inclusion criteria 
Consecutive patients with undiagnosed mediastinal lymphadenopathy on CT or PET-
CT scan will be considered for trial entry. In order to reflect clinical practice as 
closely as possible and avoid selection bias, all consecutive patients will be included. 
Patients must have enlarged (>1cm in short axis) MLNs in lymph node stations 
accessible to EBUS-TBNA. Prior to the trial, these patients would have been referred 
for mediastinoscopy. 
3.2.2 Exclusion criteria 
 
Patients without informed consent, those with anterior mediastinal lesions or with 
contra-indications to EBUS or mediastinoscopy will be excluded. 
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Section 4 Patient Management 
 
4.1  Trial Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consecutive patients with 
undiagnosed mediastinal 
lymphadenopathy  
Exclusion criteria: 
1. Contra-indication to 
mediastinoscopy or 
EBUS-TBNA  
2. No consent 
 
3. Anterior mediastinal 
lesion 
EBUS-TBNA 
Bronchoscopy 
 
Positive Negative 
Diagnosis Diagnosis 
Mediastinoscopy  
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4.2 Endobronchial Ultrasound and Bronchoscopy 
EBUS-TBNA is performed in the ambulatory care setting by dedicated respiratory 
specialists with an interest in the procedure (NN, SJ, GS). Intravenous sedation is 
provided by midazolam and fentanyl. The linear echoendoscope is introduced via the 
mouth into the trachea. Topical anaesthesia with lidocaine is applied. Mediastinal 
lymph nodes are visualised and sampled using the standard EBUS technique, as 
previously described
37
. Vessels are located using the doppler function and are 
avoided. A 22G or 21G needle will be used and between 3 and 5 passes per node will 
be performed
38
. Samples will be smeared directly onto slides and air-dried. Any 
tissue cores obtained will be placed in formalin for histological examination. Needle 
wash is sent for microbiological examination and culture for tuberculosis and fungi. 
 
Once EBUS-TBNA is completed, the EBUS scope will be replaced with a standard 
videobronchoscope. Endobronchial biopsies will be taken from any endobronchial 
abnormalities and transbronchial biopsies will also be performed in patients who are 
suspected of having sarcoid. The procedure will last in total 30 - 45 minutes. 
Cytological samples may be examined on-site by a cytologist to assess sample 
adequacy. Patients are observed for 2 hours after the procedure and then allowed 
home.  
 
4.2 Mediastinoscopy 
 
Mediastinoscopy is performed by specialist thoracic surgeons at the Heart hospital or 
University of South Carolina. Under general anaesthesia, the surgeon makes an 
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incision above the suprasternal notch. A videoscope is then passed behind the 
sternum and mediastinal structures are directly visualised. Visible lymph nodes are 
biopsied. At least one biopsy is obtained from lymph node stations 2, 4 and also 7 
when possible. Patients are discharged the same day or admitted overnight for 
observation at the surgeon’s discretion. 
 
4.3 Cyto-histological Samples 
 
All samples are examined by pathologists with specialist experience in thoracic 
specimens.  
 
4.4 Diagnostic criteria 
 
The following diagnoses are applied to pathological results: 
 
Non-caseating granulomas – sarcoidosis 
 
non-caseating granulomas and positive tuberculosis culture – tuberculosis 
 
Caseating granulomas or Granulomas with necrotic material – tuberculosis 
 
Malignant cells – malignancy (immunocytochemistry or immunohistochemistry may 
be performed to determine the origin of the primary tumour) 
 
Reed Sternberg cells – Hodgkin’s Lymphoma 
 
In cases where EBUS-TBNA has failed to provide a definitive diagnosis, the patient 
will be referred for mediastinoscopy.  
In cases where EBUS-TBNA and mediastinoscopy have failed to yield a diagnosis, 
patients will be followed clinically for a period of 6months - 1 year including 
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interval CT scans and assessment of MLN size. This will ensure that no cases of 
malignancy or active tuberculosis are overlooked. 
 
4.5 Management after diagnosis achieved 
 
Once a pathological diagnosis has been reached, the patient’s care is continued by 
the referring physician or surgeon. 
 
 
Section 5 Potential complications of procedures  
 
5.1   Endobronchial ultrasound and bronchosocpy 
 
No serious complications have been observed in the literature on EBUS-TBNA. At 
UCLH and MUSC, over 500 procedures have been performed without any adverse 
events. 
5.2 Mediastinoscopy 
 
Mediastinoscopy is the standard procedure for the diagnosis of MLN. It is associated 
with a mortality rate of 0.1% and morbidity of 1%, most commonly recurrent 
laryngeal nerve injury, penumothorax or tracheal injury.  
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Section 6 Healthcare Costs 
 
6.1 Healthcare costs of the new strategy (EBUS-TBNA followed by 
mediastinoscopy if necessary) will be compared to the standard of mediastinoscopy 
alone. A decision tree model will be employed. 
 
Section 7 Statistical considerations 
7.1  Endpoints 
The primary endpoints are the proportion of mediastinoscopies prevented and cost.  
Secondary endpoints are length of hospital stay, sensitivity and diagnostic accuracy 
of EBUS-TBNA.  
7.2 Analysis method 
Demographic and clinical characteristics of the study population will be summarised 
using mean, standard deviation, median, or counts and percentages, depending on 
their type and distribution.  
 
The one sample z test will be used determine if there is a significant reduction in 
mediastinoscopies due to EBUS-TBNA. The one sample t-test will be used to 
investigate whether the cost of EBUS-TBNA significantly differs from that 
associated with mediastinoscopy. We do not anticipate the distribution of cost to be 
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too skewed. However, a bootstrapping method will be used as a sensitivity analysis 
(Barber and Thompson, Stats in Medicine 2000). 
 
Test accuracy will be estimated using sensitivity and negative predictive value 
(NPV) with 95% binomial confidence intervals.   
 
The length of hospital stay will be summarised using median and interquartile range.  
 
Results from this study will be reported according the Standard of Reporting 
Diagnostic Accuracy Guidelines
39
. 
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7.3 Number of subjects required for the study 
 
The mean cost for mediastinoscopy is known to be £3226 based on current NHS 
tarrifs. A small proportion of patients may experience complications and incur 
additional costs (e.g. staying in the hospital for an additional day). A standard 
deviation of £1400 is assumed to allow for that. A difference of £500 in cost on 
average would be considered to be acceptable if EBUS-TBNA significantly reduced 
the number of mediastinoscopies. A total of 75 patients will be required to detect a 
mean difference of £500 in cost associated with bronchoscopy, assuming an 80% 
power and 2.5% significance level (since the Bonferroni correction is applied to 
adjust for multiple significance testing). This sample size is also sufficient to give 
the study adequate power to assess whether the proportion of patients undergoing 
mediastinoscopy is reduced by 40%, assuming the same power and significance 
level. The sample size has been calculated using the statistical software STATA 
version 10. 
 
7.4 Recruitment period 
 
Two patients per week are expected to be eligible for the study. At least 90% of 
these patients will be recruited. Therefore 72 patients should be recruited within 1 
year. The trial is scheduled to open in May 2009 and conclude in May 2011.
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Section  8 Data Collection 
 
8.1  Data to be collected: 
Initials, DOB 
Enlarged mediastinal LNs 
LN station(s) involved 
Parenchymal abnormalities (mass or nodules) 
 Location of parenchymal abnormalities 
Pre-procedure PET? 
 Positive?  
Clinical diagnosis 
Date of EBUS-TBNA 
Operators 
LN station(s) sampled 
Size of node 
Number of passes 
Bronchoscopy: Y/N 
Endobronchial biopsies Y/N 
Transbronchial biopsies Y/N 
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BAL: Y/N 
Total time of procedure 
ROSE: Y/N 
EBUS pathology result 
Bronchoscopy pathology result 
Mediastinoscopy: Y/N 
LNs sampled 
Complications 
Mediastinoscopy pathology result 
Total inpatient stay 
Culture results 
Final diagnosis 
Clinical follow-up at 6 months and 1 year if no diagnosis is made 
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 8.2 Data Handling and record keeping 
The above anonymised data will be entered into a specifically designed Microsoft 
Access database. The database will be password protected and kept on a secure 
computer at the host institution. Data entry will be performed by a clinical trials 
practitioner (independent to the investigators) with double entry on 20% of the 
patients.  
  
The Data Protection Act 1988 will be strictly adhered to. Data will be stored for 3 
years after trial completion and then destroyed. Drs Navani and Janes and Professor 
Silvestri retain responsibility for data collection, recording and quality. 
 
Section 9: General issues related to the conduct of the trial 
  
9.1 Regulations and confidentiality of data  
 
Access to the data will be restricted to appropriate trial personnel for the purposes of 
the research and analyses of results only. 
 
Patient name and address details will be included in the information obtained, but 
will be kept separate from the medical details. A unique identification number will 
link the name to the medical details. 
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Specific personnel at University College London Hospital (UCLH), as trial sponsors, 
and national regulatory authorities, may access data.  
 
The trial personnel, UCL and any regulatory bodies will keep data confidential. 
Patient names will not be used in any reports about the study and all data is stored in 
accordance with the Data Protection Act 1998.  
 
9.2 Data Protection  
The trial personnel will act to preserve patient confidentiality and will not disclose or 
reproduce any information by which patients could be identified. Data will be stored 
in a secure manner and the study will be registered in accordance with the Data 
Protection Act 1998 with the Data Protection Officer at UCL. 
 
9.3 Ethical approval  
Ethical approval will be obtained and this protocol forms part of the application. 
 
9.4 Declaration of Helsinki and Good Clinical Practice  
The study will be conducted according to the recommendation of the Declaration of 
Helsinki (2000 Edinburgh, Scotland) and in accordance with the ICH principles of 
Good Clinical Practice.  
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9.5 Participant informed consent  
The Investigator is required to explain the nature and purpose of the study to the 
participant prior to study entry. A participant information sheet will be given to the 
candidate and written informed consent obtained before entering in the study.  
 
9.6 Idemnity & Compensation  
Non negligent harm: University College London, as sponsor, will provide insurance 
against claims for compensation for injury caused by participation in this trial (ie 
non-negligent compensation). Patients wishing to make a claim should address their 
complaint in writing to the chief investigator in the first instance. 
Negligent harm: Where studies are carried out in a hospital, the hospital continues to 
have a duty of care to a patient being treated within the hospital, whether or not the 
patient is participating in this trial. University College London does not accept 
liability for any breach in the hospital’s duty of care, or any negligence on the part of 
employees of hospitals. 
 
9.7 Publication policy  
We intend to disseminate findings from the research in peer-reviewed journals. 
Clinicians and researchers involved in the project will be acknowledged in written 
papers. 
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Section 1: Background 
 
1.1 The burden of lung cancer 
 
Lung cancer is the biggest cancer killer in the UK, accounting for more than one in 
five cancer deaths. Over 38,000 new cases are diagnosed each year and in 2004, 24% 
of cancer mortality in men and 19% of mortality in women was due to lung cancer
1
. 
Lung cancer continues to have an enormous impact on national mortality and 
currently accounts for 6% of all deaths and 22% of all deaths from cancer in the UK. 
 
1.2 The importance of accurate staging 
 
Accurate staging of non-small cell lung cancer is a critical step which determines 
both the treatment modality and the prognosis. This is currently best accomplished 
via a multidisciplinary approach involving surgical, respiratory, oncology and 
radiology input in order to establish whether or not curative surgical resection is 
possible. Preoperative mediastinal lymph node staging separates initial operative 
versus non-operative status. Patients without mediastinal nodal metastases are 
considered operative candidates, while patients with central or contralateral 
mediastinal nodal metastases are treated primarily with chemotherapy and external 
beam radiotherapy
2
.  
Staging is used to predict survival and guide therapy. However, even with clinical 
stage I disease, the 5 year-survival rate after surgery is only 50%. Approximately 
60% of cancer recurrences are likely to be from micrometastatic involvement at 
presentation, which is currently not detectable with existing diagnostic and staging 
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modalities
3
. Patients with clinical stage II disease (with hilar lymphadenopathy) have 
a five-year survival rate after surgery of 30%. At clinical stage
 
IIIA, the 5-year 
survival rate is 17%, and at stage IIIB it
 
is only 5%.
4
 These patients are generally 
treated with combined
 
chemotherapy and radiotherapy. The 5-year survival rate for
 
patients with stage IV disease is virtually nil, and this disease
 
is treated either with 
chemotherapy and supportive care or with
 
supportive care alone. It is therefore 
critical
 
to stage patients accurately as the treatment modalities and
 
subsequent patient 
outcomes vary widely based on stage designation. 
Several invasive and non-invasive methods exist to diagnose and stage lung cancer, 
and most patients require more than one. Inadequate staging or indeed incorrect 
staging of the mediastinal nodes can have the catastrophic consequences of a missed 
opportunity to operate or more commonly an inappropriate operation leading to high 
morbidity and worse outcome. 
 
1.3 Techniques for staging lung cancer 
 
Most centres perform a thoracic and upper-abdominal computed tomography (CT) 
scan first to assess whether to carry out a fibro-optic bronchoscopy (FOB) or trans-
thoracic CT guided fine needle aspiration of the primary cancer. This provides the 
diagnosis and then patients are investigated for secondary lesions. This often results 
a in second invasive biopsy after 18-F-deoxyglucose positron emission tomography 
(PET) scan.  
Accurately determining the status of mediastinal nodes is of paramount importance 
in determining treatment and prognosis. Non-invasive methods for staging include 
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CT with intravenous contrast administration, PET, as well as simultaneous 
acquisition CT-PET fusion imaging. Invasive mediastinoscopy has been considered 
the gold standard for mediastinal evaluation. The advent of the newer techniques of 
endoscopic ultrasound (EUS) and endobronchial ultrasound (EBUS) provides 
minimally invasive approaches for accurately staging lung cancer. 
 
1.3.1 Computed tomography (CT) 
 
A CT scan is widely available, relatively inexpensive and is always performed as a 
preliminary step in patients in whom a clinical diagnosis of lung cancer is suspected.  
It is the most commonly employed modality for assessing the mediastinum in lung 
cancer. Intravenous contrast is useful for distinguishing vascular structures from 
lymph nodes as well as delineating mediastinal invasion by centrally located 
tumours. Various criteria exist to define the malignant involvement of mediastinal 
nodes. The most widely used criterion is a short-axis lymph node diameter of ≥  1 
cm on a transverse CT scan.  
 
A recent systematic review of 35 studies from 1991 to June 2006 analysed the 
accuracy of CT in diagnosing mediastinal metastases
3
.  The combined studies 
yielded 5,111 evaluable patients and the pooled sensitivity and specificity of CT 
scanning for identifying mediastinal lymph node metastasis were 51% (95% CI, 47 
to 54%) and 86%  (95% CI, 84 to 88%) respectively. Therefore CT has only a 
limited ability to diagnose or exclude mediastinal metastasis. The results from this 
systematic review mirror those of other large meta-analyses
5,6
. 
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The limitations of CT are highlighted by a false positive rate of 40% in mediastinal 
lymph nodes and the fact that 5 to 15% of patients with clinical T1N0 (stage I) 
tumours are found to have positive lymph node involvement at surgery
7
. Therefore 
CT can overstage and understage and cannot solely determine mediastinal lymph 
node status in patients with NSCLC. CT does however provide anatomical data that 
can guide the location and modality to be used for subsequent procedures for 
accurate staging. 
 
1.3.2 Positron Emission Tomography (PET) 
 
PET scanning is an imaging modality based on the biological activity of neoplastic 
cells. A standard uptake value of < 2.5 is often used as a threshold for normality, but 
non-neoplastic processes including granulomatous and other inflammatory diseases 
as well as infections may also demonstrate PET positive findings. The lower limit of 
spatial resolution is currently 7 to 10 mm, however, smaller lesions may be detected 
depending on the intensity of uptake of the isotope in abnormal cells
8
. Additionally, 
well differentiated low-grade malignancies, particularly bronchoalveolar cell 
carcinoma are known to have higher false-negative rates
9
.
 
 
A systematic review of the accuracy of PET for the non-invasive staging of the 
mediastinum in patients with NSCLC evaluated 44 studies between 1994 and June 
2006
3
. The results from 2,865 patients were analysed and pooled estimates of 
sensitivity and specificity for identifying mediastinal metastasis were 74% (95% CI, 
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69 to 79%) and 85% (95% CI, 82 to 88%) respectively. PET provides limited spatial 
resolution and integrated PET-CT scanning may represent an improvement over both 
techniques separately
10
, although the total number of patients evaluated by this 
hybrid technique is small. PET or PET-CT is certainly an improvement over CT 
alone and negative predictive values may approach 97% when used in combination. 
However, given a false positive rate of up to 40%, all positive findings in surgical 
candidates should be confirmed by biopsy
11
.  
 
1.3.3 Surgery 
 
Mediastinoscopy is currently considered to be the gold standard for determining the 
mediastinal node involvement from cancer. However, it has the limitation of 
sampling only the left and right para-tracheal, carinal and sub-carinal nodes, leaving 
nodes in the aorto-pulmonary window to be explored by anterior mediastinotomy. 
The posterior and inferior nodes are not accessible to surgical techniques. While 
mediastinoscopy cannot sample all mediastinal nodes, it can however detect 
microscopic disease even in small nodes. Overall, the sensitivity of mediastinoscopy 
is 78% and the false negative rate 11% in meta-analysis
12
. 
 
1.3.4 Endoscopic ultrasound (EUS) 
 
EUS guided needle aspiration of mediastinal lymph nodes through the wall of the 
oesophagus is performed with a negligible risk of infection or bleeding as a day-case 
procedure. EUS provides us with an alternative method of diagnosing and staging 
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mediastinal nodes and is also able to examine abdominal structures including the 
celiac axis nodes, the left lobe of the liver and the adrenal glands via the oesophagus. 
Lymph node stations accessible by EUS include levels 4L, 5, 7, 8 and 9 (figure A). 
EUS guided needle aspiration is more suited to left sided nodes as compared to the 
right due to the anatomical location of the oesophagus
13,14
. EUS has been shown to 
be an accurate and cost-effective technique in mediastinal lymph node staging with a 
sensitivity of 84%
12
. EUS-FNA has also been shown to decrease the number of 
subsequent futile thoracotomies
15
 but may be underutilized
16
. By performing EUS 
alone as the first test 
in lung cancer patients, Singh et al made the diagnosis in 82% of cases
17
. This 
method was more accurate at diagnosing metastases in the mediastinum than CT and 
PET and was also superior to CT at diagnosing extra-thoracic disease. Other studies 
of patients with lung cancer requiring mediastinal evaluation have also found that 
EUS was more sensitive and specific than CT and PET
14, 18-21
. Indeed EUS may also 
be more accurate than mediastinoscopy
22
 and one study has shown that 37% of 
patients with a negative mediastinoscopy had metastatic nodes on EUS
20
. 
 
1.3.5 Endobronchial Ultrasound (EBUS) 
 
The endobronchial application of ultrasound was first described in 1992 and has 
been commercially available since 1999. More recently a video-bronchoscope with a 
convex linear ultrasound probe has been developed that allows for real-time 
ultrasound-guided transbronchial needle aspiration as a day-case procedure. EBUS 
can be used to sample the highest mediastinal, upper and lower para-tracheal, 
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subcarinal lymph nodes, as well as hilar lymph nodes (figure A). Lymph node station 
not accessible by EBUS include levels 5,6,8 and 9, which can be reached by EUS. A 
22-guage needle is fed through the working channel and multiple passes are made 
until diagnostic tissue is obtained. The needle allows cores of tissues to be obtained 
and immunohistochemistry can be performed 
 
EBUS guided needle aspiration is superior to traditional transbronchial needle 
aspiration (TBNA) in all stations in a large, randomized study
23
 and has high 
sensitivity 90% (range 79-95%), diagnostic accuracy (97.1-98.9%) and negative 
predictive value (89.5-96.3%) as shown in several case series
24-29
. The average false 
negative rate was 24%
12
. In one series of 502 patients the range of lymph nodes 
accessed included levels 2R (n=53), 2L (n= 40), 3 (n=35), 4R (n=86), 4L (n=77), 7 
(n=127), 10R (n=39), 10L (n=43), 11R (n=40) and 11L (n=33). Lymphocytes were 
present (indicating adequacy of specimen) in 94.5% of cases and the diagnosis was 
established from the lymph node biopsy in 93.5% of cases
30
. Some of these lymph 
node stations are frankly inaccessible by any other modality. EBUS may be 
combined with EUS in the same procedural setting
29
 and sub-centimeter lymph 
nodes even as small as 4mm can be reliably sampled
26
. Until the false negative rate 
is more clearly defined, negative EBUS biopsy results are confirmed by surgical 
staging modalities. 
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1.4 Diagnosis and staging in a single test 
 
Traditionally, the management of the suspected lung cancer patient begins with 
techniques to confirm the diagnosis and to differentiate small cell from non-small 
cell lung cancer. Once the diagnosis and histological type has been established (e.g. 
with CT guided percutaneous biopsy for a peripheral lung lesion) attention turns to 
evaluating the stage, which determines treatment options for the patient. Staging of 
non-small cell lung cancer focuses on defining the disease stage of the mediastinum, 
as almost all patients with extra-thoracic metastases will have metastatic mediastinal 
nodes
31
. Approximately 80% of patients in the UK present with inoperable disease. 
Therefore obtaining tissue from the mediastinum as a first test after CT scan would 
provide sufficient histological and staging data to guide treatment decisions in 80% 
of patients. The ultrasound guided techniques of EUS and EBUS offer a minimally 
invasive, day-case, relatively inexpensive and sensitive method of sampling the 
mediastinum. 
 
In the operable patient with no extra-thoracic disease, NICE guidelines suggest that 
FDG-avid mediastinal lesions on PET require histological confirmation before 
surgery is precluded. Despite this, mediastinoscopy appears to be under-utilized in 
clinical practice
32
. However, ultrasound techniques would improve the staging of 
patients with lung cancer and should render mediastinoscopy redundant in most 
cases. Mediastinoscopies are time consuming and expensive, cause delay with 
surgical transfer, have some morbidity and a lower sensitivity than ultrasound 
techniques. When EBUS is combined with EUS guided needle aspiration, the range 
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of nodal stations amenable to needle biopsy is extended to include all stations except 
prevascular (level 6) lymph nodes and sub-centimeter lymph nodes even as small as 
4 mm can be reliably sampled. 
 
Accurate diagnosis and staging of lung cancer in a single test, by ultrasound guided 
aspiration of mediastinal nodes, would obviate the need for further and more 
expensive investigations like PET scan. In addition the number of mediastinoscopies 
and futile thoracotomies would also be drastically reduced. By reducing the number 
of outpatient attendances and unnecessary investigations and operations, ultrasound 
guided diagnosis and staging would represent significant saving in healthcare costs, 
one study demonstrating $11,000 per patient saving in North America
33
.  
 
1.5 Why is a clinical trial needed? 
 
The recent development of mediastinal ultrasound investigation has been quickly 
incorporated into the patient pathways across Europe and the United States. The 
evidence discussed has determined that it is safe and accurate. Yet few centres in the 
United Kingdom currently use these investigations and then after other 
investigations such as traditional bronchoscopy and PET. We believe introducing an 
ultrasound investigation as a first test after CT will speed the patient pathway and 
reduce the number of tests, mediastinoscopies and futile thoracotomies required in 
these patients, hence improving patient care and considerably reducing costs. To 
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date, a study comparing patient pathways with and without EBUS / EUS has not 
been carried out. 
 
We wish to clearly demonstrate that using EBUS / EUS as a first test after CT scan is 
superior to current practice so that both Hospital Care Trusts and Primary Care 
Trusts can see the financial rewards of this new pathway as well as the improved 
service for patients. This should then encourage a wider uptake of these methods 
across the UK. 
 
 
Section 2: Trial Design 
 
2.1 Hypothesis 
 
EUS (endoscopic ultrasound) or EBUS (endobronchial ultrasound guided 
transbronchial needle aspirate) as a first test after CT scan in the diagnosis and 
staging of lung cancer will result in a reduction in the time from first outpatient 
referral to treatment decision, a reduction in the total number of PET scans, 
mediastinoscopies and futile thoracotomies, fewer outpatient attendances and a 
reduction in NHS healthcare costs. 
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2.2 Objectives 
 
We aim to prove this hypothesis by: 
 
1. Assessing the time from first consultation to decision to treat and the number of 
tests and outpatient attendances required in patients receiving standard care 
compared to patients in the new diagnostic pathway containing EBUS / EUS as a 
first test. 
 
2. Prospectively diagnosing and staging 80% of consecutive lung cancer patients 
with a single procedure (EUS or EBUS), after an initial CT. 
 
3. Comparing NHS healthcare costs of diagnosing and staging lung cancer in 
patients who have received current standard care and those patients who have had 
EUS or EBUS as their first investigation. 
 
We aim to show that EUS or EBUS after a neck, thoracic and upper abdominal CT is 
a safe, sensitive and efficient first diagnostic test for lung cancer patients with intra-
thoracic disase. It has the advantage over current techniques of being able to 
accurately determine the histological diagnosis and stage the patient’s disease in a 
single procedure. We envisage that this will significantly reduce the need for further 
expensive investigations such as PET and mediastinoscopy. In addition, as it is a 
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single day case procedure, we will aim to demonstrate that a lung cancer patient 
pathway involving EBUS and EUS will require fewer outpatient attendances and 
overall will result in substantial savings in healthcare costs. 
 
We also aim to calculate the sensitivity and negative predictive value of EBUS and 
EUS guided mediastinal aspiration in the diagnosis of lung cancer, since all negative 
results will be followed by functional imaging or surgical biopsy, the current gold 
standard of care. 
 
Section 3: Trial entry 
 
3.1 Recruitment 
 
The retrospective arm will include 40 consecutive patients from each of 5 North 
London Cancer Network Hospitals who were referred with suspected lung cancer 
dating backwards from June 2007. The institutions participating in the retrospective 
arm are The Royal Free Hospital, The Whittington Hospital, The North Middlesex, 
Barnet Hospital and University College Hospital.  
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The prospective arm will be comprised of consecutive patients recruited from the 1
st
 
April 2008. All patients referred with suspected lung cancer to University College 
Hospital, The North Middlesex Hospital, The whittington and other North London 
Cancer Network hospitals will be recruited, until 168 patients in total are included. 
3.2 Patient selection 
 
This will be as follows: 
3.2.1 Inclusion criteria 
 
 Consecutive patients suspected of lung cancer on CT scan 
 Written informed consent 
 Able to tolerate fibre-optic bronchoscopy, mediastinoscopy and 
thoracomtomy if neccessary 
 
3.2.2 Exclusion criteria 
 
 Evidence of severe or uncontrolled systemic disease that makes it undesirable 
for the patient to participate in the trial 
 Any disorder making reliable informed consent impossible 
 Patient unlikely to tolerate bronchoscopy 
 Patients with extra-thoracic disease, supraclavicular lymphadenopathy or 
pleural effusion 
 
3.3 Randomisation 
 
Block randomisation will be performed. The arms will be stratified for recruiting site 
and the presence or absence of mediastinal nodes ≥1cm. Patient registration, 
recording and collection of data will be the responsibility of the PI. The patient will 
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be allocated to the control or active pathways and given a unique identification 
number. This number will be quoted on all subsequent forms and samples from the 
trial. 
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Section 4: Patient Management 
4.1.1 Trial Flowchart 
 
Consecutive patients 
with suspected lung 
cancer – multicentre 
recruitment 
Evidence of extra-
thoracic disease or 
pleural effusion: 
proceed to distal 
biopsy or pleural 
aspiration: Exclude 
Exclusion criteria: 
1. Unable to give 
reliable consent 
2. Unable to tolerate 
bronchoscopy 
Evidence of intra-
thoracic disease 
only: 
RANDOMISE 
84 patients: 
Prospective 
control arm – 
Best current 
management: 
Flowchart 4.1.2 
84 patients: 
Prospective 
active arm – Best 
current 
management 
including EBUS / 
EUS: Flowchart 
4.1.3 
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Target GP Referral for 
suspected lung cancer 
Staging CT scan of 
neck, thorax, upper 
abdomen and first OPA 
Evidence of extra-
thoracic metastases 
amenable to biopsy 
Bronchoscopy or CT-
guided biopsy 
Intra-thoracic disease only or 
disease with inaccessible extra-
thoracic metastases 
Radiology guided 
biopsy of distant 
metastasis 
MDT and 2nd OPA 
Multimodality 
treatment 
MDT and 2nd 
OPA 
Not candidate for 
radical treatment 
PET or CT-PET scan  
MDT and 3rd  OPA 
Mediastinum PET 
negative and 
mediastinal nodes 
<1cm 
Surgery 
with 
curative 
intent 
N2/3 positive on PET scan 
or mediastinal nodes > 1cm 
Mediastinoscopy 
No N2/3 
disease 
N2/3 disease 
confirmed 
Flowchart 4.1.2: Current 
Diagnostic and Staging pathway 
for Lung Cancer: Adapted from 
the NICE, ESTS34 and ACCP 
guidelines12. 
Blue boxes represent 
procedures, tests and outpatient 
appointments necessary for 
diagnosis and staging. Red 
boxes represent outcome. 
Candidate for 
radical treatment 
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Staging CT scan 
of neck, thorax, 
upper abdomen 
and first OPA 
Evidence of 
extra-thoracic 
metastases 
Radiology guided 
biopsy of distant 
metastasis 
MDT and 2
nd
 
OPA 
Multimodality 
treatment 
Disease confined to thorax only or 
disease with inaccessible extra-
thoracic metastases 
Endobronchial or endoscopic 
ultrasound guided mediastinal 
aspiration 
MDT and 2
nd
 
OPA 
N2/3 disease 
confirmed 
Negative mediastinum on 
EBUS/EUS 
PET scan then MDT 
and 3
rd
 OPA 
Mediastinum PET 
neg and mediastinal 
nodes <1cm 
Surgery 
with 
curative 
intent 
N2/3 positive on PET scan 
or mediastinal nodes > 1cm 
Mediastinoscopy 
No N2/3 
disease 
N2/3 disease 
confirmed 
Target GP 
Referral for 
suspected lung 
cancer 
Flowchart 4.1.3: A new 
diagnostic pathway 
incorporating EBUS/EUS. 
75% of patients are 
expected to follow the 
pathway with dashed 
arrows. 
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4.2 The retrospective arm 
Data will be collected from 40 consecutive lung cancer patients in each of 5 of the 
North London Cancer Network hospitals (University College Hospital, Royal Free 
Hospital, Barnet Hospital, Whittington Hospital and North Middlesex Hospital). The 
patients will have been diagnosed with lung cancer dating backwards from June 
2007. There will therefore be a total of 200 patients in the retrospective arm. 
 
For each patient, the following data will be collected: 
 
 Name, Hospital number, Unique Identification Number, Date of birth, 
Gender, Ethnicity 
 Date of 1st appointment 
 Pack.year history 
 Occupational Risk 
 Family history of lung cancer 
 Significant co-morbidity (the presence of an illness which would normally be 
recorded on a death certificate) 
 Would tolerate bronchoscopy 
 Performance status (WHO-ECOG) 
 FEV1 (% predicted) 
 Source of referral 
o GP, urgent / emergency / suspected lung cancer 
o GP, routine 
o Other consultant 
o Radiology 
 First appointment within 2 weeks of receipt of referral? 
 Dates of outpatient appointments until diagnosis and stage 
 Number of days until diagnosis and stage 
 Number of tests required to determine diagnosis and stage 
o CT scan 
o Bronchoscopy 
o CT guided biopsy (?Complications ?Inpatient stay) 
o PET scan 
o USS liver / abdomen 
o Bone scan 
o CT / MRI Brain 
o Mediastinoscopy 
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 Proven histological diagnosis: cell type 
 Stage (+ size and location of mediastinal nodes if available) 
 Number of days from first appointment to treatment 
 Any active treatment (within 6 months of diagnosis) 
 Treatment with curative intent (Surgery, Radical radiotherapy) 
 Time from diagnosis to death (if applicable) 
 Reason for exclusion 
 
4.3 The prospective control arm 
 
Patients recruited into the control arm will be managed according to the usual 
practice of the hospital lung cancer multidisciplinary team (MDT). Flowchart 4.1.2 
provides a template for best current practice, as suggested by the American College 
of Chest Physicians, European Society of Thoracic Surgeons and NICE. However, 
we do not expect that this flowchart is strictly adhered to in lung cancer MDTs. The 
trial is designed to change current clinical practice and therefore management in the 
control arm will reflect current clinical practice, as determined by the MDT, 
including the use of conventional TBNA where available. Drs Janes and Navani may 
be present but will not influence the investigations performed. This is in order to 
avoid any bias. Data on each patient, as described in section 4.2, will be collected. 
 
4.4 The active arm: The new diagnostic pathway incorporating EBUS & EUS 
 
Patients randomised into the active arm will be managed according to the pathway 
shown in flowchart 4.1.3. Patients with intra-thoracic disease only will have EBUS 
or EUS guided mediastinal aspiration as an initial investigation after CT scan. 
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Patients with enlarged anterior, hilar or subcarinal nodes will proceed to EBUS. 
Those with enlarged posterior mediastinal nodes will proceed to EUS. Patients who 
have no evidence of enlarged mediastinal nodes (≥ 1 cm) will still undergo EBUS or 
EUS as a first investigation as ultrasound guided aspirations may detect metastatic 
disease in up to 40% of patients with a radiologically normal mediastinum
26,33
. The 
pattern of lymph node metastases is predictable and therefore either EBUS or EUS 
can be selected based on the site of the primary lesion (see Table 1). 
 
 
Table 1: Site of mediastinal lymph node metastases and initial investigation 
according to site of primary lesion, when initial staging CT scan shows no enlarged 
mediastinal nodes. 
 
4.5 The practical aspects of endobronchial and endoscopic ultrasound 
 
EBUS and EUS are very similar to standard bronchoscopy and endoscopy 
respectively. Patients randomised to the active arm will be asked to remain nil by 
mouth for 4 hours prior to the procedure. EBUS or EUS will be carried out by 
304 
dedicated specialist physicians with an interest in the procedures. The investigations 
are carried out under conscious sedation. Where endobronchial disease is directly 
visualised, biopsies will be taken through a fibre-optic bronchoscope as well as 
ultrasound guided mediastinal aspirations. The EBUS or EUS procedure will last 
approximately 30 - 40 minutes. They will be discharged the same day and seen in 
clinic at the next available appointment with the results of the procedure and MDT 
discussion. 
 
4.6 Cyto-histological processing 
As agreed with Dr Mary Falzon (Consultant Histopathologist at UCH), samples 
obtained by ultrasound guided mediastinal aspiration will be on smeared slides and 
processed according to routine laboratory protocols. Where available, samples will 
also be placed in liquid cytology solution e.g. cytolyte, allowing tissue blocks to be 
made and immunohistochemical stains performed. 
 
Each patient undergoing an ultrasound biopsy will be consented to have two samples 
stored for research. The samples will be used to examine the quality of the 
cytological preparations and determine whether these samples can be used for RNA 
and DNA work. Subsequent samples will have their DNA or RNA stored as per 
laboratory protocol for bronchial samples for future research. Dr Navani will carry 
out these tests in the laboratory of Dr Sam Janes in the Centre for Respiratory 
Research. If the samples taken for the clinical aspects of patient management are 
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insufficient, then the samples taken for research purposes would be analysed for 
patient benefit. 
 
4.7 Management after diagnosis and staging complete 
 
Once a tissue diagnosis is obtained and TNM staging is completed, patients will 
continue to be managed by the MDT of the hospital to which the patient was 
referred. Guidance on further management is provided by the NICE guidelines
2
. 
 
Section 5: Adverse event reporting 
 
Adverse events will be recorded for all patients from time of randomisation to 
treatment decision. Serious adverse events (which require reporting) are death or 
prolonged hospital stay. 
 
5.1 Endoscopic and endobronchial ultrasound   
 
There are no common complications specifically related to endobronchial ultrasound 
or endoscopic ultrasound guided needle aspiration. All procedures will be carried out 
by specialist physicians with a dedicated interest in EUS, EBUS and bronchoscopy 
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and the British Thoracic Society guidelines for bronchoscopy will be strictly adhered 
to. 
 
Section 6: Cost 
6.1 Economic analysis 
The procedures, investigations and outpatient appointments will be costed at the time 
of the study closure as per the national tariffs or best estimates of procedure cost. 
These costings will be applied to the retrospective, prospective control and active 
arms and decision tree analysis. 
 
Section 7: Statistical considerations 
 
7.1 Endpoints 
The primary endpoint is the time from first outpatient appointment to decision to 
treat. 
Secondary endpoints are: 
 The health care costs of diagnosing and staging lung cancer 
 The number of tests and outpatient visits a patient requires to be diagnosed 
and staged with lung cancer 
 The proportion of lung cancer patients that are diagnosed and staged with a 
single test after CT scan 
 The time from first outpatient appointment to treatment 
 The number of mediastinoscopies 
 The number of futile thoracotomies 
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The sensitivity and negative predictive value of EBUS and EUS in lung cancer will 
also be calculated. In addition, endpoints will also be analysed according to the 
presence or absence of enlarged mediastinal lymphadenopathy 
 
7.2 Number of subjects required for the study 
The retrospective arm will contain 40 patients from each of 5 hospitals within the 
North London Lung Cancer network (University College Hospital Trust, North 
Middlesex Hospital Trust, The Whittington Hospital Trust, Barnet Hospital Trust, 
and The Royal Free Hospital Trust), totaling 200 patients. 
 
The prospective control arm and active arms will each comprise 84 participants (168 
in total). In the retrospective arm and the prospective control group, we would 
expect that patients will require 2 or 3 investigations and outpatient appointments 
before a diagnosis and stage is reached, taking 30 days. This study aims to show that 
patients will only require 1 investigation and subsequent outpatient appointment, by 
using the newer techniques of EBUS and EUS and therefore reduce the time from 1
st
 
appointment to treatment decision to 14 days. We anticipate that 66% of patients will 
be diagnosed and staged with one test in the active arm, compared to 33% in the 
control arm. Based on 99% power and 2-sided test of significance, we would require 
a total of 168 patients (84 patients in each arm). The sample size calculation was 
carried out by Richard Stephens in the MRC Clinical Trials Unit, London. 
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Section 8: General issues related to the conduct of the trial 
  
8.1 Regulations and confidentiality of data  
Access to the data will be restricted to appropriate trial personnel for the purposes of 
the research and analyses of results only. 
Patient name and address details will be included in the information obtained, but 
will be kept separate from the medical details. A unique identification number will 
link the name to the medical details. 
Specific personnel at University College London Hospital (UCLH), as trial sponsors, 
and national regulatory authorities, may access data.  
The trial personnel, UCL and any regulatory bodies will keep data confidential. 
Patient names will not be used in any reports about the study and all data is stored in 
accordance with the Data Protection Act 1998.  
 
8.2 Data Protection  
The trial personnel will act to preserve patient confidentiality and will not disclose or 
reproduce any information by which patients could be identified. Data will be stored 
in a secure manner and the study will be registered in accordance with the Data 
Protection Act 1998 with the Data Protection Officer at UCL. 
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8.3 Ethical approval  
Ethical approval has been obtained from the Charing Cross Research Ethics 
Committee on behalf of the National Research Ethics Service. REC reference 
number 07/H0711/127. 
 
8.4 Declaration of Helsinki and Good Clinical Practice  
The study will be conducted according to the recommendation of the Declaration of 
Helsinki (2000 Edinburgh, Scotland) and in accordance with the ICH principles of 
Good Clinical Practice.  
 
8.5 Participant informed consent  
The Investigator is required to explain the nature and purpose of the study to the 
participant prior to study entry. A participant information sheet will be given to the 
candidate and written informed consent obtained before entering in the study.  
 
8.6 Quality control and quality assurance  
A pilot study using EBUS and EUS in the diagnosis and staging in lung cancer will 
be performed to ensure the techniques employed match national standards. During 
the trial there will be meetings every 2 months to ensure these standards are 
maintained. The lack of blinding in the study will mean that no bias is introduced. 
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8.7 Idemnity & Compensation  
Non negligent harm: University College London, as sponsor, will provide insurance 
against claims for compensation for injury caused by participation in this trial (ie 
non-negligent compensation). Patients wishing to make a claim should address their 
complaint in writing to the chief investigator in the first instance.  
Negligent harm: Where studies are carried out in a hospital, the hospital continues to 
have a duty of care to a patient being treated within the hospital, whether or not the 
patient is participating in this trial. University College London does not accept 
liability for any breach in the hospital’s duty of care, or any negligence on the part of 
employees of hospitals. 
 
 
8.8 Publication policy  
We intend to disseminate any findings from our research in peer-reviewed journals. 
All clinicians and researchers involved in the project will be acknowledged in 
written papers. 
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